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Summary
Colorectal cancer (CRC) is the second or third most common cancer 
in Western countries, and its incidence is rising. Among the hereditary 
forms Familial Adenomatous Polyposis (FAP) is a rare, dominantly 
inherited disease which is caused by germ-line mutations of the Adenmatous 
Polyposis Colorectal Cancer (APC) gene. A second form of CRC that 
shows familial aggregation is Hereditary Non-Polyposis Colorectal Cancer 
(HNPCC).
The main aims of this study were: (i) to assess microsatellite 
instability in the tumour of patients with colorectal carcinoma and (ii) to 
identify germ-line mutations in two mismatch repair genes, using a variety 
of techniques.
To do this, in two groups of unselected patients, 30 pairs of normal/tumour 
DNAs and 47 RNA samples were made available for microsatellite 
instability studies and mutation analysis, respectively. Nine polymorphic 
markers were chosen for microsatellite instability analysis including: 
D13S160, D2S119, D8S282, D18S34, 635/636, D2S123, LPLCA- A, 
D2S378, LPLCA, B. Using this approach, 30% (9/30) of the tumours 
exhibited instability at one or more loci (RER+). There was no significant 
difference between age and sex in patients with or without microsatellite 
instability.
Using the reverse transcriptase polymerase chain reaction (RT-PCR), 
the entire coding sequence of the hMSH2 gene was amplified in either two 
or three overlapping segments. By employing RNA and DNA based 
techniques a number of germ-line mutations were found in the hMSH2 and 
hLMHl genes. The mutations included: one novel splice site mutation 
responsible for exon 15 skipping, two novel deletions of exons 2-6 and 2-8 
from the mRNA transcripts, four different mRNA deletions at different sites 
in the hMSH2 gene, one missense mutation at exon 6 and three intronic 
mutations at positions +9, -10 and +19 in intron 1, 11, and 14 respectively. 
A variation of the published sequence was also found at 3’ end of the 
untranslated region in the HMSH2 gene.
None of the families in this study were large enough for linkage 
analysis. In one HNPCC family, one splice site mutation was found at 
position +5 in intron 15. This resulted in exon 15 skipping from transcripts 
and produced a truncated hMSH2 protein. This germ-line mutation was 
present in 4 affected members of the family, but was not present in the 
healthy members of the family or in 177 other colorectal cancer patients. 
The individual who bears this germ-line mutation showed a RER+ 
phenotype in the tumour sample.
A patient whose tumour was RER+ had a deletion of exons 2 to 6 
inclusive which resulted in an out-of- frame deletion of codons 71-359. This 
deletion created a premature termination codon within exon 7 at nucleotide 
position +3 from the splice site. No genomic mutations were found which 
could account for the exon skipping. No other member of the family was 
available for further investigation.
A patient with a tumour showing the RER+ phenotype had a deletion 
of exons 2 through exon 8 inclusive which resulted in an out-of- frame 
deletion of codons 71-466. This deletion also created a premature 
termination codon within exon 9 at position +12 from the splice site. No 
genomic alterations were found which could account for the exon skipping. 
This individual was the only member of the family available for 
investigation.
Four different partial mRNA deletions in different exons were found. 
Three of them produced premature termination codons. No alteration could 
be found by sequencing the genomic splice sites, or in the corresponding 
exons. One of the partial deletions was found in four unrelated individuals. 
The breakage points of the aberrant mRNAs were not located at the splice 
site junctions in any case. In order to clarify whether or not these partial 
mRNAs deletions are normal, RT-PCR from 20 healthy individuals was 
carried out. The whole coding sequences of the hMSH2 gene were amplified 
in three overlapping fragments and no extra bands were observed. These 
results indicate that none of the mRNA deletions reported in this study are 
common normal variations.
A T to C transition was found in a short polypyrimidine tract in intron 
12 at nucleotide position -6. Particularly, short poylypyrimidine tracts at 
the 3’ end of the intron have been shown to effect mRNA splicing 
(Roscigno et al. 1993), but this mutation had no affect on the mRNA 
splicing process, since no short transcript was found. It was, however, found 
in 15% of the normal population when 86 normal chromosomes were tested.
A G to A transition was also found at codon 322 in exon 6 which 
changes glycine to asparatic acid. Since glycine is a non- polar neutral 
amino acid and asparatic acid is an acidic one, it is likely that the polarity of 
the protein will be changed. The frequency of this mutation in the normal 
population was 4%, when 62 normal chromosomes were analysed.
A C to G transversion was also found in the intronic region of exon 
1 at nucleotide position +9. This mutation had no effect on RNA splicing, 
since no short transcript was found. The frequency of this mutation was 
45% when 66 normal chromosomes were studied.
It is believed that the majority of hMLHl mutations cluster at the exonic 
region 15-16. These two exons were amplified by PCR followed by SSCP in 
patients as described ealier. On sequencing the genomic DNA, an A to G 
change was found at position -19 in intron 14. Further study showed this 
mutation in 44% of the normal population when 60 normal chromosomes 
were examined. No alteration was found in exon 16 of the hMLHl gene 
either by SSCP or by PCR, as described by Lahti et al. (1995). All of the 
point mutations which were found in this project were confirmed by 
enzymatic assays.
The results of this study provide further evidence that the hMSH2 
gene is involved in a proportion of patients with colorectal carcinoma in the 
West of Scotland, and show that frameshift mutations are the most common 
cause of the disease. This study also showed that the mutations in the 
hMSH2 gene are scattered thoughout its entire coding sequence, without any 
sign of hotspots or common mutations. HNPCC is a heterogeneous disease, 
and only the simultaneous application of all available screening methods 
guarantees the highest probability of detecting all existing mutations.

1.1. Colorectal cancer
Cancer is a complex family of diseases, and carcinogenesis, the conversion of a
normal cell into a cancer cell, is a complex multistep process. Clinically, cancer is a large 
group of diseases, perhaps a hundred or more, that vary in age of onset, rate of growth, 
state of cellular differentiation, diagnostic detectability, invasiveness, metastatic 
potential, response to treatment, and prognosis. In terms of molecular biology, however, 
cancer may represent a relatively small number of diseases caused by similar molecular 
defects in cell function, and resulting from similar alterations to a cell’s genes. 
Ultimately, cancer is a disease of abnormal gene expression (Ruddon, 1995).
Colorectal cancer (CRC) is the second or third most common cancer in the 
Western countries with a cumulative life incidence of 5-6% and its incidence is rising. It 
is rare in the third world ( Ruddon, 1995). Up to 90% of all CRCs are sporadic. Among 
the hereditary forms, Familial Adenomatous Polyposis (FAP) is a rare, dominantly 
inherited disease leading to cancer and is caused by germ-line mutations of the APC 
gene (Kinzler et al. 1991; Nishisho et al. 1991; Groden et al. 1991; Joslyn et al. 1991). 
Affected patients have several unusual phenotypic features, most notably the presence of 
thousands of benign tumours lining the entire large intestine. FAP accounts for about 1% 
of CRC cases in the western world (Jarvinen, 1992).
1 .1 .1 . Hereditary nonpolyposis colorectal cancer (HNPCC)
A second form of CRC that shows familial aggregation is hereditary
nonpolyposis colorectal cancer (HNPCC). It is more common than FAP, accounting for 4 
to 13 % of all CRC in industrial nations (Lynch et aL 1993). It is impossible to reliably 
distinguish patients with this form of CRC from sporadic cases on physical examination 
alone, as neither have diffuse polyposis, or other unusual stigma.
In the past, the definition of HNPCC was exclusively based on pedigree 
structure and age at onset. The International Collaborative Group (ICG) on hereditary 
nonpolyposis colorectal cancer suggested three obligate criteria known as the 
Amsterdam criteria or ICG-HNPCC (Vasen et al. 1991) 1- At least three relatives 
with histologically verified colorectal cancers; one of them should be a first degree 
relative to the other two (familial adenomatous polyposis should be excluded). 2- At least 
two successive generations should be affected. 3- In one of the relatives, colorectal
cancers should be diagnosed when they are 50 years of age or less.
These criteria favour a typical form of HNPCC. For example, the requirement 
of two successive generations excludes families with low penetrance and de novo germ- 
line mutations. On the other hand, the definition ignores tumours other than colorectal, 
and thus potentially excludes families in which tumours in other organs are frequent. 
Finally, the age requirement obviously excludes families in which penetrance is delayed.
The high susceptibility to cancer often leads to the occurrence of more than 
one tumour at the same time (synchronous tumours), and to repeated occurrences 
(metachronous tumours). Further characteristics of HNPCC are : younger age at onset 
(average 40 - 45 years) than in sporadic CRC (over 60 years); more often right-sided 
tumours (approximately two-thirds) than in sporadic CRCs (approximately one-third), 
with no explanation thus far of the difference in sideness ( Bufill, 1990); a generally 
unfavourable histology (poor differentiation) with a prognosis that is paradoxically 
better than in sporadic CRC.
Tumours in HNPCC, as in sporadic CRC, develop via a precancerous growth 
called an adenoma. Sporadic CRC can be prevented by colonscopic screening and 
removal of adenomas (Winawer et al. 1993); recently, the same has been shown for 
HNPCC (Jarvinen et al. 1995).
Much attention has been paid to the spectrum of tumours that occur in 
HNPCC. There is no explanation for the observations that some organs are, and others 
clearly are not, susceptible to cancer in this condition. Approximately two-thirds of the 
tumours seen in members of the HNPCC families under study were in the colorectum, 
with the rest in other organs. Among these, the endometrium, stomach, pancreas, bile 
ducts, kidney and ureters are most clearly involved, whereas other tumours in, for 
example, breast, sarcoma, skin, and lung may or may not arise as a result of the inherited 
susceptibility. Clarification of this point is obviously of major interest and can only be 
done by determining who has, and who does not have, the predisposing mismatch repair 
gene mutation that occurs in each family. In the large family reported by 
Warthin,(1913,1925,1931)endometrial and stomach cancer predominated, whereas later 
generations of the same family display a predominance of CRC.
The incidence of HNPCC estimates vary widely. The highest estimates could 
imply a frequency of 1 in 200 or higher (Houlston et al. 1992). A more commonly
quoted estimate, 1 in 2000, would still place HNPCC among the commonest heritable 
disorders, in the same order as cystic fibrosis and fragile X syndrome. Other estimates 
are lower, such as that made by Bodmer et al. (1994), who claimed that HNPCC is rarer 
than familial adenomatous polyposis in which the incidence is of the order of 1 in 8000 
to 1 in 15000.
The great variation in estimates of incidence is due to the lack of objective 
diagnostic criteria other than pedigree structure. Most attempts to determine the 
incidence of HNPCC begin by pedigree analysis in order to determine the proportion of 
those who have HNPCC, in a given study population of colorectal cancer patients.
1.1 .2 . Tumourigenesis in colorectal cancer
Colorectal carcinomas have proven to be an excellent model system in which 
to study the role of hereditary factors, environmental carcinogenesis, oncogene 
activation, and tumour suppressor gene inactivation in the initiation and progression of 
human solid tumours (Fearon et al. 1990; 1992).Tumours of various stages of dysplasia 
and malignancy, from benign adenomas to invasive cancers, can be obtained surgically. 
There is a clear familial predisposition for some of the cases, and a variety of genetic 
mutational events have been identified in the disease tissue (Figure 1. 3). In addition, 
there is a clinically definable progression from adenoma to malignant neoplasia. It is 
important to note that although there is evidence for a preferred order of the genetic 
changes rather than their specific sequence that is important in the initiation and 
progression of the neoplastic process (Fearon et al. 1990,1992). For example, more than 
90% of the colon carcinomas studied had two or more genetic alterations, and 7% of 
early adenomas had more than one of the four component genetic alterations observed in 
the cancer cells [(Fearon et al. 1990) (see Figure 1.1)]. As early adenomas progressed to 
intermediate and late adenoma stages, the number of tumours with more than one genetic 
change went to 25% and 94% respectively. Some late-stage adenomas had all four of the 
common genetic mutations, indicating that probably more than these four events are 
required for progression to malignancy. Another interesting point is that most, if not all, 
colorectal cancers, appear to have similar mutational changes irrespective of hereditary 
factors or environmental exposure (Fearon et al. 1990).
The highly propensity of patients with the autosomal dominant familial adenomatous
polyposis syndrome (FAP) to develop colorectal carcinomas has provides an important 
clue to the predisposing genetic alterations that are involved in the initiation and 
progression of this type of cancer.
Affected individuals may develop hundreds or thousands of adenomatous polyps in their 
colons and rectums. Only a small percentage of these go on to become malignant, 
consistent with the multi- hit hypothesis of cancer. The inherited , affected gene present 
in FAP has been cloned and is called APC (adenomatous polyposis coli). The APC gene 
is mutated in the germ-line of FAP patients. Most often, these are point mutations or 
frameshift mutations, and, in a few cases, gene deletions. In any case, all the inherited 
mutations lead to inactivation of the APC gene, which is located on chromosome band 
5q21. These data suggests that APC is a tumour suppressor gene.
That the APC gene is also involved in non-hereditary, sporadic cases of 
colorectal cancer is supported by the fact that allelic losses of 5q21 are seen in 35% to 
60% of patients with no known familial predisposition. The data support the concept 
that one or both alleles of the APC gene are lost or inactivated at an early stage in the 
development of colorectal cancer, since 5q allelic losses are detected often in small, early 
adenomas (Vogelstein et al. 1988).
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Figure 1. 1: A genetic model for colorectal tumorigenesis. Tumorigenesis proceeds 
through a series of genetic alterations involving oncogenes (ras) and tumour suppressor 
genes. The three stages of adenomas, in general, represent tumours of increasing size, 
dysplasia, and villous content (Fearon et al. 1990).
Another locus that maps to chromosome band 5q21 and is altered in colorectal 
cancer is called MCC (mutated in colorectal cancer). This MCC gene appears to be 
inactivated in about 15% of sporadic colorectal cancers (Kinzler et al. 1991). Loss or 
inactivation of the APC and MCC genes may be involved in increasing the rate of 
proliferation of the affected mucosal cells, thus increasing the chance for subsequent 
genetic abnormalities to occur.
Another early change that occurs in the genome of early adenomas is loss of 
methyl groups from DNA. About one-third of DNA sequences from adenomas show loss 
of methyl groups (Feinberg et al; 1988). Hypomethylation has been correlated with 
activation of silent genes and with alterations of chromosome condensation. The latter 
may lead to mitotic nondisjunction, resulting in gain or loss of chromosomes. Activation 
of genes involved in cell proliferation, such as c-myc and tyrosine kinase gene 
products, is also higher in colorectal cancer than in normal colonic mucosa. This would 
also contribute to the hyperproliferative state resulting from inactivation of tumour 
suppressor genes.
Activation of the ras proto-oncogenes has been implicated in a number of 
human cancers, including colorectal carcinoma. Mutations in the k-ras gene have been 
identified in about 50% of colonic adenomas larger than 1 cm in diameter, and in 50% of 
colorectal carcinomas, but in only about 10% of adenomas smaller than 1 cm (Vogelstein 
et al; 1988). Such ras mutations, usually in codons 12 or 13, tend to be observed in more 
dysplastic adenomas and are thought to be related to conversion of cells bearing these 
mutations into carcinomas.
Allelic losses-sometimes called loss of heterozygosity (LOH) because they are 
detected by RFLPs (restriction fragments length polymorphism)-of additional tumour 
suppressor genes appear to be a key to later stages in colorectal tumorigenesis. These 
losses usually involve only one of the two parental alleles, and the other allele may or
may not be inactivated by mutation. These lost genetic loci are thought to contain tumour 
suppressor genes. Subsequently, the first locus that appears to be lost in colorectal 
tumour progression is chromosome 18q. This region is deleted in 50% of late adenomas 
and more than 70% of carcinomas (Vogelstein et al. 1988). A candidate tumour 
suppressor gene located in the 18q band, DCC (deleted in colorectal carcinoma), encodes 
a protein with putative cell adhesion properties. Its expression is reduced or absent in 
colorectal carcinomas, suggesting its involvement in normal cell-cell or cell-extracellular 
matrix interactions required to maintain a normal state of differentiation.
The most common allelic deletion seen in colorectal cancer involves a large 
portion of the p region of chromosome 17. Loss of part of 17q is infrequently observed 
in adenomas at any stage, but it is observed in over 75% of colorectal carcinomas. 
Furthermore, in several patients in whom tumour progression was observed, 17q allelic 
losses correlated with progression of individual tumours from adenoma to carcinoma 
(Fearon et al. 1990; Vogestein et al. 1988). The common segment lost from 17q is now 
known to contain the p53 allele tumour suppressor gene (Baker et al. 1989). Loss and or 
mutation of p53 alleles has now been observed in a wide variety of human cancers. Point 
mutation of one p53 allele and loss of the remaining normal allele is a common finding 
in colorectal cancer, suggesting that the wild-type p53 gene inhibits later events in 
colorectal carcinogenesis; when it is lost, this control is abrogated. In some tumours, 
however, an intermediate stage may occur; for example tumour cells may express one 
mutant and one wild- type p53 gene. Even in this situation, however, there is evidence 
that the mutant gene product, by binding to it or otherwise blocking the function of the 
normal p53 protein, has a so-called dominant negative effect (Fearon et al. 1990). 
Nevertheless, the data indicates that colorectal carcinomas with 17q allelic losses are 
commonly more aggressive than those without them (Kern et al. 1989).
Allelic losses in addition to those noted for chromosomes 5q, 18q and 17q 
have been observed in colorectal cancer. These include regions from chromosomes lq, 
4p, 6q, 8p, 9q, and 22q (Fearon et al. 1990; Fujiwara et al. 1993) One or more of these 
losses can be seen in 25% to 50% of patients. On the average, colorectal cancers contain 
four or five allelic losses. Patients with more than that number generally have a poorer 
prognosis. The majority of colorectal carcinoma have 17p and 18 deletions, suggesting 
that the suppressor genes contained in those bands are crucial to the carcinogenic
process. Other regions are lost in a more heterogeneous manner. This suggests that they 
may represent suppressor genes, any combination of which, if lost, could result in further 
clonal expansion and uncontrolled proliferation of the affected cells. This heterogeneity 
in allelic loss patterns could account for some of the observed differences in the 
biological properties and clinical course of individual patient’s tumours.
As noted above, defects in DNA mismatch repair genes have also been 
detected in colon cancer. The first one discovered was the hMSH2 gene, homologous to 
the bacterial mutS repair gene, found on human chromosome 2p. A second common 
mismatch repair gene defect has also been found . This gene is located on chromosome 
3p21 and appears to be altered in 33% of HNPCC cases. The gene is called hMLHl and 
is homologous to mutL mismatch repair gene of E.coli . These data strongly suggest that 
, in addition to activation of oncogenes and inactivation of tumour suppressor genes, 
defects in DNA repair account for a major predisposing cause of human cancer.
In summary, the data indicate that although there is an overall sequence of 
genetic alterations in colorectal carcinogenesis, it is the progressive accumulation of the 
alterations that is the most consistent property of colorectal cancers.
1. 2. Mutator phenotype in colorectal cancer
The mutator genes are a group of genes which when mutated themselves can
increase the frequency of other genetic mutations up to 100,000 fold above the wild type 
(Fowler et al. 1974). Mutator genes are well known in lower organisms like E.coli and 
Salmonella. The mutator phenotype refer to this high mutator strain of simple organism. 
Mutation in mutS (mut stands for mutator phenotype) and mutL genes in E.coli could 
increase the rate of mutation 100-fold above the wild type (Siegel et al. 1964; 1975). 
Mutation in some particular genes like mutD, in E.coli could increase the rate of 
mutation 1000-100,000-fold (Fowler et al. 1974). It is believed that replication error 
during DNA replication is the cause of mutator phenotype in the majority of the HNPCC 
tumours, and in a small number of sporadic cases. The finding of mutator phenotype in 
the majority of HNPCC tumours was unexpected, but not surprising, since it was studied 
in detail many years ago in lower organisms. This new mutator mechanism for cancer 
has been discovered by the detection of somatic mutations at simple repeated sequences, 
in the course of searching for the hereditary nonpolyposis colon cancer genes. These
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mutator phenotypes are termed microsatellite instability (Thibodeau et al. 1993), 
ubiquitous somatic mutations (Ionov et al. 1993), genetic instability (Han et al. 1993), 
and replication error (Parsons et al. 1993). Microsatellite instability at simple repeat 
sequences can accumulate due to failures of the strand specific mismatch repair system to 
recognise errors due to slippage by strand misalignment (Streisinger et al. 1966) of these 
unstable sequences (Strand et al. 1993). Four different genes on chromosomes 2, 3 and 7 
have been characterised, and defects of these genes lead to a genetic instability in which 
short sequences or microsatellites are characteristically altered in patients with colorectal 
carcinoma.
Genomic instability at short tandem repeat sequences reflects malfunction in the 
replication repair of DNA. Therefore, it is also referred to as the replication error (RER) 
phenomenon or mutator phenotype. The abnormality appears as an extra or absent allele 
in the tumour DNA when compared with normal DNA from the same person, indicating 
that a gain or loss of short repeat units has occurred. Such alterations reflect a 
malfunction in the replication or repair of DNA which persists throughout the lifetime of 
the tumour (Parson et al, 1993; Shibata et al, 1994). Microsatellite repeats are scattered 
throughout the human genome (it has been estimated that about 100,000 microsatellite 
repeats are scattered throughout the genome), about 85% of colorectal cancers from 
HNPCC patients shows microsatellite instability, and a majority of microsatellite loci are 
apparently involved (Aaltonen et al. 1993 & 1994). Thus, in HNPCC tumours, the total 
number of mutations at microsatellite loci alone could be as high as 85,000 per cell. 
Approximately 15% of apparently sporadic colorectal carcinomas exhibit microsatellite 
instability. RER+ colorectal tumours, whether representative of HNPCC or sporadic, are 
characterised by almost unique clinical and pathological features (Aaltonen et al. 1993; 
Ionov et al. 1993; Loth et al. 1993). The genetic background of mutator phenotype may 
not be the same in HNPCC and in sporadic cases. In HNPCC, microsatellite instability is 
believed to be due to a germ-line mutation plus a somatic event inactivating the second 
allele of the mismatch repair gene involved. Liu et al. (1995) found that only one in ten 
patients with RER+ sporadic colorectal tumour had a detectable germ-line mutation in a 
mismatch repair gene, suggesting that hereditary forms may not be very common in this 
group. Additionally, only three of seven sporadic tumour cell lines with microsatellite
instability had mutations in MSH2, MLH1, PMS1, or PMS2, implying that a significant 
fraction of sporadic RER+ cancers arise from mutations in other genes. It has been 
reported that a mutation in DNA polymerase may cause microsatellite instability in some 
sporadic tumours (da Costa et al. 1995). However, the mutator phenotype is not restricted 
to cancers belonging to the HNPCC tumour spectrum but occurs with variable 
frequencies in cancers not occurring in excess in HNPCC, such as lung cancer ( Merlo et 
al. 1994; Shridhar et al. 1994).
1 .2 .1 . M utator phenotype occurs at an early stage of tumourigenesis
Repetitive sequences are short and specific sequences, present throughout the
eukaryotic genomes, including both non-coding and coding regions. These are repeat 
sequences from mono - to hexa-nucleotides, which are dispersed throughout the 
eukaryotic genomic DNA. The length of repeats vary among individuals and also 
between species. As a result, they have shown great utility as genomic markers. In the 
human genome there are 50, 000 - 100, 000 interspersed (CA)n blocks, with the range of 
(n) being roughly 15- 30 (Hamada and Kakunaga 1982, Hamada et al. 1982, 1984a; Sun 
et al. 1984; Tautz and Renz 1984; Gross and Garrad 1986; Braaten et al. 1988). The 
function of the (CA)n repeats is unknown, but it has been proposed that they serve as 
hotspots for recombination (Slightom et al. 1980), and also some work has suggested that 
DNA can be exchanged between these duplicated sequences or participate in gene 
regulation. Additionally, areas of interest can be studied further though positional 
cloning (Botstein et al. 1980; Weber etal. 1989; Weber, 1990;).
Repeated DNA sequence families which do not include functional gene 
members are composed of arrays of tandem repeats, or of individual repeat units 
interspersed with other DNA sequences including: satellite DNA, minisatellite DNA, 
microsatellite DNA, interspersed repeats (Alu family) and the Kpn (LI) family. 
Expansion or deletion of alleles could create a microsatellite shift or novel allele on the 
autoradiogram as shown in Figure 1. 2.
Genomic instability is a landmark for some sporadic and hereditary cancers of the colon. 
Young et al. (1993) reported that genomic instability occurred in colorectal carcinomas, 
but it is rare in adenomas. They analysed 108 carcinomas and 46 adenomas with 4-15 
microsatellite markers, and reported 6.5% MI in patients with colorectal carcinoma.
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Figure 1. 2: Microsatellite alteration can be detected by PCR-based microsatellite 
analysis. The occurrence of an insertion or deletion mutation in the repetitive sequence 
alters the size of one allele and creates a microsatellite shift or novel allele on the 
autoradiogram. LOH: loss of heterozygosity.
Shibata et al. (1994) found several human tumour cell lines with up to 1,000- 
fold increases in mutation rates for endogenous microsatellite sequences, relative to 
normal or tumour cells without the mutator phenotype, and showed that genomic 
instability occurs very early in tumorigenesis. They showed MI in several single cell 
lines in vitro and in vivo. They examined three different adenomas, which were found 
adjacent to a carcinomas, and found MI in all of them. Their results demonstrated that MI 
occurs very early in colorectal carcinogenesis and continues to take place during tumour 
evolution and progression. However, it has been documented by many groups that MI
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occurs very early in tumorigenesis (Aaltonen et al. 1994; Patel et al. 1994; Melo et al. 
1994). Figure 1. 3 demonstrates genomic instability in early stage of tumorigenesis.
Figure 1.3. Genomic instability occurs in the early stage of tumorigenesis. Open circles 
represent normal cells, shaded circles represent cells with unstable DNA. If genomic 
instability occurs at the two cell stage 50% of tumour cells have unstable DNA. In the 
case of mutation at later stages the proportion of cells with genomic instability is smellier.
1 .2 .2 . Microsatellite instability in other diseases
Microsatellite instability is a common feature in HNPCC and in some of the
sporadic CRC and related diseases such as endometrial cancer (Risinger et al. 1993;
Burks et al. 1994; Peltomaki et al. 1993), gastric cancer (Strickler et al. 1994; Chong et al.
1994; Han et al. 1993; Mironov et al. 1994; Rhyu et al. 1994), pancreatic cancer (Han et
al. 1993), prostatic cancer (Gao et al. 1994) and also in breast (Patel et al. 1994;
Peltomaki et al. 1993), bladder cancer (Gonzalez et al. 1993; Dalbagni 1993), leukaemia
(Cross et al. 1994), Muir-Torre syndrome [(Muir-Torre syndrome is characterised by
the presence of at least one sebaceous tumour and visceral malignancy) (Honchel et al.
1994)], head and neck cancer, and also lung cancer (Mao et al. 1994), small cell lung
cancer (Merlo et al. 1994), non-small cell lung carcinoma (Shridhar et al. 1994). MI has
been also reported in primary neoplasms from HIV+ patients (Bedi et al. 1995). MI has
not been reported in testicular cancer so far. Mutations within small repeated sequences
in the TGF beta type II receptor have been found in several cell lines, and nude mouse
xenografts of tumours of the microsatellite mutator phenotype (Benson et al. 1995;
Markowitz et al. 1995). This finding suggests that the TGF beta receptor mutation is a
common target for diverse mutator genes in colon cancer, and also aborted embryos
(Kiaris et al. 1996). Recently, MI was reported within the coding sequence of the insulin
like growth factor II receptor (IGFIIR) from patients with ulcerative colitis associated
colorectal cancer (Souza et al. 1996). These alterations are most easily detected by
analysis of microsatellite polymorphic markers, which seem particularly prone to
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insertions or deletions in such tumours. In the hereditary form of colon cancer, MI is 
generally due to germ-line mutations in one of four mismatch repair (MMR) genes 
(Liu et al. 1995a). However, mutations in mismatch repair genes have so far been 
demonstrated in only a small percentage of sporadic cancers or cell lines derived from 
colorectal carcinomas ( Liu et al. 1995; Borresen et al. 1995).
1. 3. The structure of the hMSH2 and hMLH1 genes
The sequences of the hMSH2 cDNA were submitted to the gene bank by 
accession number U0405. The hMSH2 gene spand about 73 kb in the genome and has a 
2.8 kb transcript with 16 exons. The largest and smallest exons are exon 3 and exon 11 
which are 279 bp and 98 bp, respectively. The largest and smallest introns are intron 8 
and intron 12 which are 17 kb and 1.0 kb respectively (Figure 1. 4). The initiation codon 
(ATG) is located within exon one at nucleotide (nt) position 69, and the termination 
codon (TAG) is located in exon 16 at nt position 2892. The hMSH2 protein is one 
member of the mismatch repair system, and has a 100 kd molecular weight. The role of 
this protein is to distinguish a G-T mismatch in the heteroduplex. Comparison of the 
hMSH2 amino acid sequences with the other known mutS homologues has shown that it 
was most highly related to the S. cerevisiae MSH2 protein (Rennan and Kolodner; 1992), 
and that these two amino acids sequences are more highly related to each other than 
many pairs of bacterial sequences. The evolutionary relationship of the known mutS- 
related proteins indicates that MSH2 is a member of a group of mutS homologues that 
includes all of the bacterial homologues, and S. cerevisiae mshl and msh2. This group of 
proteins contains all of the members known to play a role in mismatch repair, and in 
which mutations of the respective genes have been found to cause a strong mutator 
phenotype in these respective organisms.
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Figure 1. 4- Diagram of the organisation of the hMSH2 locus. The boxes represent the 
individual exons from 1 to 16. The size of each exon is given at the top of each one (bp) 
and the size of each intron (kb) is given below the region between individual pairs of 
exons. Shaded boxes represented conserved region in the gene.
After cloning and mapping the first gene to the chromosome 2p, Papadopoulos et 
al. (1994) searched for additional homologous of bacterial and yeast mutator genes. The 
results of this study indicated that the hMLHl gene was located within band 3p21.3. This 
gene spand in about 85 kb in the genome and has a 2.7 kb transcript with 19 exons. The 
biggest exon has 473 bp (exon 12) and the shortest exon is exon 7 with 194 bp (Wijnen 
et al. 1996). The schematic diagram of this gene is presented in Figure 1.5.
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Figure 1.5. Schematic presentation of the genomic organisation of human hMLHl gene. 
Exons and introns are presented by boxes and horizontal lines respectively. Shaded boxes 
represent the conserved region in the gene. The Figure is not to scale.
1. 4. DNA repair
Not all interactions of chemicals and irradiation with DNA produce mutations. 
In fact, all cells have efficient repair mechanisms that repair such lesions. DNA repair 
mechanisms include sets of enzymes that survey DNA for specific kinds of damage, 
remove the altered portion of DNA, then restore the correct nucleotide sequence. The 
important role of DNA repair in human cancer has been established by the finding that a 
number of inherited defects in DNA repair systems predispose individuals to getting 
cancer. Genetic instability is a component of the familial cancer phenotype. For example, 
patients with xeroderma pigmentosum, ataxia telangiectasia, and Bloom’s syndrome 
have a genetic instability that results in a predisposition to cancer (Mckinmen et al. 
1987., Cleaver et al. 1968., German et al. 1989). These syndromes are inherited as 
autosomal recessive diseases, but there is no reason that a dominant gene could not 
produce a similar result.
DNA repair is an important molecular defence system against agents that cause 
cancer, degenerative disease, and ageing. The faithful transmission of genetic 
information is paramount to the survival of a cell, an organism, and a species. There are 
at least three different ways in which mismatch nucleotides arise in DNA. First, physical 
damage to the DNA can give rise to mismatched bases. For example, the deamination of 
5-methylcytosine creates thymine and therefore a G-T mispair (Friedberg, 1985). 
Secondly, misincorporation of nucleotides during DNA replication can yield mismatched 
base pairs, nucleotide insertions and deletions (Modrich,1991). Thirdly, genetic 
recombination produces regions of heteroduplexes resulting from the pairing of two 
different parental DNA sequences. Mismatched nucleotides produced by each of these 
mechanisms are known to be repaired by a specific enzyme system (Friedberg,1990; 
Modrich, 1991). The results of the first and third ways are DNA adducts, while the result 
of the second way is misincorporation of nucleotide in the DNA.
DNA repair in Escherichia coli
Since mutations are the primary cause of inheritable disease and cancer, they may
also contribute to the ageing process, and it is important for individual cells to preserve 
the integrity of their genetic material. Study of the molecular systems responsible for 
maintenance of genetic integrity became available more than 20 years ago with the 
identification of Escherichia coli mutants that display a marked increase in the rate of 
spontaneous mutation. The genetic defects in this strain are known to inactivate mutation 
avoidance systems that are critical for the maintenance of genetic stability.
Several different DNA mismatch correction pathways have been identified in E. 
coli. These are important pathways of mutation correction. Enzyme systems that 
recognise and process mispaired bases have been identified in both prokaryotes and 
eukaryotes. E. coli possesses multiple mismatch repair pathways that are distinguished 
on the basis of mispair specificity and size of excision repair tracts associated with 
correction. The products of four genes, the mutH, mutL, mutS and mutU proteins are 
essential for E.coli methyl-directed mismatch repair, a system that ensures the precision 
of both chromosome replication and genetic recombination. The importance of this 
fidelity device has been demonstrated by the fact that inactivation of the corresponding 
human pathway is the primary cause of certain types of cancer.
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1.4 .1 . Long - patch mismatch correction
The best defined mismatch repair pathway in E. coli is mut HLS pathway that
promotes a long patch (approximately 2 kb) excision repair reaction that is dependent on 
the mutS and mutU (uvrD) gene products (Figure 1. 6). This is a methyl directed system 
and displays a broad specificity for different mispairs. Efficiency of correction efficiency 
depends on the nature of mismatch and can also be influenced by the sequence in which 
the mispair resides. This pathway recognises the state of methylation of each DNA strand 
at d(GATC) sequences and directs repair to the transiently undermethylated nascent 
DNA strand, using the methylated parental strand as a template. A heteroduplex bearing 
d(GATC) modification on both DNA strands is not a substrate for methyl-directed repair. 
Hemimethylated DNA is corrected on the unmethylated strand, with the modified strand 
serving as a template, and unmethylated molecules are corrected on one strand or the 
other. Mismatches corresponding to base- base mispair, insertion/ deletion of a few 
nucleotides in one strand of the helix are also subject to efficient methyl-directed repair 
in vivo. The importance of this is that methylated strand is recognised as the original 
sequence, thus mutations do not arise.
1.4 .2 . Initiation of mismatch correction
Ten different proteins and enzymes are involved in mismatch correction. These
are products of the mutH, mutL, mutS genes, DNA helicase II, single strand DNA 
binding protein (SSB), exonuclease I, exonuclease VII, RecJ exonuclease, the replicative 
DNA polymerase III holoenzyme, and DNA ligase. Of the proteins involved in methyl- 
directed repair, only mutS is capable of specific interaction with a heteroduplex in the 
absence of other components. The multifunctional 97 kd product 
of the muts gene binds to mispairs. The mismatch is recognised by this protein. MutS 
also has weak ATPase activity in the presence and absence of DNA and promotes the 
formation of alpha-shaped loop structures from heteroduplex DNA.
MutH protein interacts with d(GATC) sites in DNA that are hemimethylated 
on the adenine, and is responsible for incision on the unmethylated strand. Analysis of a 
new homogenous preparation of the 25 kd mutH protein revealed a single activity, an 
extremely weak, Mg2+-dependent endonuclease that incises the unmethylated strand of 
hemimethylated DNA 5 to the G of d(GATC) sequences.
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Figure 1. 6. Schematic diagram of the DNA mismatch repair system in the E.coli. Note 
that hemimethylation is on the template strand only.
No simple activity has been attributed to mutL, in contrast to mutS and mutH. MutS 
binding to a mismatch protects about 20 base pairs against DNasel attack, but in the
presence of mutL and ATP, the protected region increases to about 100 base pairs. This 
effect is independent of the presence of a d(GATC) site within the heteroduplex. MutL is 
homodimer (70 kd)2 protein. Molecular interactions responsible for the mutL dependent 
effects observed in vitro have not been defined. One possibility is that mutL functions as 
a protein-protein interface between mutS and mutH.
1.4 .3 . The excision reaction
Three different proteins, mutS, mutL, and mutH act in a co-ordinated fashion
to make a single strand nick at a hemimethylated d(GATC) sequence in the newly 
replicated strand. MutS binds to the mismatch and forms a complex with mutL that 
brings the unmethylated d(GATC) into close proximity to the mismatch, leading to 
cleavage by the mutH nuclease. Excision proceeds in either the 3 to 5 or the 5 to 3 
direction from the nick to the mismatch. Several in vivo observations also suggest bi­
directional action, and this has been confirmed by biochemical findings (Modrich, 1991). 
When the unmethylated d(GATC) sequences located 3 to the mismatch, a 3 to 5 
hydrolytic activity is necessary. Exonuclease I is sufficient in this respect (Lahue et al. 
1989; Lehman et al, 1964). However, if an unmethylated d(GATC)sequence resides 5 to 
the mismatch, excision is dependent on a 5 to 3 exonuclease VII or RecJ (Chase et al. 
1974; Lovett et al. 1989).
1. 4.4. Repair and replication fidelity
Now, it is clear that methyl- directed mismatch correction contributes in a
major way to the fidelity of chromosome replication in E.coli (Modrich, 1991). 
Mutations in mutH, mutL, mutS or mutU result in a 100- 1000 fold increase in 
spontaneous mutability (Cox, 1976). Mutations leading to a deficiency in the Dam 
methylase, the enzyme responsible for d(GATC) methylation, also result in 
hypermutability (Marinus,1984; Marinus et al, 1974). Overproduction of this enzyme 
also leads to a mutator phenotype (Herman et al, 1981; Marinus et a l , 1974). Mutations 
in mutDS have been attributed to the response of the methyl-directed pathway to DNA 
biosynthetic errors. The mutDS mutations, which affect the proof-reading exonuclease 
activity of DNA polymerase III holoenzyme, is one of the strongest mutators known, 
increasing spontaneous mutability by factors of 1,000 to 100,000 (Cox, 1973). This large 
increase in mutation rate is paradoxical, in view of the in vitro demonstration the
17
exonuclease editing increases fidelity of the polymerase III reaction by a factor of only 
10- 200 ( Fresht et al, 1983). It has been clarified that in addition to the associated 
deficiency in DNA polymerase III proof-reading activity, mutDS strains are also 
defective in methyl-directed mismatch correction (Schaaper, 1988; Damagnez et al. 
1989). So, DNA polymeraselll holoenzyme participates directly in methyl-directed 
mismatch repair.
1. 4. 5. Very short - patch mismatch repair
Mismatch- repair systems that are characterised by short excision repair tracts,
about 10 nucleotides or less, have been discovered in both prokaryotes and eukaryotes. 
One of these short pathways is named VSP (Very Short Pathway), and was identified for 
the first time in prokaryotes by Lieb (1981). This repair system is able to correct a G to 
T mismatch to G-C. The existence of this system has been confirmed by heteroduplex 
transfection experiments (Zell et al, 1987), which have shown only G-T in this system 
being corrected to G-C.
5’- CTWGG 5’- CCWGG
3-G G W CC 3 - GGWCC 
W indicates A or T, the d(CCWGG) is the recognition site for the Dam DNA cytosine 
methyltransferase of E.coli , which modifies the internal cytosine residue within the 
sequence. These sites are hot spots for mutation. The VSP pathway functions as a 
mutation avoidance system to restore G-T mismatches, which are generated via 5- 
methylcytosine deamination, to G-C base pairs ( Zell, 1987; Jones et al, 1987).
Biological experiments have implicated four proteins in the VSP reaction, i.e. mutL, 
mutS, DNA polymerase I and the product of the vsr gene, which is adjacent to that 
encoding the Dam methylase (Dzidic et al, 1989). Since mutL and mutS function in both 
methyl- directed and VSP repair, interaction of these proteins with a G-T mispair in the 
d(CCWGG) sequence context may serve to direct repair to the appropriate pathway ( 
Modrich, 1991). Although no information on the mechanism of VSP repair is available, 
it has been observed that overproduction of VSP proteins partially overcomes the 
dependence of the reaction on mutL and mutS (DasGupta et al. 1982). This suggests that 
the VSP product may initiate the chemical steps involved in VSP correction, with mutL 
and mutS serving a regulatory function (Modrich, 1991).
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1. 4. 6. Mut Y mismatch repair in E. coli
Both in vitro and in vivo experiments have demonstrated the presence of a
second short- patch repair system in E.coli. The specificity of this system is for G-A
mismatches, which are repaired to G-C base pairs (Lu et al. 1988). Transfection
experiments also showed that the mutY mismatch repair system can repair A-C to G-C
(Radicella et al, 1988). This pathway is independent of mutH, mutL, mutS and DNA
helicasell (Su et al. 1988), and does not require the presence of d( GATC) sites within
heteroduplex (Au et al. 1988). A failure to process G-A mismatches to G-C base pairs
can largely account for the mutator phenotype associated with loss of mutY function. The
mutY gene produces a 36 kd protein in near homogeneous form and it has been
demonstrated that it functions as an adenine glycosylase specific for G-A mispair (Au et
al. 1989). The hypermutability associated with mutY mutations (Nghiem et al. 1988) and
the associated defect in G-A to G-C mismatch repair suggests that this pathway corrects
G-A biosynthetic errors in which the mismatched adenine is on the new DNA strand.
Since G-A mispairs are also subject to methyl- directed correction, it is evident that E.
coli can use multiple mechanisms to exclude this mismatch from newly synthesised
DNA. This may reflect the multiple conformation states uniquely available to this
mispair.
1. 4. 7. Rec F- dependent system in E.coli
This system was discovered by Fishel and Kolodner (Fishel and Kolodner,
1989; Fishel et al. 1986) as a short-patch repair system in E. coli. The RecF system is
able to repair short insertions and deletions in heteroduplex DNA. The mechanism of this
pathway is not clear yet, but it is independent of mutH, mutL, mutS and DNA helicase II
(Fishel et al. 1986), and it functions on DNA containing symmetrically modified
d(GATC) sites.
1. 5. Linkage analysis of HNPCC susceptibility genes
Early reports of the existence of human mismatch repair systems were published
by Hare and Taylor (1985) and Glazer et al. (1987). These reports followed the
demonstration that extracts of human cells contained mismatch binding proteins (Jiricny
et al. 1988; Stephanson & Karran 1989). These data was supported by Holmes et al.
(1990) and it was shown in a bi- directional nick directed fashion (Thomas et
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al. 1991) of the E.coli system (Modrich 1991). The first evidence of the existence of 
mismatch repair deficient mutants came from the studies of Karran et al. (Branch et al. 
1993), who demonstrated that two mutator cell lines resistant to methylating agents 
lacked a major mismatch binding activity. These finding were confirmed by experiments 
showing that the methylation tolerant human mutator cell line is deficient in mismatch 
repair in vitro (Kat et al. 1993). High mutating strains of E.coli and Salmonella 
typhimurium were originally isolated by Treffers et al. (1954) and Miyake et al. (1960). 
Another mutator strain in E.coli also discovered by Siegel and Bryson (1964). Thus, the 
occurrence of a high mutation rate in some strains of bacteria and yeast has been 
described a long time ago. A similar observation has been reported in Drosophila 
(Plough et al. 1941). Reenan and Kolodner (1992a, b) reported two mutS homologous 
genes, mshl and msh2 in yeast, whose amino acid sequences are highly homologous to 
mutS in E.coli. The mshl and msh2 are involved in mismatch repair in the mitochondria 
and nucleus, but it was shown that the disruption of msh2 mutant in yeast elevated the 
rate of spontaneous mutation 70-100 fold over that of wild type. The similar results have 
been reported in bacteria for mutS (Siegel et al. 1963; Siegel et al. 1974; Cox et al. 1972) 
and also for mutL (Siegel et al. 1975). Thus, this group of genes is well known in bacteria 
and in yeast. Based on this knowledge, two different groups in 1993 used two different 
methods for mapping candidate gene(s) for CRC. When genomic instability was 
observed in the tumour of HNPCC kindreds, a link between mutator phenotype in E.coli 
and genomic instability in the tumour of HNPCC kindreds was immediately established. 
Therefore a search for a gene with predicted function was started. Vogelstein’s group 
used a panel of human-mouse and human-rat hybrid cell line followed by the FISH 
technique (Leach et al. 1993). Kolodner’s group (who found the mutS gene in yeast) used 
360 bp PCR products from the mutS gene as a probe, and used both S. cerevisiae DNA 
and human cDNA as templates. The resulting 360 bp fragment was purified and a 
number of independent clones were obtained and sequenced (Fishel et al. 1993). The first 
HNPCC susceptibility locus was mapped and assigned to chromosome 2p by linkage 
analysis by Peltomaki et al. (1993). Thus in attempting to clone the gene, positional 
cloning strategies were combined with the search for a candidate gene with a DNA 
repair function. A human homologue of the mutS gene in bacteria (Modrich, 1991) and 
msh2 gene in yeast ( Reenan et al. 1992) was cloned (Fishel et al. 1993; Leach et al.
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1993) and named MSH2 (mut £  Homologous). They chose two large kindreds with 
HNPCC, families C and J, for linkage analysis. The C kindred originated from North 
America and the J kindred from New Zealand. The mean ages of onset of CRC were 
41.1 years (SD= 13.1) and 44.4 years (SD= 15.5), respectively. Extracolonic cancers 
were observed in both families. They began a systematic search through the whole 
genome with 345 informative microsatellite markers. Marker D2S123 [AFM093xh3] 
showed a highly significant two-point lod score of 6.39 at a recombination fraction of 
zero in family C and 1.45 in family J. There was no recombination between HNPCC and 
D2S123 in either family, suggesting very close linkage. With two flanking markers 
D2S119 (Distal to D2S123) and D2S136 (proximal to D2S123), recombination was 
observed in both families. Further analysis by using 96 markers from chromosome 2 
placed locus D2S123 at a position 5 cM distal to D2S5, which has been mapped to 2pl5- 
16 by in situ hybridisation, linkage and somatic cell hybrid analysis. The localisation of 
an HNPCC gene to chromosome 2 in kindreds from two different continents proved the 
existence of a genetically determined form of this disease. Aaltonen et al. (1993), 
studied an additional 14 smaller kindreds and linkage analysis excluded in 3 families by 
lod scores less than 
-2.0, suggesting genetic heterogeneity.
To determine whether mutations of other mismatch repair genes could cause 
HNPCC Papadopoulos et al. (1994) searched for an additional homologues of bacterial 
and yeast mutator genes by scanning a database of human genes. In this search three 
genes were identified that had significant similarity to the yeast mut L I and was therefore 
termed hMLHl (mut L Homologous). The other genes had slightly greater similarity to 
the yeast mutL homologue PMS1 (Eost Meiotic Segregation) and were denoted hPMSl 
and hPMS2 respectively.
The sequence of these three clones was used to design primers for PCR reaction assays 
with human genomic DNA as template. Somatic cell hybridisation studies localised the 
hMLHl, hPMSl and hPMS2 genes to chromosomes 3, 2 and 7, respectively. The 
hMLHl gene was of particular interest because markers on chromosome 3p21 had been 
linked to HNPCC in several families. To determine the precise chromosomal location of 
hMLHl, a genomic DNA clone was used for fluorescence in situ hybridisation to human 
chromosome spreads. Of ~50 spreads analysed, 40 had a doublet signal on at least one
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chromosome 3 homologue. Doublet signals were not detected on any other 
chromosomes. Detailed analysis of 17 individual spreads indicated that the hMLHl gene 
located within band 3p21.3. Detailed linkage analysis of HNPCC families showed that 
the responsible locus is centred at markers D3S1611 and D3S1277, and is delineated by a 
1-cM interval bordered by markers D3S1298 and D3S1561. No recombinations were 
observed between markers D3S1611 or D3S1277 and cancer susceptibility. The hMLHl 
gene was <85kb and became an excellent candidate for the HNPCC gene on 
chromosome 3p21. The sequence of the hMLHl gene was derived from cellular RNA, 
an open reading frame (ORF) began 42 nucleotides downstream of the 5’ end of the 
cDNA, and contained 2268 nucleotides. Figure 1. 4 summarises relevant data on the four 
human DNA mismatch repair genes whose germ-line mutations have been implicated in 
HNPCC.
The discovery of sequence homologies between the pm sl gene of S.cerevisiae 
and the E.coli mismatch repair gene mutL (Kramer et al. 1989), as well as between the 
E.coli mutS gene, the mouse msh3(Lmion et al. 1989) and human hMSH3(Fu)ii and 
Shimada, 1989), implied that the mismatch repair systems of all organisms are closely 
related (below Figure). These latter findings were key to the identification of the human 
mismatch repair genes.
Bacteria
Yeast
Human 
cDNA, bp 
Amino acids
mutH mutL
S \
pmsl mlhl
I
hPMSl hPMS2 hMLHl 
2,795 2,586 2,268
932 862 765
mutS
/ \
mshl mshl
J X
h M sm  h M sm  
2,727 
934
Figure 1. 7 Presentation of mismatch repair genes from bacteria to human, their cDNA 
length and the number of corresponding amino acids is shown.
1. 6. The molecular pathology of single gene disorders
A mutation is any change in the nucleotide sequence of a genome. The process of
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mutation is mutagenesis and an organism showing an altered phenotype as the result of a 
mutation is a mutant. Not all mutations produce recognisable mutants, some mutations 
will occur in non-coding regions of the genome and have no detectable effect on the 
phenotype. These silent mutations are probably frequent in higher eukaryotes, where the 
larger part of the genome is located in the non-coding sequence. Mutations can occur at 
any stage of development and may give rise to patches of mutant tissue. The size of the 
patch depends upon the time during development at which the mutation occurred, but 
these somatic mutations do not affect the gametes and can not be passed on to the next 
generation. However, in the case of germ-line mutations in the sex cells, mutant gametes 
are produced and the mutation can be transmitted to the next generation. However, some 
environmental factors such as ionising radiation and chemicals can increase the rate of 
mutation. In some parts of the genome, due to presence of methylated cytosine residues, 
the rate of mutation is high and deamination of this base produces thymine (T), which is 
not recognisable by the DNA repair system.
Point mutations involve a single nucleotide pair, or sometimes a few adjacent 
nucleotide pairs, within the DNA. There are two types of point mutations which affect 
gene expression in different ways:
(i) Base substitutions: A particular base pair is replaced by a different base pair. These 
substitutions are known as transitions, where a purine (A, G) replaces for purine and a 
pyrimidine (C, T) replaces for pyrimidine, and transversion when a purine replaces for 
pyrimidine, and vice versa. When one base is changed by another, there are two possible 
choices for transversion, but only one for transition. The base thymine can undergo two 
possible transversions (T to G, or T to A) but only one chance for transition (T to C).
(ii) Frame shift mutations: Since proteins are encoded by a triplet of nucleotides the 
loss or insertions of one, two or four nucleotides in the coding region of a gene will alter 
the reading frame out of sequence. Therefore substitutions, deletions and insertions could 
be the cause of frame shift mutations.
The effect of mutations on the reduction of gene products will be described below:
1.6 .1 . Mutations which affect transcription
(i) Promotor mutation: It has been shown that several point mutations in the promotor
region of a gene either within or adjacent to the promotor sequence could cause reduction
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of a gene product. These mutations emphasises the importance of these highly conserved 
regions of DNA and confirm their proposed promotor function.
(ii) Inversion: This occurs when a region of DNA is back -to- front with respect to its 
normal orientation in the genome. In a patient with the phenotype of 8P thalassemia, in 
which there is no 8 or p globin chain production, an inversion was found. The inversion 
involves a region of DNA between the 8 and y globin genes. There is also a small 
deletion at each end of the inversion.
(iii) Deletion: In most types of a° thalassemia both a  globin genes are lost. In a + 
thalassemia there is a deletion involving chromosome 16 which leaves a single functional 
a  gene. Duchenne muscular dystrophy (DMD) and haemophilia are further phenotypic 
examples of this type of mutation. The main cause for gene deletion is unequal crossing 
over, which occurs in meiosis or mitosis. There are many genes as member of multigene 
families such as colour vision gene family and also alpha and beta globin gene clusters. 
It is possible that two pairs of homologous chromosomes misalign at meiosis or mitosis. 
Unequal crossing over in this situation between mispair chromosomes or sister 
chromatids can lead to gene deletion in one chromosome and gene duplication in another 
chromosome. Duplication of several exons in familial hypercholesterolaemia and also 
unequal crossing over in Alu repeating on the short arm of the X chromosome and Y 
chromosome are further examples of this type of mutation (Lehrman et al. 1987; Rouyer 
etal. 1987).
(iv) Insertion: When one or many nucleotides are inserted at different positions along 
the gene, an abnormal protein results. It has been found that lipoprotein lipase deficiency 
(LPL) may result from gene insertions.
(v) Fusion genes: This type of mutation is a result of abnormal crossing over between 
two non-homologous chromosomes. For example, in colour vision and colour blindness, 
the genes for the red and green pigments lie in a tandem array on the X chromosome, on 
which there is a single red pigment gene and variable numbers of green pigment genes. 
Many of the different forms of the red/green colour blindness result from unequal 
crossing-over between the red and green pigments with the production of different 
numbers of fusion genes (Weatheral 1992).
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1.6 .2 . Mutations which affect mRNA splicing
This type of mutation has been reported in many diseases such as retinoblastoma,
neurofibromatosis type 1, colon cancer, acute intermittent porphyria, thalassemia, breast 
cancer and other disease. However, these types of mutations could be divided into the 
following groups:
(i) splice junction mutations, (ii) cryptic splice site mutations in intron and also in exon, 
(iii) consensus sequence mutations and (iv) mutations in poly A residues.
1 .6 .3 . Mutations which affect translation
The ultimate product of a gene is protein, produced in the cytoplasm by a process
called translation. The following mutations have an effect on this process:
(i) Mutations at initiation codon: Mutation at initiation codon could result in no 
product from the affected gene.
(ii) Nonsense mutations: A number of point mutations, deletions or insertions have 
been reported in different genes which, could make the transcription of a normal gene 
product impossible. All of above mutations are able to produce a premature termination 
codon, resulting in the synthesis of a truncated protein.
(iii) Frame shift mutations: These types of mutations are potentially pathologic, as 
they cause a shift in the translational reading frame of the corresponding proteins. By 
altering the reading frame downstream of the mutation, the polypeptide is often truncated 
due to the formation of a premature termination codon. This type of mutation has been 
reported in many genes.
(iv) Termination codon mutations: If point mutation occurs in the stop codon, a 
longer peptide will result. In this situation, a number of nucleotides which are normally 
located in the untranslated region would integrate in the coding sequence. A new 
termination codon, a few nucleotides down stream of the mutation, will be created.
1 .6 .4 . Repetitive genomic mutations and disease
In the past five to six years a number of diseases have been characterised by the
expansion of a trinucleotide repeat within the coding and non-coding sequences of the 
genes. Examples of this type of disease are presented in Table 1. 1. In some of these 
disease the trinucleotide repeats are within the coding sequence, for example: 
Huntington disease (HD), Spinal and bulbar muscular atrophy (SBMA), or Kennedy
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Disease Location 
of gene
Location 
of repeat
Repeat
sequence
Normal
length
Full
length
Reference
Huntington
disease
4p Coding (CAG)n 9-35 37-
100
*
Kennedy
disease
xq Coding (CAG)n 17-24 40-55 La Spada et 
al. 1991
Spino-
Cerbellar
ataxia
1(SCA1)
6p Coding (CAG)n 19-36 43-81 Orr et al. 
1993
Dentatorubral
pallidoluysian
12p Coding (CAG)n 7-23 49-
>75
Nagafuchi et 
al. 1994
Machado- 
Joseph disease 
(MJD,SCA3)
14q Coding (CAG)n 12-36 67-
>79
Kawaguchi 
etal. 1994
Fragile X site 
A(FRAXA)
Xq 5’ UTR (CGG)n 6-54 200-
>1000
Fu et al. 
1991
Fragile X site 
E (FRAXE)
Xq ? (CCG)n 6-25 >200
Fragile X site 
F
(FRAXF)
Xq ? (GCC)n 6-29 >500
Fragile 16 site 
A
(FRA 16 A)
16q ? (CCG)n 16-49 1000-
2000
Myotonic
dystrophy
(MD)
19q 3 UTR (CTG)n 5-37 50-
4000
Fu et al. 
1992
Friedreich
ataxia
9q Intron (GAA)n 7-22 200-
>900
Campuzano 
etal. 1996
Table 1.1: Presentation of different diseases caused by trinucleotide repeat expansions.
*: The Huntington’s disease collaborative group, 1993
disease, Dentatorubral pallidoluysian (DRPLA), Machado-Joseph disease (MJD). In 
some, such as Myotonic dystrophy (DM), and Fragile X syndromes (FRAX), the repeats 
are located in the non-coding region of the gene.
  9
In patients with MD there is a (CTG)n repeat in the 3 untranslated region of a 
gene encoding a protein kinase. This repeat is polymorphic and varies in size between 5
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and 37 repeats in unaffected individuals, whereas in affected patients there are between 
50 and 4000 CTGs. Relatively little is known about the precise mechanism of the 
mutation process although it has been reported that in FRAX syndrome full mutation 
does suppress the transcription process, resulting in the absence of the encoded protein 
(Me Conike-Rosell et al. 1993) which is associated with mental retardation in affected 
individuals.
1.7. Mutation detection methods
The identification of mutations in DNA is an important goal in research, and also
in diagnostic laboratories. Based on the nature of mutations two major groups of 
techniques can be used: (i) identification of known mutations and (ii) identification of 
unknown mutations.
1. 7.1. Identification of known mutations
The presence of known mutations can be searched using the following methods:
1 .7 .1 .1 . Allele-specific oligonucleotides (ASO)
This technique is based on the hybridisation between target DNA and
oligonucleotide probes. This method takes advantage of the difference in stability of 
hybrid probes with target DNA that may or may not match perfectly (Wallace et al. 
1979). Two oligonucleotide probes with about 20 base pairs are required. One has 
normal sequences and the other one has mutant sequences. The normal probe hybridises 
to the normal DNA but not to the mutant DNA and this is true for the mutant probe. 
Both radiolabelled or fluorescent labelled probes can be used. This technique does not 
require electrophoresis but two normal and mutant probes are required. This technique 
has been applied to many diseases such as thalassemia and haemophilia.
1. 7 .1 .2 . Amplification refractory mutation system (ARMS)
This technique was described for the first time by Newton et al. in 1989. It was
based on the fact that PCR elongation requires a specific 3’ end and DNA Taq 
polymerase lacks the 3’ exonucleolytic proof reading activity. In practice, two 
independent PCR amplifications for each patient with a wild-type or mutant primer and a 
common primer should be performed. Internal primers are added in the same reaction as 
a control. By single PCR amplification a result is obtained. This is a very good method 
for detection of common mutations. By using different mutant primers many
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mutations can be screened in a single PCR reaction.
1. 7 .1 .3 . Artificial introduction of restriction sites
This technique is based on the fact that mutations can usually create or abolish
sites for a particular restriction enzyme. Otherwise, a restriction site can be introduced to 
the 5’ end of the primer. (Cohen and Levinson, 1988). In this method an artificial 
restriction site is introduced at the 5’ end of the primer, with one base pair mismatched 
close to the site of mutation. The presence of the mutation will make the proper 
recognition site for a particular enzyme. Digestion of the PCR products followed by 
electrophoresis will identify the presence or absence of the mutation in DNA.
1. 7. 2. Identification of unknown mutations
The choice of the most appropriate screening technique is influenced by the size
and structure of the gene and also the nature of the mutation in question. The spectrum 
of mutation ranges from visible chromosome rearrangements to single base substitutions. 
Therefore, the identification of unknown mutations is divided into two different groups;-
(i) identification of large alterations and (ii) identification of single base change and/or 
small sequence alterations.
1 .7 .2 .1 . Identification of large gene alterations
A large gene alteration is a mutation in which more than 500 bp of the gene is
rearranged (Grompe, 1993). This type of mutation could be detected by the following 
methods:-
Molecular cytogenetic techniques:
In the last few years cytogenetic analysis has been improved by using fluorescent 
in situ hybridisation (FISH) techniques and also comparative genomic hybridisation 
(CGH). By using these techniques, micro-deletions or insertions and also aneuploidy 
could be detected. In brief, FISH labelled DNA probes are hybridised to the chromosome 
in interphase or to metaphase spreads. This technique is particularly suited for the 
detection of chromosomal rearrangements that can not be detected by conventional 
cytogenetics. CGH is a modified FISH technique in which differentially labelled test and 
reference DNAs are co-hybridised on normal target metaphase chromosomes to assay 
copy number differences (Kallionieemia et al. 1992).The smallest possible chromosome 
abnormality that CGH will detect has not yet been defined. This technique has the
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potential to provide genome wide screening for complex chromosome abnormalities, 
particularly in solid tumours, in a single experiment and does not require metaphase 
spread from affected individuals.
Southern blot hybridisation
This technique was developed by E. Southern in 1975 and is based on DNA 
digestion by restriction enzymes followed by agarose gel electrophoresis and then 
hybridisation with radiolabelled probe. By using the appropriate enzyme and probe large 
alterations in the gene may be detected by the presence or absence of extra bands or 
alterations in band intensities, in the case of heterozygous status in autosomal dominant 
diseases. No detailed of knowledge of the structure of a gene is required. This technique 
has been used to detect trinucleotide repeat expansions in patients with myotonic 
dystrophy and also in Fragile X (Fu et al. 1991, Harly et al. 1992).
Pulsed field gel electrophoresis (PFGE)
This technique is in principle, very similar to Southern blotting. Gel 
electrophoresis in conventional Southern blotting can not separate DNA fragments more 
than 20 kb. Larger fragments, of 100-500 kb, can not pass through the pores of the gel. 
This method is based on the periodical change of the orientation of the electrophoretic 
field. Therefore, the large molecules must re-orientate and find a path through the gel 
matrix in other direction. The larger molecules require longer time to re-orientate than 
shorter ones. This allows the resolution of DNA fragments of 100-1000 kb in size, and 
even larger. The resultant gels can be blotted and hybridised to the appropriate probe. 
PFGE allows the identification of major deletions and also chromosomal rearrangement 
in a single experiment.
Multiplex PCR
The structure and sequence of a gene is required for this technique. In multiplex 
PCR, amplification of several segments (usually up to 5-6 segments) could be carried 
out in a single PCR reaction. Deletions are indicated by the absence of some of the 
bands in the multiplex pattern in homozygous status. In autosomal dominant diseases 
deletions are seen as 50% reduction of band intensities in a quantitative analysis of the
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multiplex PCR reaction. Multiplex PCR has been used in screening for deletions in 
DMD in which 60% of cases represent deletions (Grompe, 1993).
1. 7 .2 .2 . Identification of single base or small sequence alterations
These methods include: single strand conformational polymorphism
(SSCP)(Orita et al. 1989), heteroduplex analysis (HA) (White et al. 1992), denaturing
gradient gel electrophoresis (DGGE) (Fischer and Lerman, 1983; Myers et al. 1985),
chemical cleavage of mismatch (CCM) (Cotton et al.1988), protein truncation test (PTT)
( Roest et al. 1993 ) and direct DNA sequencing (Gyllensten, 1989).
Single strand conformational polymorphism (SSCP)
The SSCP is based on the migration of single stranded DNA (ssDNA)
structure(Orita et al. 1989). ssDNA has a tendency to fold up and form complex
structures. The electrophoresis mobility of such structures on the gels depends on their
conformations, and also on their lengths. SSCP is a PCR based method, and after
denaturing radiolabelled or nonradiolabelled PCR, products o f a desired region of
genomic DNA or RNA were loaded on nondenaturing polyacrylamide or MDE gels.
Alteration in a DNA sample that differs from a standard DNA can be identified by a
comparative mobility shift during gel electrophoresis, if the base change results in a
change of conformation. This method is the most simple and popular technique in
molecular biology. Its efficiency has an inverse correlation with the size of the PCR
products.
Heteroduplex analysis (HA)
The HA is based on the fact that the mobility of heteroduplexes is less than
homoduplexes on the polyacrylamide gel (White et al. 1992). The efficiency of this
method for fragments less than 200 bp is very high and alteration such as insertions,
deletions and single base substitutions are detectable. The gel for HA is exactly the same
as SSCP.
Denaturing gradient gel electrophoresis (DGGE)
The DGGE is another PCR based method in which DNA migrates through a
gradient gel. In this method the gradient of denaturant is increased from one side of the
gel to the other. Migration is continuous until the heteroduplex DNA reaches a position
in the gel where the strands melt and separate, after which the denatured DNA does not
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migrate any further. This method is able to detect a single base pair difference between 
normal and mutant DNA.
Cleavage of mismatch analysis
These techniques are based on the cleavage of mismatches between target DNA
and a probe. The three different forms of this group of techniques are: (i) chemical 
cleavage mismatch analysis (ii) Rnase A cleavage (iii) enzyme mismatch cleavage.
(i) Chemical cleavage mismatch analysis(CCM)
The CCM is based on certain chemicals which can react with single stranded 
bases of DNA to make them susceptible to cleavage by piperidine (Cotton and Cambell., 
1989). In CCM, the radiolabelled probe from the normal individual will hybridise with 
test DNA and can be modified by hydroxylamine and osmium tetroxide. The modified 
base will cleaved by piperidine. After chemical treatment, the products are loaded on the 
denaturing polyacrylamide gels, followed by electrophoresis and autoradiography.
(ii) Rnase A cleavage
This technique is based on the fact that Rnase A is able to cleave a mismatch 
base in a single strand RNA probe. It was described for the first time by Myers in 1985. 
In this method labelled wild- type RNA probes hybridise to double stranded target DNA 
to form RNA/DNA duplexes. In the case of mutation the enzyme will recognise and 
cleave single -stranded RNA at the site of the mismatch. The cleaved product is 
separated by denaturing polyacrylamide gel electrophoresis and then by autoradiography. 
The efficiency of this method is about 50% (Grompe, 1993). By using sense and anti­
sense strands of an RNA, each mutation has two chances of being detected by Rnase A 
cleavage.
(iii) Enzyme mismatch cleavage
The basis of this technique is the fact that bacteriophage resolvase is able to 
recognise and cleave mismatched nucleotides (Mashal et al. and Youil et al. 1995). This 
enzyme is able to cleave branched DNA and can cleave DNA at the site of mismatch. 
Wild-type radiolabelled DNA hybridises to target DNA and the site of mismatch in 
heteroduplex DNA is cleaved by resolvases. The cleaved products are separated on 
nondenaturing polyacrylamide gel, followed by electrophoresis. This technique has this 
advantage to predict the nature and the precise position of mutation and of being 
applicable to fragments of more than 1 kb. The sensitivity of this technique is about
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90%, and it is able to detect all possible mismatches as well as deletion mutation.
Protein truncation test (PTT)
The PTT is one of the newest methods for detecting any forms of frame shift
mutation resulting in premature terminations of translations (Roest et al. 1993). DNA or 
RNA can be used with this technique. In large exons, like the exon 15 in the APC gene 
or exon 11 in the BRCA1 gene, the DNA can be used, otherwise the RNA should be 
converted to cDNA by RT-PCR and then used for PTT. The 5 site of the forward primer 
should carry a signal for transcription and translation. The cDNA or DNA is put into a 
coupled transcription-translation cell free system, which uses the T7 promoter to make 
mRNA, and the translation initiator to translate it. The protein product is then run on a 
SDS-PAGE, followed by autoradiography. Truncated protein results in a shorter protein, 
compared to the standard. The size of truncated protein reveals the position of the 
mutation.
Direct DNA sequencing
The direct DNA sequencing is the final step for all positive screening results.
For some small genes, like p i6 and the globlin genes, this could be used as a screening 
method. Double or single stranded PCR products could be used for this technique. The 
two main methods for direct DNA sequencing are based on the chemical method 
developed by Maxim and Gilbert (1977), and the enzymatic method which was 
developed by Sanger et al. (1987).
1.8. Spectrum of mutations in mismatch repair genes
Five different mismatch repair genes that predispose to HNPCC have been
identified. Germ-line mutations have been reported in the hMSH2 and hMLHl genes. 
Mutations in hPMSl and hPMS2 have been described in only one kindred each 
(Nicoladies et al. 1994). To date, no germ-line mutations have been described for a fifth 
DNA mismatch repair gene, GTBP/pl60 (Papadopoulos et al. 1995). However, since 
1993 a total of 33 germ-line mutations including missense mutations (Leach et al. 1993; 
Liu et al. 1994; Moslein et al. 1996, Froggatt et al. 1996), nonsense mutations (Leach et 
al. 1993; Buerstedde et al. 1995; Mostein et al. 1996), small deletions (Kolodner et al. 
1994; Wijnen et al. 1995; Buerstedde et al. 1955; Mostein et al. 1996), small insertions 
(Lazar et al. 1994; Wijnen et al. 1995), large deletions including one exon skipping
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(Leach et al. 1993), and multiple exon skipping (Liu et al. 1994, 1995), and insertions 
(Liu et al. 1996), have been reported in the hMSH2 gene. About 75% of these mutations 
are out-of-frame mutations resulting in truncated proteins. Only a small fraction of the 
mutations have been missense mutations. However, two/thirds of the mutations reported 
in this particular gene could cause truncated proteins. Although, some clusters of 
mutations are present in the exon 7 and exon 12, no common mutation or hotspot has 
been reported in this gene to date. A summary of mutations found in the hMSH2 gene is 
presented in appendix 1. A high percentage of mutations in the hMSH2 gene result in 
truncated proteins. This suggests that the protein truncation test may be the preferred 
method to screen for hMSH2 defects. Missense mutations could be harder to interpret 
because not every change in amino acid sequences alters the function of the protein. 
HNPCC appears to follow the Knudson model (two hit model). According to this model, 
a heterozygous mutation in one of the mismatch repair genes in the germ-line gives a 
predisposition to cancer. Tumour development requires inactivation of the wild-type 
allele by somatic mutation or its loss.
Distribution of mutations in HNPCC and sporadic cases are different, only a 
small fraction of sporadic CRCs with RER+ phenotype carry a mutation in MMR gene 
(Figure 1.8). Leach et al. (1993) reported four mutations, one polymorphism and one 
somatic mutation. Two mutations causing truncated proteins are due to exon 5 skipping 
from transcripts, and the other a C to T transition that changes arginine to a stop codon. 
Kolodner et al. (1993) reported a mutation at position -6 in intron 12 in the hMSH2 gene. 
In this paper, the sequence of the hMSH2 was also reported, and due to this mutation it 
was concluded that this is the susceptible gene for colorectal cancer. Liu et al. (1994) 
reported missense mutations in exons 8 and 5. Exon 15 skipping from transcripts was 
reported as well as a deletion from nt 1981- 2073, due to a C to T transition that creates a 
new splice donor site within exon 12. A
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Figure 1. 8 Comparison of mutations in HNPCC and sporadic colorectal cancer.
deletion in exon 13 was also found, and another deletion from exon 8 to exon 15.
They were not able to find the cause of the last two mutations at the genomic 
level. However, five of six mutations reported by Liu et al. were frameshift mutations. 
Kolodner et al. (1994) reported a 2 bp deletion in exon 12 in a Muir-Torre syndrome. 
Liu et al. (1995) reported in colorectal cancer patients aged less than 35 years, missense 
and nonsense mutations, in exons 11 and four respectively. Froggatt et al. (1995) 
confirmed exon five skipping from transcripts by an enzymatic assay, and claimed that it 
is a common mutation in the American people and North England population. Wijnen et 
al. (1995) reported seven mutations, all of which are frameshift mutations. He also 
reported three exonic and one intronic polymorphisms. Buerstedde et al. (1995) reported 
one frame shift and one point mutations in exons 3 and 7 due to a two base pair deletion 
and a C to T substitution respectively. He also reported two polymorphisms in intron 10 
at positions -8 and +10. Moslein et al. (1996) studied 6, 19 and 20 patients including 
sporadic, familial and HNPCC cases, respectively. She reported no mutation in sporadic 
cases, two mutations in familial (10%) and also five mutations in HNPCC (25%) cases. 
However, mutations were not found in 50% of HNPCC cases. Contribution of mismatch 
repair genes in HNPCC families is shown in Table 1.2 (Liu et al 1995). In the large 
study carried out by Liu et al. (1996) HNPCC mutations were not detected in 14 of 48 
families, although in some HNPCC kindreds, genetic linkage to hMSH2 or hMLHl could
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be demonstrated. However, a deletion was found in the exon 7, and a 173 bp insertion in 
the same exon, both of these mutation were frameshift mutations. The cause of these 
mutations at genomic level could not be found. In this paper, a three bp deletion in exon 
12 and exon 5 skipping from the transcript were also reported.
Table 1.2: Contribution of repair genes in HNPCC
Gene Chromosome Contribution to HNPCC
hMSH2 2P21-22 31%
hMLHl 3P21 33%
hPMSl 2q31-33 2%
hPMS2 7p22 4%
Two frameshift mutations due to deletion of CA in exon 10, and a TG insertion in 
exon 12, were reported by Nystrom- Lahti et al. (1996). Luce et al. (1995) detected 
truncated proteins for either hMSH2 or hMLHl in 6 of 12 HNPCC kindreds, but reported 
the nature of the underlying genomic DNA defect for only 2 of them ( this will be 
discussed later o n ). A C to T transition in codon 622 (exon 12) and the same alteration 
in codon 406 in the exon 7 was reported twice. Deletion of codon 596 in the exon 12 was 
reported three times. The reminder of the mutations were only reported once. Therefore, 
about 90% of mutations were reported only once, suggesting that mutations in this gene 
are population related. No germ-line mutations have been reported in exons one, two, 
five, eleven, and fifteen (see appendix 1). The pattern of mutations in hMSH2 and 
hMLHl are compared to each other in Figure 1.9. As illustrated, the pattern of mutations 
in both member of the mismatch repair family looks the same, although frameshift 
mutations in HMSH2 are slightly higher than hMLHl(84% in contrast of 60%). However, 
most of the mutations in these two genes predicted to cause truncated proteins, while 
substitution in hMLHl is more frequent than hMSH2.
35
30.0%
_______ hMSH2_______________  hMLH1__________
■  Frameshift □  Substitution □  Small deletions & insertions
Figure 1.9. Comparison of germ-line mutations in two members of mismatch repair 
family.
Recurrence of mutations in hMSH2
The genetic heterogeneity of the disease, the complexity of the genes involved
and the wide intragenic distribution of the germ-line mutations make a low chance for
recurrence of mutations in mismatch repair genes. At the time of writing this section, not
more than 80 germ-line mutations were reported for the two main genes which
predispose to colorectal cancer and among them few germ-line mutations have been
reported by different groups. These mutations are discribed below:
There is a cluster of mutations in exon 7 and 12 but there is no sign of a hotspot
in this gene. A number of mutations have, however, been reported by different groups
including: (i) exon 5 skipping from transcript due to A to G transition at position -3,
resulting in-frame-deletion of exon 5 (Liu et al. 1995; Froggatt et al. 1995). As will be
discusses later, it is believed that this is a founder mutation in the gene, (ii) three base
pair deletion at codon 532 resulting in-frame-deletion of asparagine reported by Liu et al.
1996; Borresen et al. 1995 and Mary et al. 1994 (iii) a C to T transition at codon 621
resulting Arginine to stop codon reported by two groups, Liu et al. 1995; Kolodner et al.
1994. (iv) exon 15 skipping from transcript due to G to T transversion at position -1
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(Wijnen et al. 1995; Liu et al. 1995) resulting in a premature termination codon within 
exon 16. Exon 2-6 deletion from transcript has been reported by Kohonen-Corish et al. 
1996. Deletion of exons 2-6, and also exon 15 skipping from transcript due to a novel 
splice site mutation, which have been found in this study could be further examples of 
recurrence of mutations in this gene.
Absence of a common mutation in HNPCC’s genes make it difficult for 
diagnostic laboratory to screen HNPCC families and their relatives who are at risk.
Founder mutations in the HNPCC families
Founder mutations have arisen once and subsequently passed on through
successive generations to present time. To date, three founder mutations have already 
been detected in HNPCC families. Two of them are in the hMLHl and the third one is in 
the hMSH2 gene. These mutations are: (i) a point mutation at splice acceptor site of exon 
6 in the hMLHl gene, resulting in the deletion of exon 5 from the transcript. This was 
found in five Finnish families (Lahati et al. 1995). (ii) Genomic deletion of exon 16 in 
the hMLHl gene, which was found in 14 Finnish families (Lahati et al. 1995) (iii) point 
mutation at splice donor site of exon 5 in the hMSH2 gene, resulting in the deletion of 
exon 5 from the transcript (Leach et al. 1993; Froggatt et al. 1995). This mutation was 
found in three Anglo-Saxon families and has been reported from England. Each of the 
three mutations is expected to lead to truncation of the protein through the loss of one 
exon. It has been shown that in the Finnish population, exon 16 mutation of MLH1 is an 
ancestral mutation, as most families carrying this mutation come from the same 
geographical region. The exon 6 mutation of MLH1 has so far been found in five 
unrelated families. Their geographical origins are confined to a small region in southern 
Finland. Moisio et al. (1996) has suggested that the spread of mutation 1 started 16-43 
generations (400-1,075 years) ago and mutation 2 some 5-21 generations (125-525 years) 
ago. The MSH2 founder mutation that results in the skipping of exon 5 has been 
observed in three families in North America, all of whom report Anglo-Saxon heritage 
(Leach et al. 1993). It has also been reported in 12% of English kindreds (Froggatt et al.
1995) suggesting a common ancestor between North American and English HNPCC 
kindreds.
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1. 9. The aims of this study
1. To identify germ-line mutations in the hMSH2 genes of patients with colorectal cancer 
in the West of Scotland.
2. To assess the level of microsatellite instability in the tumours as a first screening step.
3. To characterise fully the mutations found, and determine if a genotype/phenotype 
correlation exists.
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CHAPTER nafo 
MATERIALS AND METHODS
2.1. Patient selection
In this project, two groups of patients were identified: those undergoing
surgery for colorectal cancer (who may or may not have a family history) and those 
with a family history of colorectal cancer who had been seen in a cancer genetics 
clinic. From 30 patients who were undergoing surgery, 32 normal and tumour tissues 
were available, including one patient with three tumours at different sites of her 
colon. There were 14 males and 16 females, age range 23-76 years, 47 RNA samples 
from some of the above patients and patients with family history of colon cancer, 
including 25 males and 22 females, age range 17-76 years, were also available for 
mutation analysis. None of the families in this study was large enough for linkage 
analysis (see appendix 2 for more information).
2.2. DNA extraction
2 .2 .1 . DNA extraction from peripheral blood
DNA was extracted from the whole fresh blood as described by Kunkel et
al, (1977).
2 .2 .2 . DNA extraction from solid tissue
DNA extraction was carried out from tumour and normal solid tissues
(Miller et el., 1988 ). A small amount of tissues were scaled (0.1 gr) and crushed with 
a mortar and pestle with 3 ml nuclei lysis buffer (10 mM Tris-Hcl, 400 mM NaCl 
and 2 mM Na2EDTA, pH 8.2) and 200pl SDS 10% and lOOpl proteinase K (10 
mg/ml). The mixture was transferred into a clean 20 ml universal tube and incubated 
in a water bath at 55°C for overnight. The digested products mixed properly by 
vortexing for about one minute and centrifuged at 25000 rpm for 15 minutes. The 
supernatant was transferred into a clean universal tube. Next, one ml NaCl 6M, was 
added and mixed vigorously by vortexing and then centrifuged for 10 minutes at 
2500 rpm. The supernatant was then transfered to a clean universal tube, and exactly 
two volumes of room temperature absolute ethanol or equal volume of propanol 2-ol 
was added and mixed gently by inversion. The DNA exploded out from the liquid 
phase. The DNA washed with 70% ethanol and dried for about 10 minutes and then 
was dissolved in appropriate volume of TE buffer (10 mM Tris-Hcl, 0.2 mM
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Na2EDTA, pH 7.5) or autoclaved distilled water. The DNA was allowed to dissolve 
for 2 hours at 37° C before quantitating.
2 .2 .3 . DNA extraction from paraffin embedded tissue
In some cases DNA extractions were carried from paraffin embedded normal
or tumour tissues. The section must be dewaxed completely before digestion by 
proteinase K. A small amount of tissues (0.1 g) were cut off and weighed from 
paraffin block and used for DNA extraction. The tissue was placed into a 1.5 ml 
eppendorff tube and 1 ml xylene added to it, and vortexed vigorously for about three 
minutes. This step is important to dissolve paraffin by the xylene. The tube spun 
down in a bench top centrifuge (eppendorff centrifuge) for 3 minutes at frill speed, at 
room temperature. The tissue was pelleted at the bottom of the tube and xylene 
removed by pipetting. The above step was repeated once more to dewax the paraffin 
properly, then the tissue was washed out by 1 ml of absolute ethanol and spun down 
for 3 minutes at full speed in a top bench centrifuge. The ethanol was poured down 
the sink. The above step was repeated once more. The tissue was dried in the same 
tube or in the plastic boat at room temperature for about 10 minutes. The tissues were 
chopped by scalpel, and then crushed by the mortar and pestle by 3 ml nuclei lysis 
buffer, 200pl 10% SDS and 100 pi proteinase K (10 mg/ml) as described in section
2.2.2. The rest of procedures were as described for DNA extraction from solid 
tissues. The only difference was that the incubation time for proteinase K digestion at 
55°C increased up to 72 hours.
2.3. Polymerase chain reaction (PCR) of microsatellite sequences
Genetic instability was detected by comparing the results from tumour DNA
with those from normal DNA. The sequence of markers, size, and anneealing 
temperature are presented in Table 2.1.
Table 2.1: The sequence of microsatellite markers and the condition of the PCR. 
Name Sequences Expected size Annealing T.
D18S34 CAG AAA ATT CTC TCT GGC TA 110 bp 55°C
(wl -2 ) CTC ATG TTC CTG GCA AGA AT
635,636 TTG ACC TGA ATG C AC TGT GA 100 bp 55° C
TTC CAT ACC TGG GAA CGA GT
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D3S240 CCA TGT CCC ATA TCT CTA CA 92 bp
(W3-4) TGA AAT CAC TGA TGA CAA TG
LPLCA.A GAG TAA AAG ATG ATC CAG TGT C 171-175 bp 
CAA CCC AGA TTT GAG CTA CGT
57° C
57° C
LPLCA,B CAT GAA TTA GAA ATC CAG TGG G 106-134 bp 
AGG TGA TGT CCC AGA GGA AC
57° C
D2S123 AAA CAG GAT GCC TGC CTT TA 197-227 bp
GGA CTT TCC ACC TAT GGG AC
55° C
D2S119* CTT GGG GAA CAG AGG TCATT 214-232 bp
GAG AAT CCC TCA ATT TCT TTG GA
60° C
D3S1293 ACT CAC AGA GCC TTC ACA
CAT GGA AAT AGA ACA GGG T
116-144 bp 53° C
D13S160 CGG GTG ATC TAA GGC TTC TA 250 bp 
GGC AGA GAT ATG AGG CAA AA
60° C
D8S282 GGG CAC AGG CAT GTG T 260-272 bp
GGC TGC ATT CTG AAA GGT TA
58° C
D2S136 AGC TTG AGA CCT CTG TGT CC 91-111 bp
ATT CAG AAG AAA CAG TGA TGG
53°C
D3S1298 AGC TCT CAG TGC CAC CCC 194-220 bp
GAA AAA TCC CCT TGT GAA GCG
53° C
D2S378 TGT GGG CTG GTC AGA TAT TC 203-217 bp
CGC TAG GAT CAC TAT GTT TTG C
53° C
* The final MgC^ concentation for this marker was 3.0mM.
2. 4. RNA extraction
RNA extraction from fresh peripheral blood was carried out, using either acid
guanidium-thiocyanate (Fluka) or Trizol solution (Gibco BRL).
2 .4 .1 . RNA extraction from whole blood using acid guanidium - thiocyanate
RNA extraction from whole fresh blood was carried out using acid guanidium
- thiocyanate - phenol - chloroform (Chomczynski et al. 1987).
RNA extraction from EDTA treated blood had a much better yield than heparinized 
blood.
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Lymphoblasts from whole blood were separated using Histopaque 1077 
(Sigma). Histopaque should keep at +4°C, but half an hour before use should be left 
at room temperature to set up and then 5 ml was poured into a cleaned universal tube. 
Five ml EDTA treated fresh whole blood was gently poured on to it by pasteur 
pipette, and centrifuged at room temperature for 30 minutes at 1500 rpm. Three 
layers were observed, upper layer: Histopaque, middle layer: lymphocytes and at the 
bottom of the tube were red blood cells. Lymphocytes or buffy coat from the middle 
layer were transferred by a clean pasture pipette to another universal tube, and 
washed once with cold phosphate buffer sulphate (PBS), then centrifuged at 14000 
rpm at +4°C for 20 minutes. Lymphocytes pellets were resuspended in one ml of 
solution D (4M guanidium thiocyanate, 25 mM sodium citrate, 0.5 % sarkosyl, 0.1 M 
beta - mercaptoethanol). Next, they were transferred equally into two eppendorf 
tubes and the following solutions were added to each tube: 50 pi of 2M sodium 
acetate, 500 pi of phenol water saturated and 100 pi chloroform-isoamyl alcohol 
mixture (49:1). The tubes were very gently mixed by inversion, and then centrifuged 
at 14000 rpm at 4 C for 20 minutes in a top bench centrifuge. The top aqueous phase 
that which contained RNA was very carefully transfered into another 1.5 ml 
eppendorf tube. Extreme care should be taken in this stage, as the middle layer 
content DNA and could be cause DNA contamination. 500pl propanol-2ol or 
isopropanol was added to the aqueous layer and mixed very gently by inversion three 
times. The mixture was kept for at least one hour a -20°C, or overnight and then 
spun down at +4°C at 14000 rpm for 20 minutes. The RNA pellet was resuspand in 
150 pi solution D. Then 150 X\ isopropanol was added to the mixture and left at 
least for an hour at - 20°C. Then, the tube spun down at 14000 rpm for 10 minutes. 
The RNA pellet was washed with 200 pi 70% ethanol and spun down at 14000 rpm 
for another 10 minutes. The RNA pellet was dried at room temperature for 10 
minutes and dissolved in 30-50 pi DEPC treated water at 55°C for 5 minutes and was 
then stored at -40° C for further analysis.
2. 5. Oligonucleotide design
The oligonucleotides are short sequences of nucleotides usually from 18 to
25 bp. One set of primers is required for amplification of a region from DNA. The
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sequence of each primer is complementary to opposite strands of the region of DNA. 
The primers are designed so that each of them extends the synthesis of DNA towards 
the other. Thus primer “F” (F stands for forward primer) directs the synthesis of a 
strand of DNA that can then be primed by primer “R” (R stands for reverse primer) 
and vice versa. This results in the de novo synthesis of the region of DNA flanked by 
the two primers.
In this project, oligonucleotides were designed using the computer 
programme, OLIGO version 3.4 (© Wojciech Rychlik; Medprobe). OLIGO is a 
program which calculates free energy (AG), hybridisation temperature and secondary 
structure of DNA or RNA based on the highly accurate measurement of nearest 
neighbour AG values.
A good sequencing primer or hybridisation probe should meet the following criteria: 
( i ) be highly specific for the intended target sequence and not base-pair to other 
regions within the template, (ii) be non self-complementary and not form dimers, (iii) 
form stable duplexes with a template under appropriate conditions.
All the oligonucleotides were synthesised on an ABI 391 automated DNA 
synthesiser. Ammonium hydroxide was used to elute the primers from the solid 
support and deprotection was carried out at 55°C for 12-16 hours. In brief, one ml of 
ammonium was used for deprotection. In every 30 minute, 100 pi of ammonium was 
injected into the column of the primer. Another one ml of ammonium was used to 
wash any residue of oligonucleotides from the column. The 2 ml ammonium was 
collected into the 2 ml screw cap tube, and incubated for O/N at 55°C. The tube was 
left on ice for 15 minute, and then 150 pi of aliquot of primer was taken and left in 
the fume hood for rapid evaporation. The concentration of oligonucleotides was 
measured by spectrophotometry and diluted as described previously. The sequences 
of the primers that have been used in this study are shown in the Table 2. 2.
Table 2.2. The sequences of the primers that have been used in this study for 
individual exon amplification in the hMSH2 gene. The primers which have been 
designed by OLIGO for this project is marked by (*).
Exon Sequence References
1 GCT TAG TGG GTG TGG GGT C* 
GGG AAA GGA GCC GCG CCA*
2 GAA GTC CAG CTA ATA CAG TGC 
CTT CAC ATT TTT ATT IT T  CTA CTC
Kolodner et al., 1994
3 GCT TAT AAA ATT TTA AAG TAT GTT C 
GCC TTT CCT AGG CCT GGA ATC TCC
Kolodner et al., 1994
5 GGC ACC AGT GGC TAT AGG* 
GTT AAG GGC TCT GAC TGC*
6 GCT TGC CAT TCT TTC TAT TT* 
CCT CTC CTC TAT TCT GTT CT*
7 GAC TTA CGT GCT TAG TTG 
GTA TAT ATT GTA TGA GTT GAA GG
Kolodner et al., 1994
8 ATC TTT TTA TTT GTT TGT TT* 
CTA GTC CAT ACG TTA TAT GA*
9 ATA GGA TTT TGT CAC TTT GTT* 
GAA TTA TTC CAA CCT CCA A*
GTC TTT ACC CAT TAT TTA TAG G 
GTA TAG ACA AAA GAA TTA TTC C
Kolodner et al., 1994
12 CCT GTT GAC AAT TTC TGT TTT TA 
CAA AGC CCA AAA ACC AGG
Kolodner et al., 1994
13 TAT GGG AGG TAA ATC AAC*
TGA GGA TAG AAG CAG TTT*
CGC GAT TAA TCA TCA GTG 
GGA CAG AGA CAT ACA TTT CTA TC
Kolodner et al., 1994
14 TGT TAC CAC ATT TTA TGT GA 
TTT CCC ATT ACC AAG TTA C
Kolodner etal., 1994
15 TGC TGT CTC TTC TCA TGC TG* 
ACT TCT TTG CTG CTG GTT CC*
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In the course of this study, the whole coding sequence of the hMSH2 was sequenced 
from different patients. The primers used for sequencing of the RT-PCR is shown in 
Table 2. 3, the primers designed by OLIGO as marked by (*).
Table 2.3. Primers used for sequencing of RT-PCR products in the hMSH2 gene.
Name Direction Exon Sequences
135* S 1 ACC GGG GCG ACT TCT ATA CG
248* S 1 CCA GGG GGT GAT CAA GTA CA
250* AS 1 ATG TAC TTG ATC ACC CCC TGG G
398* AS 2 CAC AAC ACT CTG CAG ATT CTT T
440* AS 2 AGA AGC CTT ATA TGC CAA AT
SC2A* S 3 GGC TTC TCC TGC CAA TCT CT
SC3A* S 3 GGT TGG AGT TGG GTA TGT GG
576 S 3 CCA CAT ACC CAA CTC CAA CC
190 S 3 TCC TCA TCC AGA TTG GAC C
SC2B* S 3 CTC CAG CAG TCT CTC CTC CG
SC4A* S 4 TGA AAG GCA AAA AGG GAG AG
SC3B* AS 4 CTC TCC CTT TTT GCC TTT CA
252 S 4 GAT GAA TAG TGC TGT ATT GCC
291 S 5 TGA CTA CTT TTG ACT TCA GCC
960* AS 5 GGC TGA AGT CAA AAG TAG TCA
1170* AS 7 AAA GTC TGC CTC AAT TCT GC
404 S 7 GTT ACC GAC TCT ATC AGG G
1351* S 8 ACC AGA AAT TAT TGT TGG C
460 S 8 GGA TCA GGT GGA AAA CCA TG
1492* AS 9 ATT CAC TGA GAT TAG GAT
513 S 10 CTG GAT TCC AGT GCA CAG
571 S 10 GAA GAA GCC CAG GAT GCC
1720* AS 10 AAT TTA ACA CCA TTC TTC
1979* S 12 TCC TAA TGA CGT ATA CTT TG
2166* S 13 GCA GAA GTG TCC ATT GTG G
718 S 13 AAT TGA AAG GAG TCT CCA CG
2350* S 14 GGG AAG AGG AAC TTC TAC CT
769 S 14 ATT GCA ACA AAG ATT GGT GC
810* S 14 GCA TGT TTG CAA CCC ATT TT
811 S 14 AAC TAT GCT TTA TCA GGT GA
2551* S 15 TTC ATG TTG CAG AGC TTG CT
812* AS 15 AGC AAG CTC TGC AAC ATG AA
2625* S 15 GGA ACC AGC AGC AAA GAA GT
2626* AS 16 CAG GTT CCA CTT TGT TTA CG
2765* S 16 CTG AAG TAA TAG CAA AGA AT
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2. 6. PCR techniques
2. 6.1. Long PCRs
There is no definition for long PCR products. In this project any PCR
products more than 1000 bp were assumed to be long PCR products. As a rule, for 
each 1000 bp one minute is required for extension. Obviously, for amplification of 
very long target of DNA, many hours are required. On the other hand, Taq DNA 
polymerase is not efficient after 4 hours, therefore either a modification in the 
normal profile of PCR or a special Taq is required.
Normal Taq polymerase is not able to amplify a long PCR product of more 
than 3 Kb. Some commercial kits for long PCR products are available as GeneAmp 
XL PCR kit (Perkin Elemer), Taqplus™ DNA polymerase (Stratagene).
In this project, two fragments in RT-PCR were 1.8 Kb (fragment one) and 2.2 
Kb (fragment two). Both of these fragments were amplified using normal Taq 
polymerase (Perkin Elemer). The only modification from the normal PCR profile 
was the increasing time in the extension for 150 seconds ( two min and half).
The longest PCR products amplified in this project were 4.4 Kb (intron 15). 
In this PCR the extension time was 4 1/2 minutes, and the total volume of reactions 
was 20 pi. A mixture of normal Taq polymerase (Perkin Elemer) and another 
Taqplus DNA polymerase (Stratagene) was applied. A combination of normal Taq 
DNA polymerase (two ratios) (Perkin Elemer) and one ratio of Taqplus DNA 
polymeraase (Stratagene) was applied. The reaction buffer was the ordinary 10X 
Perkin Elemer buffer as described in 2.2.
2 .6 .2 . Asymmetric PCR amplifications
Single stranded PCR products were generated by asymmetric PCR
amplification as described by Gyllensten and Ehrlich (1988). Asymmetric PCR 
products were used for direct DNA sequencing. After amplification of double­
stranded PCR products, the whole products (about 100 pi) were loaded into the low 
melting Nusieve agarose (FMC) gel. The expected bands were excised from the gel 
and incubated at -20°C for O/N. Eight pi of the gel aliquot was used for asymmetric 
amplification, using limited lower or upper primer which was diluted 100 times from 
normal primer. Amplification in a total volume of 50 pi was performed for not less
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than 40 cycles. The asymmetric PCR products were visualised by ethidium bromide 
staining following agarose gel electrophoresis, as will be described later in this 
chapter.
2 .6 .3 . Reverse Transcriptase- Polymerase Chain Reaction (RT-PCR)
Reverse- transcriptase PCR (RT-PCR) amplifications of the hMSH2 cDNA
were performed on the total RNA from whole fresh blood of colorectal cancer 
patients. To synthesise the first strand of the cDNA, three approaches were applied. 
In the first approach specific primer was applied as a downstream primer, in the 
second one oligo (dT) and in the last one random hexamer. Random hexamer was 
the best for synthesising the first strand of cDNA.
The length of the whole coding sequencing of the hMSH2 gene is 2.8 kb and 
has 16 exons. The whole coding sequence of the hMSH2 gene was synthesised as 
either two or three overlapping fragments. The first fragment encompassed codon 1 
to codon 628, and the second fragment encompassed from codon 250 to codon 934. 
In some cases it was not possible to do so due to contamination in the RNA or low 
quality of RNA. In such cases the cDNA was amplified in three overlapping 
fragments.
One microgram of total RNA plus one of the specific primer oligo (dT), or 
random hexamer were used as a downstream primer. The limitation of the specific 
primer was the specific annealing temperature, and it took time to optimise the RT- 
PCR. The disadvantage of oligo (dT) was its inability to amplify further than 1.5 kb 
away from the 3 end of cDNA. Random hexamer was found to have none of these 
disadvantages in my experiments.
RNA and the downstream primer were mixed in one DEPC treated eppendorf 
tube, and incubated at 65°C for 10 minutes. After 10 minutes the tube was 
transferred onto the ice bucket, and the following solutions were added: five pi of the 
first strand buffer 5X (25 mM Tris-Hcl, pH8.3, 375 mMKCl, 15 mM MgC12) 200 
mM dNTPs (dATP, dCTP, dGTP, dTTP), 10 Mm DTT and 2pl (200 U/pl) murine 
malony leukaemia virus-reverse transcriptase (Gibco BRL). Short vortex and 
centrifugation were applied to collect all the contents at the bottom of the tube. The 
tube was incubated for 60 minutes at 40°C. At the end of reverse- transcriptase 5-8 pi 
of the reverse transcript aliquots was used for PCR amplification using Taq
Al
DNA polymerase Perkin elmer) in 30-50 pi total reactions. The cDNA was amplified 
during 35 cycles of PCR. Two large overlapping fragments were amplified, at 95°C 
for one minute followed by 35 cycles thereafter at the same temperature for 30 
seconds, 58°C for one minute and 72°C for 2 minutes and 30 seconds. The final 
extension was 72°C for 10 minutes.
At the end of amplification 3 pi of PCR products was loaded onto 1-1.5% 
SeaKem agarose gels and stained with ethidium bromide, then visualised under U.V. 
light. The rest of PCR products were loaded into the 1.5% low melting agarose gel 
(Nusieve agarose) and expected products were excised from the gel. The excised 
band was transferred into the 1.5 ml eppendrof tube and kept at -20°C for further 
analysis.
2. 7. Purification methods
Purification of PCR products depends on the size of the products. By
purification of PCR products unincorporated dNTPs, primers and enzymes were 
removed. Different methods were applied for purification of PCR products 
including: GENECLEAN II® kit (BIO 101 inc.), 4 M ammonium acetate- 
isopropanol precipitation.
2 .7 .1 . Purification of PCR products using the GENECLEAN II® kit
Purification of PCR products was carried out using a GENECLEAN II® kit
for any products less than 500 bp according to manufacturers instructions. In brief, to 
one volume of PCR products, 3 volumes of Nal were added. The tube was mixed 
and placed at room temperature (rtm) for 15 minutes to allow binding of the DNA to 
the silica matrix. Every 1-2 min the tube was mixed by vortexing to ensure that the 
GLASSMILK stays suspended. Silica matrix and DNA were pelleted by 
centrifugation at 12000 rpm for 5 seconds. The supernatant was poured off into the 
sink. Another centrifugation was applied to collect the remainder of the Nal. The 
white pellet was usually firm enough to remaine intact when pouring out the liquid 
contents of the tube. The pellet was washed twice with cold NEW WASH. The 
supernatant was removed from the second wash, the tube was then spun down for a 
few seconds, and the last bit of liquid was removed. The pellet was resuspended in an 
appropriate volume of TE buffer or distilled water (DW). The tube was incubated for
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5 min at 55°C. Then a brief vortexing was applied. The DNA was pelted by 
centrifugation for 30 seconds. The supernatant containing the eluted DNA was 
carefully removed in a new tube. One pi of eluted DNA was loaded into 1% agarose 
gel to estimate the recovery of DNA. The gel was stained with ethidium bromide 
followed by electrophoresis, then visualised on a UV box. All the materials were 
provided within the kit.
2. 7.2. DNA recovery from agarose gels using the GENECLEAN II® kit
The DNA band was excised from low melting Nusive agarose gel on the UV
box in less than one minute, to minimise damage to DNA. The DNA band was
placed into a prescaled 1.5 microcentrifuge tube. The tube containing the DNA band
slice was weighed, and the weight of the DNA band was determined. Three volumes
of Nal were added to agarose gel and then placed in the tube for 5 min at 55°C. After
a minute or two, the contents of the tube were mixed and returned to the water bath.
After about five min, the agarose gel was dissociated completely. Five pi of
GLASSMILK was added to the tube. The remaining steps are as described in section
2. 5.6. 1.
2.7.3. PCR purification using 4M ammonium acetate and isopropanol 
precipitation
The greatest advantage of this method is that all the materials are usually 
present in any molecular laboratory. There is no need to order any specific materials 
or reagents. As a result, this method is very cheap and efficient. All the asymmetric 
PCR products regardless of the size and all the double stranded PCR products less 
than 500 bp were cleaned using this method. In brief;
• to one volume of PCR products, one volume 4M ammonium acetate and 2 
volumes isopropanol were added;
• the microcentrifuge tube was kept on ice for 10 min;
• the DNA was pelted after 15 min centrifugation at high speed on the top bench 
centrifuge;
• the supernatant was poured off and 400 pi of 70% ethanol was added to the pellet 
followed by 5 min centrifugation as before;
• the supernatant was poured down the sink and the pellet was dried for either 10
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min at room temperature or 3 min at 55°C on the thermocycle.
• the dried pellet was resuspended in an appropriate TE buffer of DW.
2. 7.4. PCR purification using NICK™ columns
This method was applied for cleaning the radiolabelled probe for Southern
blotting (section 2. 6. 3) The probe was labelled as described in section 2. 5. 8. 1. The 
column was rinsed thoroughly with 400 pi IX SSC. The probes (20-40 Al) were 
added to the top of the column followed by adding 400 pi of IX SSC buffer.
* 32Unincorporated a- [ p]dCTPs was permitted to drip down to the container provided 
and the labelled probes were collected. This has been achieved by careful 
monitoring(mini-monitor, series 900) of the drops which passed through the face of 
the monitor located at the bottom of the column. A further 400 pi of IX SSC was 
added to the column, and the labelled probes were collected when the signals were at 
high peak. Two pi of cleaned labelled probe was added to 2 ml of scintillation 
solution, and incorporated a-[ p] dCTP was measured by Liquid Scintillation 
Counter (WALLAC 1409).
2. 8. Labelling methods
Labelling methods were used for different techniques including CCM,
Southern blotting, and labelling the DNA markers. One pCi of a- [32p]- dCTP 
(Amersham) was used as a radioactive material for internal labelling of the PCR
32products, or 8- [ p] dATP for the DNA size markers.
Two different approaches were applied for labelling of the PCR products: (i) 
internal labelling (ii) end labelling.
2 .8 .1 . Internal labelling methods using Taq DNA polymerase or the Klenow 
enzyme
In this method, the PCR content was prepared as a normal way. 0.5 pi of the 
a- [32p]- dCTP was added to the PCR content before adding Taq polymerase. The 
content, of the tube were mixed and collected at the bottom of the tube by brief 
centrifugation. The PCR content was layered by enough mineral oil. The tube was 
placed on the automatic thermocycle for amplification.
In this method, the radioactive materials were incorporated as one of the four 
essential dNTPs in the DNA.
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A random Primed DNA Labelling Kit (Boehringer Mannheim Bio.) was used 
for internal labelling according to the manufacturer’s instructions. In brief, PCR 
products were cleaned as described in section 2. 5. 6. Cleaned DNA (50 ng) was 
denatured for 5 minutes at 95°C, and then kept on ice. In a 40 pi reaction the 
following materials were added:
(I) 6 pi dATP, dGTP, dTTP mixture (prepared by making a 1+1+1 mixture), (II) 4 
pi reaction mixture, (III) 5 pi, 50 pCi[a32p] dCTP, 3000 Ci/mmol (IV) 2 pi Klenow 
enzyme, (V) made up to 40 pi with DW, (VI) incubated for at least half an hour at 
37°C.
The reaction was stopped by placing the tube for 10 minutes at -20 C or 15 minutes 
on the wet ice. All the probes for Southern blotting were labelled by the above 
methods.
2 .8 .2 . End labelling method using T4- Kinase
9
This method could be used for 5 end labelling of the primers, DNA size 
markers or any other end labelling DNA fragments. In a total 10 pi reactions the 
following material were added; lp l of 10X One-Phor- All Buffer Plus (Pharmacia), 
50 ng DNA, 0.5-1.0 pi 5-[32-p] dATP, 2 pi T4-kinase, adjusted to 10 pi by DW. The 
tube was incubated at 37°C for 30 min and the reaction was stopped when the tube 
was placed at -20°C for 10 minutes.
2.9. Gel electrophoresis
2 .9 .1 . Agarose gels
Agarose (Flugene) gels were used for checking the PCR products, southern
blotting or for excising the band from the gel for asymmetric PCR. For different 
purpose different concentrations were used. One percent agarose gels were used for 
checking the PCR products. Small horizontal apparatus gel (GibCo BRL) was used 
for checking the PCR products.
2. 9.2. Polyacrylamide gels
Normally, two different types of these gels were used: denaturing
polyacrylamide gel and non-denaturing polyacrylamide gel.
There are many different denaturing systems but these using urea, formamide
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and alkali as denaturants are the most common. In this research the urea was used in 
all the experiments as a denaturant. These types of gels were used either for 
sequencing or CCM. The difference between these two is the composition of the 
buffer, as will be described.
2 .9 .3 . The DNA sequencing gels
The standard 40 cm long sequencing kit (Bio Rad) was used for sequencing.
The thickness of the gel was 0.4 mm. The 8% gel was prepared as follows: in a clean 
beaker 22.4 g urea was scaled and to it 12 ml acrylamide (19:1), 3 ml 20X Glycerol 
Tolerant Gel Buffer (20X GTG: 216g Tris-base, 72g Taurine, 4g Na2EDTA.2H20, 
the total volume adjust to one litter) were added . The total volumes was adjusted to 
60 ml with distilled water. The gel was mixed for 5 minutes by stirrer, to it 200 pi 
APS 10% and 100 pi TEMED was added. The gel mixed properly and was poured 
into the kit.
2 .9 .3 .1 . Preparation of denaturing polyacrylamide gels for sequencing
The front and back plates were cleaned by washing with the detergent and tap
water, then dried using a clean tissue.
• The two plates were cleaned by ethanol and dried by cleaned tissue to remove any 
residual dirt.
• The back plate was siliconized in the fume hood using 3 ml silicon.
• The apparatus was assembled and sealed the bottom of the kit using either 
plasticine or 10 ml polyacrylamide sequencing gel.
• The gel, that had been prepared already, was poured by 50 ml syringe from the 
comer of the kit, and positioned the sample well former. The gel was left for about 
60 minutes to be polymerised.
• The running buffer was IX GTG and the gel was prewarmed at constant 70 W for 
45 minutes. During the running the gel was kept warm in a constant 52-54 W. The 
temperature of the gel was between 45°C-50°C.
The same gel was used for CCM and microsatellite instability analysis, but 
TBE 10X (Tris- Base 108g, Boric acid 55g, Na2EDTA 9.3g, the total volume 
adjusted to one litre by distilled water) was used for gel preparation. The running 
buffer was IX TBE buffer.
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2 .9 .3 .2 . Preparation of non-denaturing polyacrylamide gels
The main difference between denaturing and non-denaturing polyacrylamide
gel is the absence of denaturant in the non-denaturing gel. The concentration of the 
gel was 6%-8% in all the experiments. The concentration of the gel used depends on 
the size of the fragments. The recipes of the gels were as shown in the Table 2.4.
Table 2.4. The recipes of two different concentration of non-denaturing gel
6% 8%
40% Acrylamide (19:1) 9 12
TBE 10% 6 6
Distilled water* up to 60 ml up to 60 ml
* To the above, 200 pi 10% APS and then 100 pi TEMED was added for 
polymerisation.
2 .9 .4 . The Mutation Detection Enhancement (MDETm) gel
TmMDE (Flowgene) is one type of acrylamide gel, but with better resolution. 
Analysis of SSCP products on MDE gels differs little from methods using 
conventional polyacrylamide. This gel was used in 0.5X for all the SSCP analysis 
with 10X TBE buffer. The gel ran at room temperature with 0.6% TBE running 
buffer. Whenever non-radioactive materials were used, the Protean II kit (Bio Rad) 
was used. In this case the gel ran at a constant 150 volts for the appropriate time, 
usually around 16-22 hours. The recipe of the MDE gel is presented in Table 2.5.
Table 2.5. Preparation of 0.5X MDE gel
Components Amount
MDE gel solution (2X) 12.5
1 OX TBE X
DW* up to 40 ml
* To the final volume, 200 pi 10% APS and then 100 pi TEMED was added for 
polymerisation.
2. 9. 5. Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS- 
PAGE)
Basically this is one type of denaturing acrylamide gel. SDS-PAGE is 
recommended for protein analysis. This type of gel was used for the protein 
truncation test (PTT). For the analysis of translation products it is recommended to
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use SDS-PAGE, with a discontinuous buffer system. A 10% acrylamide resolving 
gel will give good separation of proteins in the range 20-100 kda in molecular 
weight. This gel has two different and distinct parts. The top part is stacking gel 
followed by separation gel, which could have a different concentration while the 
concentration of the stacking gel is usually 5% (figure 2.1). All the experiments were 
carried out in 0.75 mm thick gel in the protein II (Bio Rad). The formulation of SDS- 
page and stacking gel is presented in the Tables 2.6 and 2.7 respectively.
2 cm
20 cm
nuiJiJinniiniui ] 5% Stacking gel
Separating gel 
8%-15%
Figure 2.1. Schematic diagram of SDS-PAGE. The top part is always 5% stacking 
gel followed by different concentration of separating gel.
Table 2.6. The formulation of SDS-PAGE with different concentration.
Component
■
8% 10% 12% 15%
30% acrylamide 5.3 6.7 8.0 10.0
1.5 M Tris pH8.8 5.0 5.0 5.0
i  , :
10% SDS 0.2 0.2 0.2 0.2
10% APS 0.2 0.2 0.2 0.2
TEMED 0.012 0.008 0.008 0.008
DW 9 3 7.9 6.6 A4 .0
Table 2.7. The formulation of 5% stacking gel
component Volume (ml)
30% acrylamide 1.7
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lM T ris pH6.8 1.25
10%SDS 0.1
10% APS 0.1
TEMED 0.01
DW 6.8
The percentage of acrylamide chosen will depend on the size of translated protein. In
the Table 2.8 the effective separation range of SDS-PAGE is presented. 
Table 2.8. The effective separation range of SDS-PAGE.
% Acrylamide linear range of separation (Kda)
15 12-45
10 15-70
5 25-200
2. 9. 5.1. Gradient SDS-PAGE
Toimprove resolution and characterise the small protein size the gradient
SDS-PAGE was used (figure 2.2). The gradient gel maker has two distinctive gel 
chambers namely reservoir and mixing chambers. The two chambers are connected 
by a valve. A side outlet port from the mixing chamber should be connected to a tube 
for delivery of the gradient to an appropriate receptacle.
A B
/ i p i
r >
c
y /
/
Figure 2.2. The gradient gel maker. A: Reservoir chamber, B: mixing chamber, and 
C: valve.
Equal volumes of two starting solutions, which define the limits of the gradient, are 
placed in the two chambers, with the valve between them closed. When the stopcock 
is opened, solution from the reservoir chamber enters the mixing solution, which is 
simultaneously withdrawn as the gradient is poured. The level of liquid in both
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chambers falls at the same rate. The concentration of solute in the mixing chamber at 
any time is a linear function of the volume poured. If the gel is poured from the top, 
the more concentrated gel monomer solution is placed in the mixing chamber, and is 
introduced first into the gel mould, with gel of decreasing concentration added from 
above. However, the lowest gel concentration, corresponding to the largest pore size, 
ends up at the top of the sandwich.
2.10. Mutation detection methods
2.10.1. Single strand conformational polymorphism analysis (SSCP)
Single strand conformational analysis is a method which typically involves
the amplification by PCR of a discrete segment of genomic DNA in the presence of 
radiolabelled or non-radiolabelled nucleotides, melting of the PCR products, and 
analysis of the single strands on a non-denaturing polyacrylamide or MDE gels. 
Polymorphic differences in strand mobility result from the effects of primary 
sequence changes on the folded structure of a single DNA strand. The mobility of 
DNA fragments depends not only on the size of them but also on its sequences. The 
last characteristic of mobility is the base of SSCP technique. The primary sequence 
difference alter the intermolecular interactions that generate a three-dimensional 
folded structure. The molecules may thus move at a different rates through a non­
denaturing polyacrylamide gel.
2.10.2 . Chemical cleavage of mismatch (CCM) analysis
The chemical reactivity of matched T and C bases to osmium tetroxide and
hydroxylamine were examined by Cotton and Campbell (Cotton and Campbell; 
1989). They showed that mismatches in DNA can be detected by chemical reactivity 
using osmium tetroxide(detecting mismatched T) and hydroxlyamine (detected C). 
This technique is a PCR base method in which, target DNA will hybridise with a 
labelled probe to make a heteroduplex. Osmium tetroxide and hydroxylamine will 
modify respectively the T and C in the hetroduplex. Modified base(s) will be cleaved 
by piperidine. Electrophorsis and autoradigraphy will be applied after modification.
2.10 .3 . Southern blotting
Southern blotting carried out as described by Southern (1975). This technique
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was applied with quick pre-hybridisation (Stratagene) solution and no depurination 
was employed.
2.10. 4. Protein truncation test (PTT)
This technique was applied and optimised for the first time in the Duncan
Guthrie Institute Of Medical Genetics for this project. PTT were applied for different 
genes namely APC (Powell et al., 1993), ataxia- telangiectasia (Telatar et al., 1996), 
DMD (Roest et al., 1993) HNPCC (Liu et al., 1994), and BRCA1 (Plummer et al., 
1995).
PTT could based on DNA or RNA. However, the forward primer should bear at the 
5 of its sequence the T7 promoter including a 29 bp for transcription followed by 7 
bp for initiation. Two commercial kits were available for this method. The 
Amersham kit was more efficient than Promega kit, the following description is 
according to Amersham kit.
2.10. 4.1. Synthesising a forward primer containing the T7 promoter
If unpublished primers were used for PTT, it is recommended that
optimisation carried out as usual and then the T7 promoter sequences are added to
9___________________________________________________________________________________________________________________________________________________________________________________________ ____
the 5 end of the primer. Next, a new long primer is synthesised for PTT. The 
synthesising of this long primer isthe same as for the ordinary one. No special 
reagent is required. The deprotection of the long primer is the same as the normal 
primer. The T7 promoter sequence that was added to the 5 end of the forward primer 
is presented below:
!__________Transcription signals_________________  t Translation signals
GGA TCC TAA TAC GAC TCA CTA TAG GGA GA C CAC CAT GGC GGT 
GCA GCC GAA GGA TG 1
2 .10 .4 .2 . Amplification of target DNA
No special technique is required. Normal PCRs were carried out. The long
PCR profiles were performed as described previously.
2 .10 .4 .3 . Purification of the PCR products
Two methods were applied for cleaning the PCR products. Both the
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GENECLEAN kit and 4M ammonium acetate- isoprppanol precipitation were 
efficient as described in section 2. 6. 6. 3. The pellets were dissolved in 5 pi Rnase
t
free water, and 0.5 pi plus 2 pi loading mix were loaded onto 1% agarose gel to 
estimate the quantity of PCR products.
2.10. 4. 4. Transcription-translation
Transcription: All experiments were carried out in 1/4 scale of the manufacturer’s 
instructions to save material, and subsequently money. All the materials were 
provided in the kit. To avoid multiple defrosting and freezing, after opening a 
transcription vial, the contents of the tube were divided into several tubes. Each tube 
contained enough aliquot for four experiments. However, the transcriptions were 
carried in a water bath at 30°C for 20 mins.
1. Transcription mix 2.0 pi
2. PCR products 0.5 pi
Total 2.5 pi
• Translation
Subsequently, while the tubes were on the bench, the following reagents were added 
to each tube:
3. Nuclease free water 1.8 pi 
4 .35S- Methionine 0.7 pi
5. Translation mix 7.5 pi
Total 10.0 pi
Translations were carried out a water bath at 30°C for 60 mins. The tubes were 
placed at -20°C to stop the reaction.
Five pi of translation products were mixed with 20 pi of loading mix (0.5 ml 
1 M Tris pH 6.8, 0.8 ml glycerol, 1.6 ml 10% SDS, 0.4 ml 2-mercaptoethanol, 0.1 ml 
saturated pyroniny solution, 4.6 ml DW). The mixtures were denatured at 95°C for 5 
mins. At the same time, 5 pi of the standard protein size marker (rainbow, 
Amersham) was mixed to 15 pi of loading mix and was denatured in the same 
condition. All the tubes were kept on the bench.
SDS polyacrylamide gels were prepared as described in section 2. 7. 5. The 12 pi of
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the sample and loading mix were loaded to each well. Electrophoresis was carried 
out at constant 200 volts. The electrophoresis was stopped when the dye reached the 
bottom of the gel. In some cases the time of running was altered according the 
necessity. The gels were fixed in 7% acetic acid for half an hour. Next, the gels were 
placed in Amplify (Amersham) for another 30 min. The gels were transferred on the 
3 mm Whatmann papers and covered by Saran film, then dried for at least 30 mins at 
not more than 60°C. The gels were exposed to the Kodak film and kept at - 20° C for 
O/N.
2.10. 5. Direct DNA sequencing
All the sequencing in this project was carried out as described by Sanger
(1997). Sequenase Version 2.0 DNA Sequencing Kit (USB) was used for direct DNA 
sequencing according to the manufacturer’s instructions. Single stranded DNA 
(ssDNA) was generated by the asymmetric PCR method previously described. To 
improve understanding this method was classified into different parts:
2 .10 .5 .1 . Annealing
Asymmetric PCR products were purified as described in section 2.7.3. The
ssDNA was resuspended in 7 pi DW and to it 1 PM (1 PM/pl) of sequencing primer 
and 2 pi of sequenase buffer (5X) were added. Annealing was carried out at 65°C for 
2 min. The tubes were allowed to cool down to 34°C over the period of 30 min. The 
tube was centrifuged briefly and was placed on the ice.
Meanwhile, for each sample 4 tubes were labelled for the 4 different 
termination mixtures. To each, 2.5 pi of dideoxytermination mix was added. The 
tubes were heated at 42C for 5 min.
2 .10 .5 .2 . Labelling
To the tube from the annealing step lp l 0.1M dithiothreitol (DTT), 2 pi
labelling mix (1:5 diluted), 0.5pl [35S] dATP (Amersham), and 2pl Sequenase T7 
DNA polymerase (diluted as: sequenase DNA polymerase: Glycerol enzyme dilution 
buffer: Inorganic pyrophosphatase; 1: 6: 1, respectively) were added. Brief 
centrifugation was applied to collect the contents of the tube at the bottom of it.
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2.10. 5.3. The termination reaction
To the each tube with 2.5 ul of dideoxytermination mix from annealing step,
3.5 pi of the aliquot from the tube from the stage labelling mixture was added. 
Amplifications were carried out at 42C for 5 min. The reaction terminated by adding 
4 pi Stop solution (95% formamide, 20 mM EDTA, 0.05% bromophenol blue and 
0.05% xylene cyanol FF).
Gel electrophoresis carried out as previously described. All the sequencing 
gel ran at a constant 52-54 W. The running buffer was IX glycerol tolerant buffer. 
The lengths of time for different gels were different, but when the bromophenol blue 
reached the bottom of the gel, sequences close to the primer were readable. The gels 
were transferred on the 3 mm Whatmann paper and covered with Saran film. 
Autoradiography was carried out as described before. Depending on the region of 
DNA to be sequenced in a particular experiment, the sequencing condition could be 
altered to provide maximum data of sequences close to the primer, or alternately 
those with a G-C rich region. '
Two alterations were employed in the sequencing method: sequences very close to 
the primer and sequences with G-C rich region.
• There are two methods for the sequence very close to the primer. One is to use 
less nucleotide in the labelling step, and the other is to use Mn buffer. The last one 
was applied to solve this problem.
Mn buffer is a buffer solution of MnC12 that can be added to normal sequencing 
reactions. A few nucleotides after primer were readable when Mn buffer was applied. 
To do this lp l of Mn buffer was added to the labelling reaction prior to adding the 
enzyme. No other alteration was necessary. The other reagents were as usual.
• To eliminate compression in regions with G-C rich regions, dITP was substituted 
for dGTP. To use dITP, substitution was carried out and dITP substituted for 
dGTP labelling mixture. Also, the reaction time decreased to less than 5 min for 
both labelling and termination. All others aspects of the sequencing remained 
unchanged.
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CHAPTER THREE 
RESULTS
3.1. Identification of microsatellite instability in tumour DNA
Thirty pairs of normal and tumour tissues were analysed from patients with
CRC. All samples were analysed for genetic instability at a minimum of two, and a 
maximum of 9 microsatellite loci. In this study, genetic instability is defined as a 
gain or loss of one allele in at least one locus. The abnormality appears as extra 
alleles that typically are observed in tumour DNA when compared to normal DNA 
from the same individual. The results of MI are presented in the Table 3.1.
Patients
PI
P2
P3
P4
P5
P6
P7
P8
P9
P10
P ll
P12
P13
P14
P15
P16
P18a
P18b
P18C
P21
P22
P23
P24
P25
P26
P31
P49
P50
P51
P52
P76
P78
N
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
Table 3.1. The results of M
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
Age/Sex
71/M
26/F
64/M
?/M
?/F
?/F?
75/F
?/F
?/M
65/F
32/M
?/M
?/F
?/F
71/M
?/F
68/F
35/F
76/M
62/M
64/M
62/M
64/F
64/F
?/F
33/F
?/M
?/M
23/M
42/F
Site
pol.
pol.
CE.
D
in 30 unselected normal/ tumours DNA. The markers
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are: 1: D2S160, 2: D2S119, 3: D8S282, 4: D18S34, 5: 635-636, 6: D2S123, 7: 
LPLCA, A, 8: D2S378, 9:LPLCA, B. ND: not done, pol: polyposis colon cancer. R: 
rectum, CE: cecum, A: ascending colon, T:- transverse colon, D: descending colon, 
S: sigmoid, ?: no information.
The average age of this group (MI+) was 58.16 years, (range 35-76 years) and the 
average age of MI’ was 54.00, (range 23-75 years). No significant differences 
between the two groups were observed (t = 0.48, P = 0.64). The MI status and the 
sites of tumours are presented in Table 3.2,
MI status
MF-----
mT
A T D S 
"2 I 1 T
Rec Pol. Total %
TT 3 T W
13 21 65.6%
Table 3.2. Location of CRC tumours. A: ascending colon; T: transverse colon; D: 
descending colon; S: sigmoid colon; Rec: rectum; Pol: polyposis colon cancer; ?: no 
information.
The group comprised 47% (14/30) males and 53% (16/30) females. No significant 
differences between females and males with or without MI were seen (X = 0.915, df 
= 1, P > 0.5). Nine main different polymorphic markers were chosen for MI 
investigation. All the markers that were chosen in this study showed RER+ in at least 
one patient. The best marker was 635/636 on the chromosome 15q. In Figure 3.1 the 
nine markers and their RER are shown.
25
20
15
10
5
Figure 3.1. Demonstration of genomic instability for nine different markers. All of 
them showed MI in at least one patient. Vertical axis represents percentage of 
genomic instability.
MI could be detected by denaturing or non-denaturing acrylamide gel and also by 
radioactive or non radioactive PCR products. In Figure 3.2 A microsatellite 
instability in a CRC patient (Patient 18) is shown when non-denaturing acrylamide 
gel was used and stained by silver staining method. In this marker extra bands were 
present in two of three tumours (tumour A and B) but not in tumour C. In Figure 3.2 
B an autoradiograph of MI has been shown for patients 22 and 26 when radioactive 
material was used. In Figure 3.3 A and B MI has been shown for patient 18 when 
markers 636/635 and D18S34 were used.
LCA
, 1
pi
i  jx a  j
D13S1&0 D8S282 635/6 36 LPLC;a .a lp
D2S119 D18S34 D2S123 D2S378
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Figure 3.2. Microsatellite instability in colorectal carcinomas. Genomic DNA 
samples from paired normal and tumour tissues were subjected to PCR amplification 
using the dinucleotide repeat markers (A) D2S123, (B) LPLCA,B. Alterations in the 
electrophoretic mobility of PCR products from tumour were compared to normal 
tissues DNA and are shown by arrowheads. Silver staining was used as a means of
32 •detection in (A), while P was used for radiolabel PCR amplification in (B). N: 
normal, T: tumour.
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Figure 3.3. Analysis of genetic instability in paired normal (N) and tumour (T) 
DNA at locus 636/636 (A), and locus D18S34 (B). MI+- tumours show deviations 
from the normal pattern (arrows). N: normal, T: tumour.
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In brief, microsatellite instability or replication error phenotype is a new molecular 
phenotype of a number of human cancers. In this part of study thirty unselected 
pairs of normal and tumour tissues were investigated for MI by using nine different 
polymorphic markers. Nine of 30 tumours were found to be MI+ in at least one 
marker (30%). There is no record for a majority of patients (25 of 30) (unknown 
cases) about the history of the disease and possible affected members in the family. 
There are two families with polyposis colon cancer and also two families with 
colorectal cancer and one family with Amsterdam criteria. MI+ was shown in six of 
25 families (unknown cases) in at least one locus. Neither of the two families with 
polyposis colorectal cancers were MI+. Microsatellatie instability was observed in 
both families with colorectal cancer and also in the family with Amsterdam criteria.
3.2. Strategy for mutation detection
3.2.1. Amplification of whole coding sequence by RT-PCR
The entire coding sequence of the hMSH2 gene was amplified in either two or three
fragments (fragments A-E) (Lynch et al., 1993; Liu et al., 1994), range 633-2096 bp 
(Figure 3.4).
2.8 kb
4 5 6 7 8 9 10 11 12 13 14 15 16
150 bp
A=1892 bp
a  = zuyo op
C =103lbp D = 1064bp E = 75U'bp"
M A B M C D E
Figure 3. 4. Amplification of the entire coding sequence of the hMSH2 gene in either 
two or three overlapping fragments. Fragment A encompasses from 5 UTR to exon 
12 (1892 bp), fragment B encompasses from exon 4 through to 3 UTR (2096 bp), 
fragment C encompasses from exon 1 to exon 7 (1031 bp), fragment D from exon 6 
through to exon 13 (1064 bp) and fragment E encompasses from exon 13 to exon 16 
(750 bp). M:1 kb DNA marker.
3. 2. 2. Optimisation of protein truncation test
The protein truncation test (PTT) was applied as a tool for mutation screening
for the first time at the Duncan Guthrie Institute of Medical Genetics in this project 
and then successfully has been utilized for mutation analysis in the BRCA1 gene at 
the same department. This technique is based on the detection of truncated peptides 
after translation of the coding sequences amplified from a patient sample by PCR. 
To enable the translation of the PCR products, a tailed primer is used to introduce an 
RNA polymerase promoter, a translation initiation sequence, and an in -frame ATG 
triplet.
It has been shown that the PTT is able to detect frame shift mutations (Powell 
et al. 1993, Telater et al. 1996, Roset et al. 1993, Liu et al. 1994 and Plummer et al. 
1995). Normally, RNA is used as a starting template in the PTT assay. However, if 
the structure of the gene of interest is favourable (containing large exons) DNA can 
also be used. The majority of genes do not contain such a favourable exon but rather 
are split into many small exons, leaving RNA as the only workable template.
Two commercial kits from Amersham and Promega were available for this technique 
and it was found that the first one works better than the last one. However, when
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RNA was available from patients, RT-PCR was carried out and the products were
electrophoresed on 1% agarose gel. In the case of any abnormal band, direct
sequencing of the abnormal band was carried out to characterise the mutation. The
RT-PCRs which did not show any extra bands were subjected to PTT. Any truncated
products were characterised by direct sequencing and the alteration was confirmed
by digestion of the PCR products by using appropriate restriction enzyme. The
enzymatic digestion was also used for screening the other members of the family and
for screening the normal population. All five forward primers in RT-PCRs contained
T7 promoter and also an initiation signal in order to generate PCR products suitable
for PTT analysis. PTT analysis was carried out as described in section 2. 10. 4. In
brief, reverse transcriptase PCR products were purified by GENECLEANII kit or by
using 4M sodium acetate-ethanol and then washing with 75% ethanol as described in
materials and methods. The pellet was dissolved in 5 /ri DEPC treated water and then
0.5 jLtl of it was used for the transcription reaction including 2.0 fi\ transcription mix.
The transcriptions were carried out in a pre-set water bath at 30C for 20 mins. The
next step, translation reactions, was carried out by adding 1.8 /xl nuclease free water, 
35O.lfil S-methionine and also 7.5 jx\ translation mix. Translations were carried out in 
the same water bath and at the same temperature for one hour. The reactions were 
stopped by placing the tubes at -20C. The synthesised protein products were 
separated on 10-15% SDS-polyacrylamide and also on a different gradient of gel 
concentration. Electrophoresis was carried out at constant 200 volts and was stopped 
when the bromophenol blue reached at the bottom of the gel (5-7 hours). The 
Protean II cell kit from Bio Rad was used for electrophoresis. The gels were fixed for 
30 mins and then soaked in Amplify (Enhancer) TM (Amersham) for half an hour 
and then dried at 60C for not less than 30 mins. The dried gel were exposed to X-ray 
film for at least 16 hrs and up to one week at -30C. The efficiency of this technique 
was improved by using concentrated PCR products and also using Amplify. 
However, this technique is not easy to use, particularly when RNA is the source for 
amplification. The presence of multiple bands due to initial translation makes it 
difficult to judge the real truncated products. However, this technique is able to 
detect pathologic mutations in two steps: PCR and then PTT. This method is very 
good for mutation analysis of large exons like exon 15 in the APC gene and also
exon 11 in the BRCA1 gene which contains more than two-third of the BRCA1 
coding sequence. The most limiting factor for efficient use of this technique is the 
availability of RNA. Most diagnostic laboratories have usually stored DNA samples 
or tissue samples which do not allow isolation of high quality RNA. However, PTT 
is able to detect translation terminating mutations only, although in some respects 
this is a major advantage of the technique, it means that it does not detect all disease 
causing mutations.
3 .3 . Identification of mutations in the HMSH2 gene
In this part of study, 48 families were investigated for mutation analysis by
RT-PCR followed by PTT and CCM. Of them, twenty-seven families had a history 
of CRC (only one of them had tumour, family 9806, MI+) and 21 families with un­
known history of CRC. DNA from tumour was available from 14 families ( 3 RER+ , 
11 RER’ ) (see appendix 1).
Different members of a family have the same pedigree number and they were 
assumed as one family although in some cases more than one RNA sample was 
investigated for mutation analysis (families 12334, 12450, 12691 and 12780, each 
had two RNA samples ). The families 11470, 11315, 11498 and 13894 had no RNA 
for mutation analysis.
3.3.1. Identification of a novel splice site mutation in patient 21 
Family history
The mother of this patient died in her 60s, due to bowel cancer. The proband 
was diagnosed at age 37 with colon cancer. Two of her brothers died of colon cancer 
and bladder cancer, and her older sister also had colon cancer. There were therefore 
five affected individuals in two generations.
Microsatellite instability
A small amount of tumour (less than 0.1 g )from patient 21 was available for
microsatellite instability analysis, therefore MI was sought using marker loci at 
D2S123 and 635/636 (Figure 3.8).
Truncated protein
Amplification of exons 4 to 16 was carried out by RT-PCR as described in
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materials and methods, and followed by PTT. In this analysis, lymphocyte RNA was 
used for RT-PCR, and the PCR product was used to generate polypeptide. When a 
shortened hMSH2 polypeptide was identified in this assay, the sequence of the 
relevant region of the cDNA was determined to find the responsible mutation. 
However, this assay showed a truncated protein for patient 21 and her sister (patient 
32) but not for a healthy member (Patient 28) of this family (fresh blood was 
available from these three individuals in this family). The result of PTT is shown in 
Figure 3. 6, and the truncated proteins are indicated by arrows.
Application of RT-PCR and CCM
Amplification of fragments E encompassing exons 14,15 and 16 by the RT-
PCR as a nested fragment within fragment B, followed by agarose gel electrophoresis 
showed a normal product (750 bp) and a shorter product (574 bp)(Figure 3. 7, A). 
Subsequently CCM was applied and revealed the presence of cleavage products in 
this segment (Figure 3. 7, B).
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(A) (B)
Figure 3.5. Genomic instability analysis in paired normal (N) and tumour (T) DNA 
at locus D2S123 (A) and 635/636 (B) for patient 21. Arrows show alteration in the 
electrophoretic mobility of PCR products from tumour compared to normal tissue 
DNA.
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Figure 3. 6. Truncated protein in two members of one family, but not in the healthy 
members of the same family.
PTT assay on RT-PCR products from colorectal cancer patients. In vitro transcription 
and translation of RT-PCR products was carried out as described in “materials and 
methods”, and the resultant labelled proteins were separated on a gradient sodium 
dodecyl sulphate polyacrylamide gel (see materials and methods). Arrows show 
normal products (75 kd) and truncated protein (60 kd) in Patient 21 and Patient 32 
(lanes 3 and 8). M: protein standard size marker “rainbow” (Amersham).Lanes 1-2 
normal, Lane 3: patient 21 (affected member of the family), Lane 4 : normal, lane 5: 
P28( healthy member of family 21), lanes 6 - 7 :  normals, Lane 8: patient 32 (affected 
member of the family), Lane 9-12: normal controls, Lane 13: negative control, lane 
14: positive control.
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Figure 3. 7. A: Detection of short transcripts in the hMSH2 gene by RT-PCR in 
Patient 21.
(A) Amplification of fragment E encompassing exons 13-16 by RT-PCR. The 
products were separated on 1% agarose gel and showed a normal product (750 bp) 
and a short products (574 bp). Lane 1: 1 kb standard DNA marker (Gibco BRL), 
Lanes 2 -7 normal control, lanes 9-11:  normal controls. Lane 8 shows additional 
product about 186 bp shorter corresponding to exon 15. B: CCM revealed a cleaved 
band in the segment E for Patient 21 (shown by arrow). Lanes 1-3 and 6: normal 
controls; lane 4: positive control; lane 5: patient 21.
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Exon skipping from m RNA transcripts
The CCM proved that the shorter PCR products are not artefacts. Application
of direct DNA sequencing on RT-PCR products showed a mixed pattern of normal 
and mutant alleles, which was not easy to understand which exon has been skipped 
from the transcript (Figure 3. 8, A). Therefore, the RT-PCR products were loaded 
onto 1.5 % low melting Nusive agarose gel and the upper and lower bands 
corresponding to normal allele and mutant allele was excised from the gel. After re­
amplification, direct sequencing revealed that the exon 15 was skipped from 
transcripts (Figure 3. 8, B). This is out of frame deletion of codons 820-878, creating 
a new termination codon 6 bp downstream of the splice site within exon 16.
A novel splice site mutation for exon 15
Exon 15 was amplified from genomic DNA, followed by direct sequencing
in both normal control and Patient 21. On sequencing the genomic DNA, the splice 
donor site on intron 15 was found to have a G to C transversion at nucleotide 
position +5 (Figure 3. 9). This mutation was heterozygous in the tumours of the 
affected individuals in this family. Since the mother of this family had died it was not 
possible to show vertical transmission of this mutation.
This splice site mutation creates a restriction site for the enzyme, DdeI, and 
was used to identify the mutation in three other affected members of the family 
(Figure 3. 10). It was not found in the healthy member or 61 normal controls. This 
enzymatic assay was also used for screening of 116 CRC patients, but no alteration 
was found.
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Figure 3. 8, A: Partial cDNA sequencing of mixed normal/mutant of patient 21 
showed a parallel pattern corresponding to the normal allele and mutant allele. N: 
normal, P: patient. B: sequencing of the shorter RT-PCR products revealed that exon 
15 is deleted from transcripts. Therefore, exon 14 joined directly to exon 16.
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GTGTC GAGAG g t t t g t c
Figure 3.9 A: Direct DNA sequencing in patient 21 showed a new splice site
mutation for exon 15 in nucleotide position +5. Altered nucleotide pointed by arrow 
and the exon/intron border is shown by a bar line. N: normal. P: patient. B: schematic 
presentation of exon/intron borders and the position of point mutation in patient 21 
and four other affected members in her family. The exon/intron border is indicated 
by a vertical line.
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129 bp 47 bp
I-------------------------------------------------------------------------------------------N ---------------►
446 bp
Mutant allele 
Normal allele
Restriction map for the DdeI restriction enzyme in exon 15 and its 5’ site of the 
hMSH2 gene.
1 2 3 4 5 6
Figure 3. 10. Enzymatic assay with the enzyme Dde I.
A G to C transversion in intron 15 creates a restriction site for the enzyme Dde I. 
Application of this enzymatic assay revealed that all four affected individuals in the 
same generation bear the same mutation. This point mutation was not present in a 
healthy member or in 117 other controls. Lane 1: DNA size marker; lanes 2, 4, 6: 
normal controls; lanes 3 and 5: patients with splice site mutation.
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Consensus value for donor splice site of exon 15
Shapiro and Senapathy (1987) described a method for potential consensus
values at splice junction sequences. Based on this method, each of 8 nucleotides at 
the 5’ splice junction site from position -2 through to position +6 have a particular 
score between 0 and 100 (see appendix 2). The final score for 5’ splice site calculated 
by a formula is given below:
Score = 100(t - min t)/ (max t - min t)
where t is the total of percentage for eight nucleotides at 5’ splice junction site and 
mint and max t are the minimum and maximum possible totals at 5’ splice site.
The total score for normal and mutant sequence at 5’ splice junction site is shown in 
table 3.3.
Table 3.3. Presentation of consensus values for normal and mutant sequences at 
donor site of exon 15.
Score 58 78 100 100 2 9 84 47 478
Normal A G G T T T G T
Position -2 -1 +1 +2 +3 +4 +5 +6 Total
Mutant A G G T T T C T
Score 58 78 100 100 2 9 6 47 400
The min t and max t for each of the eight nucleotides is shown below:
Position -2 -1 +1 +2 +3 +4 +5 +6 Total
M int 13 4 0 0 2 8 5 15 47
M axt 58 78 100 100 57 71 84 47 595
Thus the consensus values for each normal and mutant sequences are given below: 
Score = 100(t - min t)/ (max t - min t)
Normal score= 100 (478-47) / (595-47) = 78.36 
Mutant score= 100 (400-47) / (597-47) = 64.18
Therefore the mutation at the 5’ splice site of intron 15 reduces the consensus 
values by 14.18%, and may contribute to exon 15 skipping from the transcript as
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demonstrated earlier.
3.3.2  Gross deletion in RNA revealed by RT- PCR
Patient 18 has three different tumours
This woman was operated on at the age of 68, due to of colon cancer. She had
three different tumours each at different sites of her colon. One tumour was in the 
cecum (Tl), the second one in the ascending colon (T2)and the last one in the 
transverse colon (T3).
MI in 8 of 9 markers in patient 18
Four specimens corresponding to three different tumours and one normal
mucosa from patient 18 were studied for microsatellite instability. MI investigation 
with 9 different polymorphic markers showed RER+ in 8. Interestingly, tumours 
showed different patterns with different markers (Figure 3.11, A-B), see also table
3.1.
A Large RNA deletion encompasses exon 2 through to exon 6
Fragment A was amplified by RT-PCR as described before (materials and
methods). This fragment was used as a target for re-amplification for a smaller 
fragment using a nested primer. Electrophoresis on 1% agarose gel on the smaller 
fragment showed two different bands, one corresponding to normal products and the 
other to shorter products. Subsequently, re-amplification of shorter products followed 
by direct sequencing was carried out. Direct sequencing on the normal allele showed 
a normal pattern, but exon 2 through to exon 6 was deleted from mutant allele 
(Figure 3. 12). This is an out-of-frame deletion of codons 71-359, creating a new 
termination codon at position +3 from the splice site in exon 7. No alterations in 
splice site junctions were found. Southern blotting of the genomic DNA, using a 
cDNA probe, after digestion with several restriction enzymes, produce no evidence 
of a deletion (Figure 3. 13).
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Figure 3. 11. Microsatellite instability with two different markers D2S123 (A) and 
LPLCA, B (B) for patient 18. This patient in MI point of view has been the best 
example in this research, as she showed RER+ with 8 of 9 markers. Interestingly, 
three different tumours in this particular patient showed different patterns with the 
same marker, suggesting different molecular pathology for different tumours. A: N: 
normal, Ta: cecum tumour, Tb: ascending tumour, Tc: transverse colon. Alteration in 
the tumour DNA is indicated by an arrow.
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Figure 3. 12. Direct sequencing of RNA in patient 18.
Sequencing of mutant allele in patient 18 revealed a deletion from exon 2 through to 
exon 6 inclusive. N: normal, M: mutant.
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Figure 3.13. Southern blotting of genomic DNA in patient 18.
Southern blotting of the genomic DNA after digestion with three different restriction 
enzymes. The first three lanes were digested by EcoRI, the second three lanes were 
digested by Taql and the last three lanes were digested by Hindlll. Lanes 1, 2, 4, 5, 7 
and 8 are normal controls. The lanes 3, 6 and 9 are patient 18.
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3. 3. 3 . Multiple exon skipping in Patient 3
This man was operated on at the age 64, due to colon cancer. No more
information about this patient and his family is available. MI studies were carried out 
with nine different polymorphic markers. MI was observed in two of nine markers 
including D18S34 and 635/636 (Figure 3.14).
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Figure 3. 14. Microsatellite instability in patient 3 using markers D13S34 (A) and 
635/636 (B). Alterations in the tumour DNA are indicated by arrows.
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Amplification of fragment A was carried out. The length of this fragment as 
mentioned before was 1892 bp. These long PCR products were used as target DNA 
for re-amplification. Re-amplification with two sets of primers as nested primers 
were carried out as shown in Figure 3.15. The downstream primer was the same for 
the two PCRs to amplify two different fragments in size, 1771 bp and 1733 bp, 
respectively. After gel electrophoresis short transcripts were present in both 
fragments, one band corresponding to normal allele and the other corresponding to 
mutant allele (Figure 3.16).
120 bp ------------- Fragment A
<   ' ----- 1892 bp    ►
U
135 ____ ^______________________lZ Z lh p .________________________________________
248 ------ ►--------------------------------------------------------------------------------------------------
1734 bp M D
Figure 3.15. Schematic presentation of two different fragments for re-amplification 
of cDNA in patient 3. Primer D was used for both primers, 135 and 248, as a down 
stream primer.
M 1 2
Figure 3. 16. RT-PCR products from patient 3 revealed a deletion from exon 2 
through exon 8, when two different sets of primers were used as nested primers as 
shown in lanes 1 and 2. M: 1 kb DNA marker.
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Re-amplification of the mutant allele in order to have enough targets for further 
analysis was carried out, followed by asymmetric PCR. Direct sequencing on the 
mutant allele demonstrated that exons 2-8 were deleted from transcripts, while the 
sequencing of the normal allele showed no alteration from normal sequence (Figure 
3.17). This mutation is out of frame deletion of codons 71-466 and creates a new 
termination codon at position +12 from the splice site in exon 9. No other member of 
this family was available for our study.
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Figure 3.17.  Multiple exon skipping in patient 3.
Partial mRNA sequencing of normal control and mutant allele in patient 3 showing 
multiple exons skipping from exon 2 through to exon 8. P: patient, N: normal.
85
Genomic sequencing on all splice junction sites was carried out and no alteration 
from the normal sequence was found. However, Southern blotting carried out using 
different restriction enzyme was unable to produce evidence of a deletion.
3 .3 . 4. Partial deletions in the hMSH2 mRNA
In these patients no tumour DNAs were available for MI studies. None of
them satisfied the Amsterdam criteria for HNPCC, but they have a positive family 
history of colon cancer and related disease.
Partial deletion including exon 9-12
This mutation was found for the first time in patient 17. In spite of the
presence of five affected individuals in this family (including the proband), the 
HNPCC criteria are still not satisfied. This young patient was operated at age 17 
because of colon cancer. Her mother died of colon cancer (the only first degree 
member ), his uncle died at age 20 due to colon cancer and his aunt at age 58 
because of the same disease. This is not sufficient to put this patient in HNPCC 
category. However, in the course of amplification of fragment D, encompassing 
exons 7-13, a short transcript was present for this individual but not for the rest of 
normal controls (Figure 3. 18A). Subsequently, re-amplification and asymmetric 
PCR were carried out on both mutant and normal alleles to produce single stranded 
DNA for sequencing. On sequencing it was demonstrated that the second part of 
exon 9 through to the first part of exon 12 was deleted from transcription (Figure 
3.18, B). However, the same mutation was found in another patient with a positive 
family history of colon cancer but who did not satisfy the HNPCC criteria. All splice 
sites in exons 9 and 12 were intact, no alteration was found by genomic Southern 
blotting.
1 2 3 4 5 6 7 8 9 10 11 12 13 14
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Figure 3. 18. A: RT-PCR products encompassing exons 7-13. Short transcripts were 
present for patients 17 and 30 but not in any other normal control. Lane 1: standard 
DNA size marker, Lane 2: patient 17, Lane 3: patient 30, Lane 3-14 : normal controls 
B: partial mRNA sequencing in patients 17 and 30 demonstrate deletion of exon 9- 
12. N: normal, P: patient.
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Partial deletion in a patient with a positive family history of cancer
This patient (Patient 63) developed colon cancer in her 30s, while her parents
were both healthy. Her grandfather (father’s side) had stomach cancer in his 50s, her 
uncle (father’s side) had throat cancer at age 50, and also her aunt (mother’s side) had 
breast cancer.
Amplification of segment C in patient 63 was carried out. As described before, the 
products of large segments were used as a target for re-amplification with nested 
primers. Re-amplification of segment A with a nested primer showed two different 
fragments, one band corresponding to normal allele and the other shorter than 
normal. Sequencing of the normal band showed normal sequence, but sequencing of 
shorter products showed a partial deletion within exon 1 encompasses codons 8-49
(Figure 3. 19). This deletion is an out of frame deletion and create a new termination
* >
codon at nucleotide position +24 from intron 1. Subsequently, splice sites at 5 and 3 
ends in exon 1 were sequenced and no alteration from the normal sequence was 
found. Genomic Southern blotting showed no evidence of deletion in DNA.
N P
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Figure 3. 19. Partial mRNA sequencing in patient 63. Sequencing of normal allele 
showed no alteration from published sequence, while sequencing of mutant allele 
documented a deletion within exon 1 encompassing codon 8 through to codon 49. 
This is an out of frame deletion and creates a premature termination codon within 
exon 1. N: normal, P: patient.
Partial deletion of exons 14-15 in patient 30
The bowel cancer is present on both maternal and paternal side of the
proband. The proband had colon cancer at age 52, but bowel cancer and bowel 
problem were very frequently present in the family (five members in two 
generations). However, the Amsterdam criteria does not meet with this family. 
Amplification of fragment E, including exons 13-16, revealed a short transcript. 
Subsequently, direct sequencing of RT-PCR products showed a deletion from exon 
14 to exon 15 (Figure 3.20 ), resulting from 380 bp deletion from transcripts. In order 
to determine the cause of this mutation, the splice site of both exons were sequenced 
and no alterations were found.
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Figure 3. 20. Partial deletion in fragment E.
Partial mRNA sequencing in patient 30 revealed a deletion about 380 bp from exon 
14 to exon 15. N: normal; P: patient.
Partial deletion of exons 4-6 in patient 73
Amplifications of fragment C for patient 73 showed two different bands. One
of them corresponds to normal size, and the other was shorter than normal. On 
sequencing of shorter products a partial deletion was found from exon 4 through to 
exon 6 (Figure 3. 21), while the sequencing of the normal band showed normal 
sequences. Amplifications of individual exons (including exons 4 and 6) were carried 
out from genomic DNA. Subsequent direct DNA sequencing either in the coding 
sequence or in intronic flanking region of correspondence exons showed no 
alteration.
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Figure 3. 21. Partial mRNA deletion for patient 73 from exon 4 - 6 .
N: normal; P: patient.
The hMSH2 transcript in the normal population
In order to find out if these mRNA deletions are normal variants in this
population or not, RNA extraction was carried out from lymphocytes of 20 healthy 
individuals with the same method as was used for patient’s RNA. RT-PCR was 
performed in two overlapping fragments. In the second round of PCR the whole
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coding sequence of hMSH2 gene was amplified by using three sets of nested primers. 
The profile and conditions of reverse transcriptase followed by PCR were the same 
as that used for patients. In the 20 healthy normal controls, no shorter products were 
observed, indicating the absence of these aberrant forms of mRNA in the normal 
population in the West of Scotland. Since some of aberrant mRNA mutations have 
been reported by different groups the possible frame shift mistake which could be 
made by taq DNA polymerase is being ruled out. In RNA splicing the branch point 
sequence, pyrimidine tract, 3’ splice site and also 5’ splice site are important 
determinants of splicing efficiency. In this study none of them was found to be 
abnormal. Another possibility is the presence of a gross genomic deletion as reported 
for example in Duchenne muscular dystrophy, but there is no documentation of this 
type of mutation in the mismatch repair genes. However, a 3.5 kb genomic deletion 
in the hMLHl gene has been reported as a cause of exon 16 missing from transcript. 
The possible site for these rare mRNA deletions could be somewhere within the 
introns which are not normally used for RNA splicing. However, the number of 
aberrant RNA splicing is not very low, although the mechanism of this particular 
phenomenon is not yet clear.
In summary, 47 families were investigated by a combination of different techniques 
including RT-PCR followed by PTT, CCM and sequencing. Splice site mutation was 
found in one case with MI+, two cases with multiple exon skipping and with MI+ 
phenotype, and four different partial mRNA deletion in different part of the gene 
(tumour was not available from these patients for MI analysis). Twelve patients 
with RER phenotype were tested and no alteration was found. No alteration was 
also found in patient 5 with RER+ phenotype. There was no RNA from patient 22 
and also patient 26 with RER+ for mutation analysis with above techniques. None of 
the aberrant RNA was present in normal population when 20 healthy individual was 
tested.
3.4. SSCP analysis of the hMSH2 gene
A combination of DNA and RNA based methods could increase the
efficiency of the mutation screening programme. Our strategy was based on RNA
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based methods, but DNA has its own advantages in that it is more stable than RNA 
and it is very convenient. Exons 1, 2, 3, 5, 6, 7, 12, 13, 14, and 15 were however, 
chosen for SSCP analysis. In these exons mutations and polymorphisms have been 
reported by others. However, 59 DNA samples from 46 families were tested for 
genomic alteration by employing SSCP (family 21 with a germ-line splice site 
mutation was excluded from this part of study).
3. 4.1. An infrequent variation at codon 322 in exon 6
Exon 6 was amplified by PCR, as described in materials and methods. The
SSCP results from this exon showed a shift band in two patients, in comparison to 
other normal controls (Figure 3.22). Asymmetric PCR was carried out to produce 
single stranded DNA for direct sequencing. On sequencing of genomic DNA in exon 
6 a G to A transition was found at codon 322 (Figure 3. 23). This mutation changes 
glycine to asparatic acid, and creates new sites for the following enzymes: ( i ) Adh I 
( ii ) Pie I ( i i i ) H inf I. This transversion also abolished two sites for enzymes Bsr I 
and Cvij I. As the H inf I was more popular than the others this enzyme was chosen to 
prove the presence of this mutation, and also for screening of the rest of the samples 
(Figure 3. 24) and also for screening 30 normal controls and it was present in three of 
them (5%).
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Figure 3. 22. Detection of mutation at the codon 322 by SSCP analysis.
The SSCP result of exon 6 showed shifted bands in two different individuals in 
comparison to normal controls. The shifted bands are indicated by arrows in lanes 3 
and 9.
94
p
T C  G A
N
T C G A
Figure 3. 23. Sequencing ofexon 6 revealed a G to A transition.
On sequencing at genomic DNA, a G to A transition was found in two unrelated 
individuals but not in any other patients. This alteration changes glycine to asparatic 
acid. N: normal, P: patient
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Restriction map for the enzyme Hinf I in exon 6 and its flanking region of the hMSH2 
gene.
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Figure 3. 24. PCR/RFLP analysis detecting point mutational changes in codon 322 of 
the hMSH2 gene. H inf I cleavage of mutant allele results in two fragments: 113 bp 
and 58 bp, while the length of normal allele is 171 bp. Lane 1: DNA size marker, 
Lanes 2, 4-9: normal controls, Lane 3: heterozygous individual.
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3.4.2 . A normal variation in the short polypyrimidine tract in intron 12
This is one of the first alterations in this particular gene, as reported by Fishel
et al. (1993) when they published the sequence of the hMSH2 mRNA. However, the 
results of SSCP in exon 13 revealed an alteration in many patients indicating a 
relatively high incidence in the region of the gene (Figure 3. 25). Direct DNA 
sequencing of exon 13 and flanking regions showed an alteration in short 
polypyrimidine tracts in intron 12, a T to C transition ( Figure 3.26). This transition 
only creates a new site for the enzyme Sfcl. The presence of this alteration was 
searched for by an enzymatic assay using Sfcl, and it was found that 16% of patients 
bear this alteration (Figure 3. 27). This frequent mutation was also present in 15% of 
normal controls (86 chromosomes from normal individuals were tested). It seems 
that this alteration is not a harmful mutation. No alteration was found in the coding 
sequence of exon 13 in the splice junction site.
1 2 3 4 5
Figure 3. 25. The SSCP analysis of exon 13 and its flanking regions in the hMSH2 
gene. The exon 13 and flanking regions were amplified by PCR and the products 
were loaded on to the MDE gel. An alteration was found in many patients. The 
shifted bands are indicated by arrows in lanes 2-4.
98
N P
TC G A  T C G A
Intron 12
Figure 3. 26. Sequencing of the exon 13 and flanking regions revealed a T to C 
transition in short polypyrimidine tracts in the 3 end of intron 12 at position -6 from 
splice site. The mutation is indicated by an arrow and the splice site is indicated by a 
bar line. N: normal, P: patient.
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Restriction map for the Sfcl in exon 13 and flanked region in the hMSH2 gene.
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Figure 3. 27. PCR/RFLP analysis of exon 13 in the hMSH2 gene.
Cleavage with Sfc I in the mutant allele produced two different fragments of 280 bp 
and 52 bp. It is very hard to see a 52 bp on the normal agarose gel. However, the size 
of normal allele was 332 bp and is indicated by an arrow. Lane M: DNA size marker, 
Lanes 1, 3 and 5: heterozygous patients, Lanes 2 and 4: normal controls.
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3. 4. 3. A normal variation in intron 1
No mutation or even polymorphism has been reported in the coding sequence
of exon one of the hMSH2 gene. Therefore it was decided to screen this individual 
exon by SSCP analysis. Amplification of exon one and it’s flanking region was 
carried out followed by SSCP analysis. The results of SSCP showed a polymorphism 
pattern in this exon (Figure 3. 28). The coding sequence of this exon has more than 
60% Gs and Cs, therefore with ordinary sequencing protocols it was not possible to 
sequence this part of the gene. This problem was solved by using dITP for dGTP. 
However, on sequencing of the genomic DNA a C to G transversion was discovered 
at nucleotide position +9 in intron one (Figure 3.29). Notably, this variation was 
found and published later by a group from Edinburgh (Bubb et al., 1996). The 
frequency of this polymorphism was found to be 45% when 66 normal chromosomes 
were tested.
Figure 3. 28. The SSCP analysis of exon one in the hMSH2 gene.
A polymorphism pattern was observed in the SSCP of exon one. The MDE gel was 
silver stained. The altered bands are shown by arrows.
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P N P
TCG A  T C G A  T C G A
Figure 3. 29. On sequencing exon 1 and it’s flanking region, a C to G transervsion 
was found in the nucleotide position +9 from splice site. The alteration is indicated 
by arrows. N: normal, P: patient.
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3. 5. Variation from published sequence
In the course of mutation analysis in this project an alteration from the
published sequence was observed in the hMSH2 gene. The importance of this 
alteration in not clear yet, but it will present as a variation from the published 
sequence in the hMSH2 gene. Interestingly, this alteration is located in the 
untranslated region (UTR) in the 3 end of this gene. However, a G instead of T was 
observed in nucleotide position -13 from termination codon (Figure 3. 30).
3. 6. Intronic mutations are frequently present in the hMSH2 gene
Leach et al., (1993) used two different sets of primers to amplify the
conserved region of hMSH2 from genomic DNA. They used one set of primers 
which were able to amplify a 1.4 kb fragment containing hMSH2 codons 616-705. 
The entire sequence of intron 12 would amplify with this primer. This primer was 
used to amplify this region followed by CCM analysis in this project. Thirty-four 
DNA samples from 32 families including 22 unknown families, two HNPCC, three 
polyposis colorectal cancer, and five families with family history of cancer were 
screened by CCM. Cleaved bands were found in five individuals from four families, 
including two affected members of an HNPCC family (Patient 21 and patient 32 
from family 8906), two unknown patients and one patient with CRC history. Some 
results of this search are presented in Figure 3. 31. It is likely that the cleaved bands 
are located in the non-coding sequences of the gene. However, none of these 
mutations were fully characterised by sequencing.
TC GA
A
A
T
A
G
T
T
■
£
UTR
Figure 3. 30. A variation from the published sequence in the hMSH2 gene.
A variation at the 3 end of the hMSH2 gene was observed in the genomic DNA. At 
nucleotide position -13 from the termination codon, a G instead of T  was observed. 
The nature of this alteration is not yet clear. The published sequence is given beside 
the photograph. The alteration is shown by an arrow. UTR: untranslated region, 
TGA: stop codon.
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Figure 3. 31. The CCM analysis of the fragment containing hMSH2 codons 616-705. 
The cleaved bands are indicated by arrows. H: hydroxylamine.
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3. 7. Mutation in hMLHl
The hMLHl is a second gene predisposing to colorectal cancer and is located 
on the short arm of chromosome 3 ( Lindblom et al., 1993; Papadopoulos et al., 
1994). It is believed that the majority of hMLHl mutations cluster at the exonic 
region 15 and 16 (Wijnen et al., 1996). These two individual exons were therefore 
amplified by the polymerase chain reaction, using primers in the flanking regions of 
the corresponding exons. Subsequently, SSCP analysis was carried out as described 
in chapter two. The SSCP results from exon 15 showed a band shift in many of the 
patients (Figure 3. 32 a). On sequencing the genomic DNA an A to G transition was 
found at position -19 in intron 14 (Figure 3.32 b). This alteration abolishes the 
restriction site for enzymes TSP 45 I and also Mae III in the mutant allele. The TSP 
45 I was chosen to screen the normal population. By means of this enzymatic assay 
it was found that 44% of the normal population bears this mutation ( Figure 3. 33).
TC G A
' /
/
(A)
N
T C G A  TC GA
in
O
x
LU
J
(C)
(B)
Figure 3. 32A. The SSCP result from exon 15 in the hMLHl gene. The alterations 
are indicated by arrows. (B) On sequencing of exon 15 and flanking region an A to G 
transition was found at position -19 in many patients and also in the normal 
population. The alteration is shown by an arrow. C: exon 15 and its flanking region. 
N: normal; P: patient.
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5’ 3’
40 bp 220 bp
4——M   --------------------------------------►
| + | Normal allele
I 260 bp J Mutant allele
Restriction map for the TSP 45 I enzyme in exon 15 and flanking region of the 
hMLHl gene.
1 2 3 4 5 6 7 8
■260 bp 
220 bp
40 bp
Figure 3. 33. PCR/RFLP analysis of exon 15 in the hMLHl gene.
Cleavage with TSP 45 I in the normal population revealed a high frequency of this 
polymorphism. Lane one : DNA ladder. Lane 2: undigested PCR products. Lanes 3, 
4 and 7: heterozygous individuals. Lanes 5, 6 and 8: homozygous individuals.
In summary, 10 different exons including exons 1, 2, 3, 5, 6, 7, 12, 13, 14, and 15
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from the hMSH2 gene and also exons 15 and 16 from the hMLHl gene were tested 
by employing SSCP in 59 individuals from 46 families. However, three alterations 
including one rare normal variation in the coding sequence of the exon 6 and two 
polymorphisms in intronic regions of the hMSH2 gene and also one polymorphism in 
the intronic region of exon 15 in the hMLHl gene were found. None of these 
variations could be the cause of disease as it was found in normal population and the 
frequency of them obtained by using appropriate restriction enzyme.
3. 8. Summary of mutations
The pathological and nonpathological mutations found in this study are presented in 
table 3. 3.
Kindreds Gene exons/introns
affected
cDNA
changes
Genomic
changes
M I
status
Protein alteration
21 hMSH2 15 exon 15 
deleted
G/gtttgt to 
G/gtttct
+ Out o f  frame 
deletion
18 HMSH2 2-6 Exons 2-6 
deleted
N I + Out o f  frame 
deletion
3 hMSH2 2-8 Exons 2-8 
deleted
NI + Out o f  frame 
deletion
17...... hMSH2 9-12 Exon 9-12 
deleted
NI N T Out o f  frame 
deletion
63 HMSH2 1 Exon 1 
deleted
NI N T Out o f  frame 
deletion
38,... hMSH2 INV 1, +9 - C to G N T No alteration
17,... hMSH2 INV 12, -6 - T to C N T No alteration
3 9 ,..., hMSH2 6 G to  A G to  A +/NT Glycine to asparatic 
-acid
29 hMSH2 14-15 exons 14- 
15 deleted
NI N T Out o f  frame 
deletion
73 hMSH2 4-6 exons 4-6 
deleted
NI - In frame deletion
5, 8 ,.. . hMLHl INV 14,-19 - A t o G - N o alteration
NI: not identified, NT: no tumour, INV: intron
Table 3. 3. A summary of mutations which are identified in this study.
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DISCUSSION
4.1. Microsatellite analysis in CRC patients
Replication error or microsatellite instability is a new phenotype of human 
cancer and also some other diseases. The MI in these disease arises from alterations 
in normal regions of the genome consisting of short sequences of repeated DNA. 
Alterations in length of microsatellite sequences between normal DNA and tumour 
DNA occurs in about 90% of HNPCC cases and in about 15% of cases of non- 
familial colorectal cancer. MI is also found in sporadic endometrial, gastric cancer 
and lung cancer which is not associated with HNPCC.
MI was chosen as a first screening step in order to assess the level of MI in the 
tumour of patients with colorectal cancer in the West of Scotland. Thirty unselected 
pairs of normal and tumour tissues were tested for genomic instability at a 
minimum of two and a maximum of nine microsatellite loci. MI+ was found in nine 
patients in at least one marker and seven patients were found to be MI+ in at least 
two or more (up to eight) markers. There was no information about the history of 
disease and possible affected members of the family for a majority of cases (28 
families). Of them, six families were found to be MI+ (21.5%) and a harmful 
mutation was found only in one family (17%). Both families with a history of 
colorectal cancer were found to be MI+ ( patient 21 and 78) with 5 and 2 affected 
members in the families, respectively. A gemline mutation was found in one of them 
(patient 21). No RNA was available for mutation analysis from patient 78. There 
were no significant differences between the average age of patients with and without 
MI, additionally no significant differences were observed between males and females 
with or without MI. Although the connection between MI and defective MMR was 
established in human tumours from members of families with HNPCC by linkage 
studies and positional cloning. It is not possible to correlate MI phenotype and 
mismatch repair gene defect in this small collection of samples as there is not enough 
inoformation to evaluate this fully. However, germline mutations in four known
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MMR genes have been causally linked to the vast majority of colorectal cancers 
with HNPCC and approximately 15% of sporadic exhibit MI phenotype. Liu et al. 
(1995) found that one in ten patients with MI+ sporadic colorectal tumour had a 
detectable germline mutation in a mismatch repair gene, suggesting that hereditary 
cases may not be very common in this group. Moreover, only three of seven sporadic 
cell lines with microsatellite instability had mutations in MSH2, MLH1, PMS1, or 
PMS2, implying that a significant fraction of sporadic RER+ cancers arise from 
mutations in other genes. Germline mutation in MMR genes seems to occur 
relatively frequently in young sporadic RER+ patients with CRC under 35 years of 
age as Liu et al. (1995) was able to find germline mutations in 5 patients (42%). It 
seems that young patients with RER+ phenotype have a high probability of carrying 
a germline mutation in one of the major MMR genes. It seems justified to propose 
that patients with RER+ sporadic CRC diagnosed under 50 years of age should be 
screened for mutations of at least two major mismatch repair genes, hMSH2 and 
hMLHl.
4.2. Mutation analysis
In this project mutational screening of hMSH2, and also two exons of the
hMLHl gene was performed. The sites and also the effects, of mutations are listed 
in Table 3.3 (chapter 3) and will be discussed below:
A novel splice site mutation at position +5 in the intron 15 of the hMSH2 
gene was found in an HNPCC family. The mother and three of her offspring had 
colon cancer, while a fourth had cancer of the bladder. Microsatellite instability was 
therefore sought and found in one of those with colon cancer (Patient 21, age 37 at 
diagnosis), using marker loci at D2S123 (Aaltonene et al. 1993) and 635/636 
(Thibodeau et al. 1993). Application of the protein truncation test showed one 
normal and one short peptide. Reverse transcriptase/PCR analysis of the region in 
the hMSH2 mRNA, containing exons 14,15 and 16, revealed a short transcript.
I l l
Subsequent cDNA sequencing indicated the loss o f exon 15. On sequencing the 
genomic DNA, the splice site donor sequence of intron 15 was found to have a G  to 
C transversion at position +5. This mutation was heterozygous in the tumours o f the 
affected individuals in this family. However, since the mother of this family had 
died, it was not possible to show the vertical transmission of the mutation.
This point mutation creates a restriction site for the enzyme, Dde I, and was
used to identify the mutation in three other affected members of the family. It was
not found in the healthy member or in 61 normal controls. The enzymatic assay was
also used to screen a further 116 colorectal patients but no alteration was found. Liu
et al.( 1994 ) and Luce et al. (1995) also reported the skipping of exon 15, caused
by a mutation at position +1 in intron 15. The deletion of exon 15 produces a
translational fem e shift and consequently a premature stop codon 6 base pairs 
>
downstream of the 5 end of the exon 16. Due to this mRNA deletion, codons 820- 
878 were deleted from the transcript resulting in a truncated peptide 58 amino acids 
shorter than normal. However, application of PTT for two affected members o f this 
family showed truncated peptides. Another member o f this family, with no history of 
colon cancer, had the same mutation but developed bladder cancer. Similar results 
have been reported by Liu et al. (1996). They reported two kindreds with a deletion 
of codon 618 in the hMLHl gene. One of them had a brain tumour characteristic of 
Turcot’s syndrome, whereas the other had no extracolonic neoplasm. The explanation 
of our observation and that of Liu et al. for this particular case could be due to 
environmental conditions or other genetic factors.
The presence of one germ-line mutation in four affected members o f one 
family could be evidence for inheritance of this mutation. It was not, however, 
possible to show the vertical transmission of this mutation in the family due to lack 
o f pathological specimens from the mother of this family who also died of colon 
cancer when she was quite old. It is believed that RER phenotype is the
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manifestation of mutation in MMR genes, and this finding could be another 
document to address this fact.
Shapiro and Senapathy (1987) described a method for potential consensus 
values at splice junction sequences. Based on this method, each of 8 nucleotides at 
the 5’ splice junction site from position -2 through to position +6 have a particular 
score between 0 and 100. The final score for the 5’ splice site was calculated (please 
see section 3.3.7) for this family and was found to be reduced from 78.36 in the 
normal allele to 64.18 in the mutant allele. Therefore the mutation at the 5’ splice site 
of intron 15 reducesthe consensus value by 14.18%, and may contribute to exon 15 
skipping from the transcript.
Two gross mRNA deletions were found in two different patients:
(i) mRNA deletion of exon 2-6 inclusive, (ii) mRNA deletion of exon 2-8 inclusive.
(i) This deletion was found in patient 18, whose microsatellite instability 
results showed replication errors in 8 of 9 markers. Interestingly, patient 18 had a 
tumour in three different sites of her colon, one of them in the ascending colon, the 
second one in the transverse colon and the third one in the descending colon. The 
results of microsatellite instability were different for different tumours, when 
examined by different markers as presented in Table 3. 1. As mentioned earlier, it is 
believed that the replication error in simple tandem repeat is due to DNA polymerase 
mistake or slippage during replication and this is the manifestation of defects in 
repair enzymes. Although the results from the three tumours seems to be different 
from each other, there are no significant differences between tumours in the proximal 
(ascending and transverse) and distal tumour (descending). Ta (ascending tumour) 
showed RER+ with 5 of 9 markers (55%), Tb (transverse tumour) showed RER+ 
with 6 of 8 markers (75%) and Tc (descending tumour) showed RER+ with 5 of 8 
markers (62%).
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The published results about the replication error and the site of the tumour in 
colorectal cancer and HNPCC are different. In general, approximately 70% of 
HNPCC colon cancers and 30% of sporadic tumours are located in the splenic 
flexure (Lynch and Smyrk, 1996). The importance of understanding this novel 
mechanism in tumorigenesis is that the RER+ is a clue to defects in repair genes. 
However, as shown in chapter three, the RT-PCR of patient 18 showed two different 
bands, one of them corresponds to the normal product, and the second one was 
shorter than normal. On sequencing of the normal band no alteration of the published 
sequence was found, but sequencing of shorter products showed a deletion from the 
3 end of exon 1 to 5 end of exon 7 (exons 2-6 deleted). This is an out-of-frame 
deletion of codons 71-359, resulting in truncated proteins due to a new termination 
codon 3 bp downstream of splice site in the exon 7.
To define the nature of these defects at the genomic level, the regions 
surrounding affected exons, which seem to be responsible for alternative splicing, 
were amplified from the normal genomic DNA of corresponding individual. No 
alterations were found either in splice junction sites or branch point sequences in any 
of related exons. The 3 end of intron 1 has the longest poly-pyrimidine tract in this 
gene, and could potentially be a good site for alteration. The role of the poly­
pyrimidine sequences in the lariat formation [pre-mRNA splicing is a two step
9
process. In the first step, the 5 splice site is cleaved and, in a co-ordinated reaction,
9 9 9
the 5 G residue of the intron is linked in a 2 , 5 -  phosphodiester linkage to an A
9 9
residue near the 3 splice junction. In the second step, the 3 splice site is cleaved, the 
exons are joined and the intron is released as a “lariat”] and exon ligation has not 
been clearly established.
Mutations in the AG dinucleotide in human p-globin intron 1 decrease the 
efficiency of lariat formation, but do not abolish this reaction (Reed and Maniatis 
1985; Ruskin and Green 1985). In contrast, deletion of the pyrimidine stretch in
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human p-globin intron 1, or an adenovirus intron abolishes lariat formation 
(Frendewey and Keller., 1985; Reed and Maniatis., 1985; Ruskin and Green., 1985) 
and spliceosome assembly (Frendewey and Keller 1985; Binddereif and Green., 
1986). This data suggested that pyrimidine tract is essential for lariat formation and 
that the AG dinucleotides increase the efficiency of this reaction. However, in spite 
of difficulties on sequencing of this region, due to slippage of DNA-polymerase, no 
alteration was found either in pyrimidine sequences or at AG dinucleotides sequence 
from normal published sequence. Southern analysis using different restriction 
enzymes (Taql, EcoKL, PstT) and different cDNA probes with various lengths were 
also unable to detect any genomic deletion. mRNA deletion from exons 2-6 inclusive 
has also been reported by another group from Australia ( Kohonen-Corish et al. 
1996), but no genomic abnormality or splice site mutations have been reported by 
them either.The absence of multiple exon skipping from transcripts is therefore 
likely to be due to mutations in regulatory regions (Liu et al. 1995) or a mutation 
within the intronic sequence (Vogelstein, personal communication) . The possible 
defects in any components which were discussed above could not be excluded. In a 
normal RNA splicing a balance between many factors are required. Similar results 
(multiple mRNA exon skipping) have been reported in this gene by other groups. 
For instance, deletions of exons 8-15 inclusive (frameshift mutation)(Liu et al. 1994) 
and many single exon skipping such as: deletion of exon 12 (Liu et al. 1996), exon 
13 (Liu et al. 1995), exon 15 (Liu et al. 1996) for the hMLHl gene and also exon 7 
and 13 (Liu et al. 1994, 1996) for the hMSH2 gene could place in this category. 
However, exon skipping from transcripts in the hMSH2 and hMLHl genes are not an 
unusual phenomenon in these two particular mismatch repair genes, and also in many 
other genes. Most of these deletions are frame shift mutations and could produce 
truncated proteins.
(ii) The second gross mRNA deletion was found in a patient with RER+ 
phenotype. Microsatellite instability was found in 2 of 9 markers (22%). The patient
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was operated at the age of 64 because of colon cancer. Amplification of segment 1 of 
this patient showed two bands, one of them was as expected and the second one was 
shorter. On sequencing of the shorter products an mRNA deletion of exon 2 to exon 
8 was found whereas no alteration was found at normal products from published 
sequence. This is an out-of-frame deletion of codons 71-359 creating a new 
termination codon, 3 bp downstream of splice site in the exon 9. No other member of 
this family was available for further study. This multiple exon skipping has been 
reported by another group from Australia who were also unable to find the cause of 
this mRNA deletion at genomic DNA (Kohnen-Corish et al. 1996). However, a 
significant number of mutations reported in MMR genes are due to defects in exons 
splicing (see Table 4.3).
Four different mRNA deletions were found in the course of mutation analysis 
in this project in several independent cases. One of these mRNA deletions was found 
in four unrelated cases (case C in Figure 4. 3). The molecular pathology of these 
mRNA deletions are disscused below:
In one patient a partial deletion was found within exon 1 encompassing 
codons 9-50. Due to this deletion 21 nt from 5 end of exon 1 and 66 nt from 3 of 
exon 1 were retained in the transcripts while the most sequences of exon 1 were 
deleted from transcripts. This is an out-of-frame deletion and created a new 
termination codon 22 bp upstream of 3 end of exon 1 (case A in Figure 4.7). On 
sequencing of genomic DNA at the 5’splice junction site of the intron 1 a C to G 
was found at position +8. Further investigation proved that this mutation was a 
normal variation, so it could not be assumed that this substitution was the cause of 
the deletion. No abnormalities were found by DNA blotting, using a cDNA probe or 
by sequencing of the coding sequence of the exon 1.
In another patient a partial mRNA deletion was found in which only 31 nt 
from the 5 end of exon 4 and 73 bp from the 5’ end of exon 6 were retained in the 
transcripts. Most part of exon 4 and the entire coding sequence of exon 5 and 61 nt of
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the 3 end of the exon 6 were deleted from the transcripts. This is an in frame deletion 
of the codons 228-340, producing a polypeptide with 115 amino acids less (case B in 
Figure 4.7). No abnormalities were found by sequencing the genomic DNA either 
within the exons or at the splice junction sites.
In four different and unrelated patients, a partial mRNA splicing was found 
from exon 9-12. RT-PCR products of corresponding patients showed two different
bands, on sequencing of short transcripts it was found that 85 nt of the 5 end of exon
*
9 are retained in the transcripts while the exons 10,11 and 52 nt of the 3 end of the
t
exon 12 were removed. It is notable that the 5 end of exon 10 and exon 11 and also 
exon 12 are located in the conserved region of the hMSH2 gene. Due to this deletion 
codons 493-603 were deleted from transcripts, resulting in a new termination codon 
at the position +102 from the 3 end of exon 12. No alterations were found within 
exon 9-12, or in any of the splice junction sites at genomic DNA. DNA southern 
blotting with different restriction enzymes with cDNA probes and also genomic 
probes were unable to find any genomic re-arrangement (case C in Figure 4.7).
»
Another similar result was found in one patient in whom the 11 nt of the 5
9
end of the exon 14 and 20 nt from the 3 end of exon 15 were retained in the 
transcripts, while the most parts of exons 14 and 15 were deleted from transcripts.
This is out-of-frame deletion of codons 742-872, creating a new termination codon
*
26 bp downstream from the 5 end of exon 16 (case D in Figure 4.7). However, no 
alterations were found on sequencing of the exons 14 and 15 and also in all splice 
junction sites.
Three of four partial mRNA deletions described here produced premature 
termination codons resulting in truncated proteins. In all of the cases mentioned
9 9
above no alteration was found at either the 3 or 5 ends of the splice junction sites, 
and also at branch point sequences in intronic regions. However, mutation or 
deletion within the intron could not ruled out.
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It is important to emphasise some of the common features of these mRNA 
deletions. Firstly, all of them have short repeats at breakpoints including 5 or 6 
nucleotides (Figure 4. 7, bold cases). Secondly, the repeats terminated at GA (case B 
and D) or GCfcase A and C). Thirdly, the short repeats in cases B and D have the 
same sequences (AAAGA), and finally case C has occurred in four unrelated 
patients.
Possible explanations for this observation are discussed below:
Novel length alleles at dinucleotide marker loci and at tetranucleotide marker 
loci are known to be formed without exchange of flanking markers. This means that 
they are not generated by unequal crossing-over. Instead, as new mutant alleles have 
been observed to differ by a single repeat unit from the originating parental allele 
(Mahtani & Willard., 1993), the most likely mechanism to explain length variation is 
a form of exchange of sequence which commences by slipped strand mispairing. In 
several cases, the patients for deletions are marked by very short direct repeats. For 
example, the breakpoints in numerous pathological deletions of the mitochondrial 
genome occur at perfect or almost perfect short direct repeats. Of these, the most 
common is a deletion of 4977 bp which has been found in multiple patients with 
Keam-Sayre syndrome. This deletion results in elimination of the intervening 
sequence between two perfect 13- bp repeats, and loss of the sequence of one of the 
repeats. Recombination does not appear to occur in the mitochondrial genome and 
Schoffiier et al. (1989) have postulated that such deletions arise by a replication 
slippage mechanism, similar to that occurring at short tandem repeats. The ends of 
the duplicated sequences, like those of the common deletions, are often marked by 
short direct repeats, and the mechanisms of duplication and deletion appear to be 
closely related (Poulton & Holt., 1994).
Splice site recognition is especially problematic in mammals, in which genes 
are usually interrupted by multiple introns, often much longer than the exons, and 
splice site sequences are not highly conserved. The mammalian 5’ splice site, branch
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site and 3’ splice site consensus sequences are /GURAGU.YNYURAC. and 
Y>1QNYAG/. respectively (where / denotes a splice site, N, any nucleotide; R, 
purine; Y, pyrimidine; and underlining, the most highly conserved positions. As
cases A and C at GC (Figure 4.7). On the other hand, the introns 2, 3, 8,12 and also 
13 of the hMSH2 gene were begun either with GA(introns 2 and 8) or GC (introns 3, 
12 and 13), suggesting that these sequences (GA or GC) potentially could act as a 
cryptic splice site in splicing proccess.
Similar observation has been reported by Ali et al. (1992) they have reported 
the same mRNA deletions in the alpha subunit of G protein. The alpha subunit of G 
proteins play a vital role in signal transduction. They found three partial RNA 
deletions (not edge to edge). In the first deletion, exon 4 has joined to exon 10 
resulting in in-frame-deletion of codons 89 to 259. In the second deletion, exon 8 
joined to exon 10, resulting in in-frame-deletion of codons 215 to 248. Interestingly, 
a penta nucleotide (G GTG G) is present in both sites of breakage points, and they 
assumed that splicing could occurs between the amino acids 214 and 249 using the
mentioned earlier in cases B and D(Figure 4.7) the repeats terminated at GA and in
A
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
CAG CCG AAG GAG ACG CTG GCG CAC GGC GAG GAC GCG CTG Normal
4 5 6 7 8 9 45 46 47 48 49 50 51
CAG CCG AAG GAG ACG C 
4 5 6 7 8 A= 124 bp
G CTG
Out-of-frame
B
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
\
ATT CTG ATC ACA GAA AGA AAA /  /TAA GGA CAA j 
222 223 224 225 226 227 2287 X 337 338 339
:a a  gga caa a g a  ctt gtt Normal
 340 341 342
A= 334 bp
ATT CTG ATC ACA GAA AGA 
222 223 224 225 226 227
ctt gtt In-frame
341 342
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
AAG AA G  A TG  CAG TCA ACA / /  CAG CTA G A T G C T GTT Normal
490 491 492 493 494 495 601 602 603 604 605
A= 328 bp
AAG A A G  ATG C ..........................................................................  CT GTT Out-of-frame
490 491 492 604 605
D
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
TCT GCA ACC AAA G A T TCA TTA - f - f -—  GCA GCA A AG AAG TGC Normal 
738 739 740 741 742 743 744 869 870 871 872 873
A= 383 bp
TCT GCA ACC AAA G A ............................................................................. AG TGC Out-of-frame
738 739 740 741 742 872 873
Figure 4. 3. Schematic presentation of abnormal splice junctions. Exons 1-16 of the 
normal transcript are indicated. The common repeat sequences before and after 
breakage point are presented in bold. Horizontal solid lines represent continuation of 
normal sequences. Dotted lines indicate the deletion of sequences between the 
indicated codons.
donor site GT (high lighted), and an unusual acceptor site TG (underlined). In the 
third deletion, exon 9 joined to exon 11, resulting in out of frame deletion of codons 
241 to 281 (second nucleotide of codon 241 joined to the first nucleotide of codon 
281). In none of the deletions described by this group was genomic alteration 
involved.
The presence of partial mRNA deletion in another gene could be a further 
documentation of this type of rare mRNA missplicing. Alex Tipping et al. (Guy’s
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Hospital, London; personal communication 1997) had similar results in 6 of 8 cases. 
He described that the starting and ending of deletions was in the middle of exons and 
in none of the cases the deleted regions began with GT or GC and ended with AG. 
They have observed eight different repeats at the breakpoints but these transcripts 
only had one copy of the repeat while the full length of the cDNA carries only two 
copies. However, they were not able to find the cause of mRNA deletions in the 
genomic DNA. At least one other observation has been reported by a group from 
Australia (personal communication) and they were not able to find the cause of 
mRNA deletion at the genomic DNA. However, it is not yet clear as to what extent 
this aberrant mRNA is important in producing stable proteins in the cytoplasm and 
whether or not it is the cause of the disease.
Four point mutaions were found in different parts of the hMSH2 gene. Three 
of them were found in the hMSH2 gene, and the fourth one in the hMLHl gene. The 
most interesting of them will be discussed below:
Fishel et al. published the results and the sequence of the HMSH2 cDNA gene 
in 1993. They also published details ofan intronic alteration at position -6 in intron 
11 of the gene. They were only able to find this alteration in affected individuals and 
concluded that the candidate gene, hMSH2, is the proper gene for non-polyposis form 
of colorectal carcinoma. This alteration, a T to C transition, is located in the short 
polypyrimidine tract in the intron, in front of the exon encoding the most conserved 
region of the protein. The importance of the polypyrimidine tract at the 3’ end of the 
intron in RNA splicing was discussed earlier. However, in this project, it was found 
that this mutation was present not only in a relatively large number of affected 
individuals but also in 15% of normal individuals (86 healthy chromosomes were 
studied). This simply showed that it could not be the cause of disease, but Fishel et 
al. (1993) concluded that the presence of this mutation in the tumour tissue, but not 
in normal tissue of the same individuals, provides a strong indication that this base 
change represents a mutation rather that a polymorphism. If the mutation analysis is
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the basis for diagnostic laboratories, maximum care should be undertaken to avoid 
misdiagnosis. It is also possible that a polymorphism is reported as a mutation such 
as the above example and vice versa such as in the following example:
Huie et al. (1994) described one splice site mutation at position -13, a T to G 
transversion in intron 1 in a patient with adult onset of the autosomal recessive 
disorder glycogen storage disease type II (GSDII). The IV S l-1 3 T to G  transversion 
in the polyprimidine tract in the acceptor splice site was found on one allele in over 
two thirds of adult onset GSDII patients studied (28/41), but was not present in 58 
normal chromosomes. RT-PCR, followed by sequencing, confirmed the splicing of 
exon 2 in individuals with IVS1-13 T to G transversion. Raben et al. in 1996 
described three mRNA splicing patterns for the same mutation which was described 
by Huie et al. in 1994, in adult lysosomal storage disease (glycogenosis type II). This 
intronic mutation creates three splice variants namely SV1, SV2 and SV3, in which 
exon 2 was partially or completely removed from transcripts. In SV1 a cryptic splice 
donor site, 36 nt downstream from exon 1 was used and exon 2 was spliced out; in
9
SV2 exon 1 splice to exon 3, and in SV3, 60 nt of the 3 end of exon 2 are retained in 
the transcript while most of the exon 2 including the initiation codon are removed. 
Maximum care should be undertaken for proper interpretation of any alteration. It is 
possible for a polymorphism to be consider as a mutation and vice versa.
To date, one polymorphism has been reported in exon 6 of the hMSH2 gene at 
codon 322 (Liu et al. 1995). According to this alteration G£C will alter to GAC 
which changes glycine to aspartic acid. However, since glycine is a non-polar amino 
acid and asparatic acid is an acidic one, it is likely that the polarity of the protein will 
be changed. This alteration was found in two unrelated and affected individuals. 
Further study of the normal healthy controls revealed that 4% of them bear this 
alteration (102 normal healthy chromosomes were studied). The presence of this 
transition in the healthy individuals put this alteration as a polymorphism rather than 
a harmful mutation. Liu et al. reported the frequency of this alteration to be 2%, but
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they did not examine more than 30 individuals. They found this polymorphism to be 
heterozygous in the normal tissue of one patient, and homozygous in the tumour of 
the same patient. This result demonstrated that one germ-line mutation of the wild 
type allele was coupled with a second somatic mutation on the second allele in the 
tumour (second hit). However, due to the low frequency of this polymorphism (4%) 
it could be an infrequent variation.
It has been reported that the majority of mutations in the hMLHl gene are 
located in the region of exon 15 and 16. These two exons and their flanking regions 
were searched for any alterations. In intron 14, a G to A was found at position -19 
relative to 5 end of exon 15. The presence of this alteration in a majority of normal 
individuals indicated that this alteration has no effect on the RNA splicing. 
Interestingly the frequency of this polymorphism is about 46% in the normal 
population (102 normal chromosome studied). Due to the very high frequency of this 
polymorphism it could be useful as a marker for linkage studies. Although one 
abnormal pattern of SCCP at exon 16 was present in two unrelated individuals, on 
sequencing of the corresponding exon no variation was found.
There are two common mutations in the Finnish population on the hMLHl 
gene. One of these two mutations is a 3.5 kb genomic deletion involving exon 16. 
This genomic deletion was searched by PCR using three primers as shown in Figure 
4. 4 (Lahti et al. 1995). Primers (1) and ( 3) amplify a fragment of 634 bp specific for 
the mutant allele. In the normal allele the distance is about 4 kb and no product could 
be obtained by normal PCR. Primers (2) and (3) amplify a 475 bp fragment specific 
for the normal allele (Figure 4.1). However, this mutation was not present in all 
patients indicating differences between populations.
More than 90% of the gene consist of non-coding sequence. Although the 
structure of the peptides will be determined by the sequence of codons within the 
coding sequence it is clear that the non-coding sequence has its own importance. It
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has been shown that intronic regions can have a suppresser effect on transcription. It 
is also clear that some sequences adjacent to the splice site exhibit a role in proper 
splicing and other sequences, particularly branch sites have an important role in 
intron removal. Some alterations to non-coding sequences may have no effect on 
splicing.
Exon 15 Exon 16 Exon 17
(i) (2)
Normal allele
(3)
Exon 15 Exon 17
lkb 
I I
Mutated allele
F ig u re  4. 1. S chem atic  p resen ta tio n  o f  p rim ers  1, 2  and  3 and  a  3.5 k b  g en o m ic  d e le tio n  in 
th e  hMLHl gene. O pen  boxes d en o te  ex o n s 1 5 ,1 6  and  17. A rro w s sh o w  th e  site  o f  p rim ers .
4 .2 .2 . Aberrant mRNA and its causes
The coding sequence regions of eukaryotic genes are interrupted by
intervening sequences (introns). In RNA splicing two different main groups are
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involved: cis acting factors (the factors that are within the gene in which the splicing 
is in progress e.g. 3’ and 5’ consensus sequences) and trans acting factors (the factors 
that are not within the gene in which the splicing is in progress e.g. 
ribonucleoproteins). The enzymatic removal of introns from pre-mRNA is preceded 
by the formation of a large ribonucleoprotein complex known as the spliceosome. 
The spliceosome is composed of five small nuclear RNAs(snRNA): U1,U2, U5, 
U4/U6 and numerous proteins that assemble together with pre-mRNA to facilitate the 
two reactions of splicing. Thus the selection of splice site, which ultimately 
determines the structure of spliced messenger RNAs and the proteins they encode, is 
accomplished by the assembly of the spliceosome at specific sites on a pre-mRNA 
splicing substrate. In splicing, the branch point, pyrimidine tract, 3’ splice site, and 5’ 
splice site are important determinants of splicing efficiency (Sterner et al.1993). It 
has also been shown that the length of the downstream intron plays a role in splice 
site selection (Dominiski et al. 1992). Dominiski and Kole have shown that short 
internal exons are ignored by the splicing machinery in vitro and in vivo, resulting in 
exon skipping. This phenomenon can be reversed by substitution of individual 
purines in the poly (Y) tract of the upstream intron with pyrimidines, suggesting an 
interplay between the tract and the downstream exon (Dominiski & Kole 1991). In 
addition to the elements mentioned above, both the sequence and the length of the 
internal exons affect splice site selection (Dominiski & Kole 1992).
The mechanism of splicing site selection in alternative splicing is poorly 
understood, and many details of this process remain to be elucidated. In several cases 
of alternatively spliced pre-mRNA, such as human immunodeficiency virus Rev 
protein, selection of splice sites appears to be regulated by specific trans-acting 
splicing factors (Dominski et al. 1992). However, specific factors may not always be 
involved, since alternative use of splice sites was shown to be affected by a change in 
the concentration of constitutive splicing factors (Ge et al. 1990; Harper et al. 1991; 
Krainer et al. 1990). The mechanism of splice site selection is complex and many
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factors are involved in this process. Some patterns of alternative splicing will be 
discussed below:
The coding sequence regions of eukaryotic genes are split by intervening 
sequences or introns which must be removed from the hnRNA by RNA splicing. An 
unspliced RNA would be degraded within the nucleus or, if transported to the 
cytoplasm, would be unable to produce a functional protein. This is due to the 
presence of many interruptions of the protein coding region (termination codons) 
within the introns. Various cases of alternative RNA splicing have been described 
(Mckeown, 1992). In RNA splicing, a single gene is transcribed in many different 
tissues and the transcripts formed are processed differentially to yield various 
functional mRNAs in the different tissues. Transcription is controlled by different 
factors and the presence of more than one promoter and also 5 and 3 ends of RNA 
have very critical roles in splicing (Young et al. 1981). In many genes, the process of 
cleavage and polyadenylation occur at different positions within the primary 
transcripts and the resulting transcripts are then differentially spliced. The existence 
of tissue-specific splicing factors which regulate alternative splicing is also indicated
» 9
by the existence of cases where transcripts with identical 5 and 3 ends are spliced 
differently in different tissues, and which therefore can not be explained by different 
usage of promoters or polyadenylations sites.
   9
The 3 end of RNA has an important role in splicing. Splicing of calcitonine 
provides a good example of this point (Rosenfeld et al. 1984; Leff et al. 1988). The 
presence or absence of particular tissues-specific factors in the nervous system and 
thyroid gland determines the pattern of RNA splicing for calcitonine. Calcitonine is a
9
peptide of 32 amino acids, and has four domains for calcium. Although the 3 end of 
this gene is different (the presence of two different polyadenylation sites), it is 
suggested that the existence of tissues-specific factors determines the pattern of RNA 
splicing. The interaction of tissues-specific factors at the site of binding could either
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inhibit or promote the use of alternative splicing in different tissues, resulting in 
different transcripts in different tissues with particular role (s).
Nonsense codons could sometimes cause defects in pre-mRNA splicing. 
These defects include: (i) skipping of the nonsense-containing exon and, in some 
examples, one or more flanking exons. ( ii ) retention of the intron (iii) use of a 
cryptic splice site in the vicinity of the nonsense codon (Maquat 1995). On the other 
hand, nonsense codons could reduce mRNA half-life. For instance, human P globin 
mRNA that cause P° -thalassemia, a recessive haemolytic anaemia, appear to reduce 
the half- life of fully splice mRNA after the mRNA has been exported to the 
cytoplasm (Maquat et al. 1981; Lim et al. 1989; 1992; Lim and Maquat 1992). For 
example, the half life of p-globin mRNA in patients harbouring a frameshift induced 
nonsense codon within exon 2 was calculated to be 30 min where the half life of non-
thalassemic p-globin mRNA was estimated to be >  16 h (Maquat et al. 1981).
In splicing, different factors are involved and include branch site sequences, 
consensus intron/exon boundary sequences, exon length (Dominski and Kole, 1991), 
five different small nuclear ribonucleoproteins (Guthrie 1991) and many other 
components (Dominski and Kole, 1992; Robbenson et al. 1990; Fabrizio and 
Abelson 1990; Mcpheeters and Abelson, 1992). Each splice site is recognized 
independently by specific factors whose interactions provides exon justaposition for 
ligation in the correct order (Robbeson et al. 1990). Abnormal transcripts and 
scrambled exons, have been reported in the deleted colon cancer gene (DCC) (Nigro 
et al. 1991) in both normal and neoplastic cell types. Exons are joined but in an order 
different from that present in the genomic DNA. The mechanisms for generating 
such scrambled transcripts are not known (Nigro et al. 1991). Mutation analysis on 
the central domain of U6RNA has shown that mutations at nt 34-62 can partially or 
completely block the splicing process (Mcpheeters and Abelson, 1992). Mutation 
analysis on the central domain of U6RNA (one of the trans acting factors in RNA
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splicing) has shown that mutations at nt 34-62 can partially or completely block the 
splicing process (Mcpheeters and Abelson, 1992). Successful exon recognition 
occurs when the balance of all of the components is sufficient to support the splicing 
process (Sterner and Berget, 1993). However, splicing is a complex process and such 
complexity is vastly increased by controlling elements that define tissues-specific 
alternative splicing patterns. It has been estimated that 100 or more gene products 
(about 2% of the yeast genome) are involved in splicing functions (Sharp, 1994), and 
therefore a mutation in any one of these could affect the whole process and perhaps 
be responsible for a mRNA deletion in which no abnormality could be found in 
genomic DNA.
A number of different mutations as described before have been reported in 
mismatch repair genes. There are some mRNA deletions including single and 
multiple exon skipping in which the authors were not able to determine the cause of 
mutations at the genomic DNA (Table 4. 2). All of these mutations could be 
potentially harmful, as they are out-of-frame deletions resulting in truncated protein. 
However, the number of published mutations in these two genes is not considerable 
when compared with published mutations in BRCA1 and BRCA2. Aberrant RNA 
splicing is not restricted to mismatch repair genes, since it has been reported in many 
different diseases such as deficiency of medium-chain acyl-CoA dehydrogenase 
(Kelly et al. 1990), adenosine deaminase deficiency (ADA) (Akeson et al. 1987), 
argininosuccinate lyase gene ( Abramson et al. 1990), Citrullinemia (Kobayashi et al. 
1990) and also in alfa subunit of G protein (Unnisa Ali et al. 1992).
Kelly et al. have reported nine different aberrant RNAs in the medium-chain 
acyl-CoA dehydrogenase (MCAD) deficiency (1990), including single and multiple 
exons missing from the transcript. MCAD is a common inherited defect in energy 
metabolism and may be fatal. The incidence of this disease in Great Britain is 1 in 
5000-10, 000 births. They found several single base changes and exons deletions 
involving many in multiple locations throughout the mRNA coding region. The gene
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has 12 coding exons and the following exon deletions were found: (i) deletion of 
exon 2 (ii) deletion of exon 5 (iii) deletion of exon 2 and 5 (iv) deletion of exon 5 
and retention of intron 3 (v) deletion of exon 2 through to exon 10 (vi) deletion of 
exon 2 and deletion of exon 7 through middle of exon 11 (vii) deletion of exon 7 
through to the middle of exon ll(viii) deletion of exons 8-10 (ix) deletion of exon 2 
and 5 as well as exon 8-10. Therefore, missplicing during RNA processing is not a 
result of a point mutation either in the donor or acceptor splicing sites (Kelly et 
a l l  990).
Table 4. 2. Summary of published aberrant mRNA deletions in mismatch repair
genes.
No. Exon Gene M utation No. o f  
kindreds
Predictated protein Reference
1 2-6 hMSH2 Del. o f  exons 2-6 1 Out-of-frame 
o f  exon 2-6
deletion Kohonen -Corish et al., 199
2 3 hMSH2 Del. o f  exon 3 1 Out-of-frame 
o f  exon 3
deletion Froggatt et al., 1996
3 7 hMSH2 Del. o f  exon 7 1 Out-of-frame 
o f  exon 7
deletion Liu et al., 1996
4 8-15 HMSH2 Del. o f  exons 8- 
15
1 Out-of-frame 
o f  exon 8-15
deletion Liu et al., 1994
5 13 hMSH2 Del. o f  exon 13 2 Out-of-frame 
o f  exon 13
deletion Liu et al., 1994 
Luce et al., 1995
6 3 hMLHl Del. o f  exon 3 1 Out-of-frame 
o f  exon 3
deletion Viel et al., 1997
7 12 hMLHl Del. o f  exon 12 2 Out-of-frame 
o f  exon 12
deletion Liu et al., 1994 
Papadopoalos et al., 1994
8 13 hMLHl Del. o f  exon 13 2 Out-of-frame 
o f  exon 13
deletion Liu et al., 1995 
Luce et al., 1995
9 15 hMLHl Del. o f  exon 15 1 Out-of-frame 
o fex o n  15
deletion L iu e ta l ., 1996
It is notable that the MCAD mRNA missplicing occurs in normal tissues but 
at a lower frequency than that of the index patients. The cause of the high rate of 
missplicing in the patient is not yet clear (Kelly et al.1990). In another paper (Akeson 
et al. 1987) an exon 4 and also exon 4 and exon 7 skipping appeared from transcript 
in the adenosine deaminase deficiency but the cause of the missing exon in the
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genomic DNA was not discovered. Genomic blotting with different restriction 
enzymes, and also DNA sequencing were done but no alteration was identified. 
Abramson et al. (1990) reported deletion of exon 7 in 5% of the mRNA of the 
argininosuccinate lyase gene from all tissue sources studied. As the length of intron 
6 is 79 base pairs and it has been stated that the minimum size of an intron required 
for efficient splicing should be around 80 bases, the size could be the cause of exon 7 
skipping from transcript. However, no alteration in splice sites or within the exon 6 
and exon 8 have been found to be considered as the cause of exon 7 skipping from 
transcript (Abramson et al. 1990).
Nakai and Sakamoto (1994) constructed a database containing aberrant 
splicing mutations of 90 genes with 209 mutations. In this database, there are 91 
cases of exon skipping including 48 mutations (53%) due to destruction of 5’ splice 
site, 29 mutations (32%) due to destruction of 3’ splice site and also 14 mutations 
(15%) with unknown aetiology. Nakai is dedicated to revising his database due to the 
increasing number of aberrant mRNA deletions without unknown eatilogy (personal 
communication). However, the number of aberrant spliced mRNAs in mismatch 
repair genes, in comparison to published mutations in these two genes, appears to be 
significant and therefore requires more investigation.
In summary, in the RNA splicing process two different groups are involved; 
cis and trans acting factors. Any abnormalities in any members of these two groups 
could be the cause of aberrant splicing. Among these factors there are some invisible 
factors e.g. GpC contents which are able to alter the secondary structure of the 
mRNA. However, mutations in introns more than 50 base pairs away from splice 
junction sites could also be the cause of exon skipping but can not be detected easily 
given a large average size of introns.
In conclusion, mutation detection in HNPCC is still problematic and difficult. 
To date, at least four different genes are known to be involved and there is no 
common mutation or hot spot in any of these genes, and mutations are distributed
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throughout the entire coding sequence. The mutation screening of hMSH2 and to a 
lesser extent hMLHl, was performed using four complementary methods. This study 
shows that the hMSH2 gene is involved in a proportion of patients with colorectal 
cancer in the West of Scotland. There was no sign of hotspots or common mutations 
in the gene. HNPCC is a heterogeneous disease, and only by employing RNA and 
DNA based methods all existing mutations be detected.
Genotype-phenotype correlation
To establish a correlation between genotype and phenotype is one of the most
important aim of any mutation screening study. Although it is still difficult to 
establish a proper link between genotype and phenotype in HNPCC.
At the beginning of this chapter it has been explained that there is a 
correlation between MI+ and germline mutations in HNPCC tumours and also in 
some proportion of sporadic cases of CRC. Indeed, MI is a reasonable tool for 
screening sporadic and familial cases of CRC in particular when patients are younger 
than 50 years of age. A tumour is composed of normal and malignant cells. It is 
possible MI could not be detect in some of the cases due to a low percentage of 
malignant cells in the piece of tumour from which DNA has been extracted. In the 
pathology department of Royal hospital, University of Glasgow, (Dr. Purdie, 
personal communication) a tumour has been defined as a mass of tissue in which 
there are more than 70% malignant cells and a normal tissue is a mass of cells in 
which there are more than 70% normal cells. However, it seems that in a mass of 
pure malignant cells either from HNPCC or sporadic tumours the range of MI+ 
phenotype might be more than the reported range in the publications (90% and 15% 
in HNPCC and sporadic cases, respectively). Therefore, due to low number of 
malignant cells in early stage of tumourigenesis some MI+ tumours, during MI 
assessment were missed.
131
In the clinic HNPCC can be classified as Lynch 1, Lynch 2 and Muir-Torre 
syndromes. Muir-Torre syndrome is thought to be a variant of Lynch syndrome and 
Kolodner et al. (1994) have been reported two germline mutations including a 
nonsense mutation and a ffameshift mutation in exon 12 of hMSH2 that are linked to 
inheritance of cancer susceptibility in these kindreds.
A germline mutation in the splice site of exon 5, resulting in exon 5 skipping 
from the transcript, has been reported by several groups from different parts of the 
glob and is claimed to be a common mutation in North-American and British 
populations (Froggatt et al. 1995).
Mutations in hMSH2 and hMLHl can cause Lynch 1 and Lynch 2. It is believed that 
the hMSH2 and hMLHl have roughly the same share in HNPCC (Nystrom-Lahti et 
al. 1996). hMSH2 was reported to account for 29% (5/17) and hMLHl for 17% 
(3/17) of English HNPCC kindreds (Fraggett et al. 1996), while the proportion of 
kindreds attributable to mutations in hMSH2 was 21% (7/34) in a Dutch series 
(Wijnen et al. 1995), and 34% (10/29) from North America (Liu et al. 1994). hMLHl 
was reported to account for 24% (8/34) of HNPCC kindreds from Japan (Han et al.
1995). It seems that the hMLHl gene is more mutable than hMSH2.
Mutation detection in HNPCC is still problematic (Kohonen-Corish et al.
1996) and difficult. To date, at least four different genes are involved. There is no 
common mutation or hot spot in any of these genes, and mutations are distributed 
through the entire coding sequence. It seems that the predisposing mutation varies 
from kindred to kindred, but a small number of recurrent mutations have been 
reported (referred to recurrence of mutation in this chapter).
Due to the heterogeneity of disease and lack of common mutations or hot 
spots in the MMR genes it seems that further study is required to make it possible to 
establish a link between genotype and phenotype.
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*
Future work
The published mutations in MMR genes from global studies indicate that 
there is no germline mutation in about 30% of HNPCC patients with RER+ and 
also no germline mutation was found in a majority of sporadic CRC cases. 
Additionally, it has been shown that the frequency of germline mutation in CRC 
patients without Amsterdam criteria is quite low and recently, as expected, a 
germline mutation in MSH6 has been reported in a family without Amsterdam 
criteria (Miyaki et al. 1997). This data suggests that there are additional CRC 
families with germline mutations in unscreened MMR genes and more mutation 
analysis of these families is required to clear up the molecular pathology of this 
heterogeneous disease. Any mutation analysis should cover at least two major MMR 
genes namely MSH2 and MLH1. The whole coding sequence of both genes should 
be search for any defect within the coding sequence of the gene, although most 
mutations are unique and quite evenly distributed, with some clustering in MSH2 
exon 12 and MLH1 exon 16.
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